Print

Search Results: (324 results)

Testing a KRAS Vaccine With Immunotherapy for Advanced Pancreatic and Colorectal Cancer

https://www.facingourrisk.org/research-clinical-trials/study/384 /testing-a-kras-vaccine-with-immunotherapy-for-advanced-pancreatic-and-colorectal-cancer

Treatment
Phase 1b treatment study enrolling adults with advanced pancreatic or colorectal cancer that has a KRAS mutation and has been previously treated with chemotherapy

This study is testing a new treatment that combines a KRAS-targeted cancer vaccine (ELI-002) with two immunotherapy drugs (balstilimab and botensilimab) in people with advanced colorectal or pancreatic cancers.

Testing COM701 Maintenance Treatment to Delay Cancer Growth After Platinum Chemotherapy for Ovarian Cancer That Has Come Back

https://www.facingourrisk.org/research-clinical-trials/study/381 /testing-com701-maintenance-treatment-to-delay-cancer-growth-after-platinum-chemotherapy-for-ovarian-cancer-that-has-come-back

Treatment
Study for women with relapsed platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer who responded to their most recent platinum chemotherapy

This study tests whether COM701 (an anti‑PVRIG immunotherapy) given every 3 weeks as maintenance can delay cancer growth after a good response to platinum chemotherapy. Adults with relapsed platinum‑sensitive ovarian, fallopian tube, or primary peritoneal cancer are randomized 2:1 to COM701 or placebo.

ADHERE: Survey about Pancreatic Cancer Screening Options for People with Inherited Risk

https://www.facingourrisk.org/research-clinical-trials/study/368 /adhere-survey-about-pancreatic-cancer-screening-options-for-people-with-inherited-risk

Surveys, Registries, Interviews
Online survey about pancreatic cancer screening for people with an inherited mutation in genes that are linked to an increased risk of pancreatic cancer

The purpose of this study is to understand knowledge and opinions about pancreatic cancer screening, access to and decision-making around screening, and how a blood-based test might influence screening among individuals with inherited (germline) mutations associated with increased pancreatic cancer risk, including APC, ATM, BRCA1, BRCA2, CDKN2A, EPCAM, MLH1, MSH2, MSH6, PALB2, PMS2, STK11, and TP53. 

Research Study on the Genetics of Breast Cancer

https://www.facingourrisk.org/research-clinical-trials/study/317 /research-study-on-the-genetics-of-breast-cancer

Surveys, Registries, Interviews
A registry for anyone aged 18 and older who lives in the United States

We are conducting a fully-online research study to learn more about how genes affect your risk of breast cancer. No office visit is required. Participants provide consent online, answer questions online about their health and medical history, and provide DNA via a saliva sample using a pre-paid mailer through the mail. In return for participation, study participants may receive information about their genetic ancestry for free.

Testing the Drug Adavosertib With or Without an Immunotherapy in People With Advanced Cancers That Have DNA Repair Changes - CHARM2

https://www.facingourrisk.org/research-clinical-trials/study/380 /testing-the-drug-adavosertib-with-or-without-an-immunotherapy-in-people-with-advanced-cancers-that-have-dna-repair-changes-charm2

Treatment
Phase 2 treatment trial for advanced solid tumors that have defects in DNA repair genes

This is a Phase 2 treatment trial enrolling adults with advanced solid tumors that have defects in DNA repair genes to test whether adavosertib alone or in combination with pembrolizumab may help control cancer growth.

Treating Advanced MSI-High or dMMR Cancers Using the Targeted Therapy MOMA-341 Given Alone or In Combination with Standard Therapies

https://www.facingourrisk.org/research-clinical-trials/study/356 /treating-advanced-msi-high-or-dmmr-cancers-using-the-targeted-therapy-moma-341-given-alone-or-in-combination-with-standard-therapies

Treatment
Treatment study for people with advanced or metastatic cancers

This trial will study the safety, tolerability, and initial effectiveness of MOMA-341, a new type of targeted therapy, alone or in combination with a standard chemotherapy (irinotecan) or together with an immunotherapy to treat people with advanced or metastatic cancers with certain types of mutations.

For Adults With Advanced/Metastatic HR+ HER2- Breast Cancer, Not Yet Treated: Join the FourLight-3 Study

https://www.facingourrisk.org/research-clinical-trials/study/379 /this-study-is-for-adults-with-advancedmetastatic-hr-positive-her2-negative-breast-cancer-who-have-not-yet-received-treatment-for-their-advancedmetastatic-disease


Phase 3 study for advanced/metastatic HR-positive, HER2-negative breast cancer

The FourLight-3 clinical trial compares a study treatment, atrimociclib combined with letrozole, against standard approved treatments. The clinical trial is for adults with advanced or metastatic HR-positive, HER2-negative breast cancer who have not received prior treatment for advanced/metastatic disease. 

Study of a New Oral Medication, Daraxonrasib After Surgery to Help Prevent Pancreatic Cancer from Returning

https://www.facingourrisk.org/research-clinical-trials/study/378 /study-of-a-new-oral-medication-daraxonrasib-after-surgery-to-help-prevent-pancreatic-cancer-from-returning

Treatment
Phase 3 treatment trial for pancreatic cancer that was removed by surgery

This study is testing whether taking daraxonrasib, a new oral cancer medicine, after surgery and standard chemotherapy can help people with pancreatic cancer stay cancer-free for longer.

Treating Advanced Cancers with BRCA or Other Related Gene Mutations Using Targeted Therapy MOMA-313 Alone or In Combination with the PARP Inhibitor Olaparib

https://www.facingourrisk.org/research-clinical-trials/study/328 /treating-advanced-cancers-with-dna-repair-mutations-using-moma-313-alone-or-in-combination-with-the-parp-inhibitor-olaparib

Treatment
Treatment study for people with advanced or metastatic cancers

This trial will study the safety, tolerability, and initial effectiveness of MOMA-313, a new type of targeted therapy, alone or in combination with the PARP inhibitor olaparib to treat people with advanced or metastatic cancers with certain types of mutations.

Treating Advanced Endometrial Cancer with Targeted Therapies (ComboMATCH)

https://www.facingourrisk.org/research-clinical-trials/study/375 /treating-advanced-endometrial-or-ovarian-cancer-with-targeted-therapies-combomatch

Treatment
Phase 2 treatment study for recurrent endometrial cancer

This clinical trial is testing whether two targeted cancer drugs taken together work better than one drug alone for treating advanced endometrial cancer that has come back or did not respond to prior treatment. To be eligible, the cancer must test positive for a biomarker known as a RAS pathway mutation.

Health and Medicine Decision-Making Study

https://www.facingourrisk.org/research-clinical-trials/study/382 /health-and-medicine-decision-making-study

Surveys, Registries, Interviews
Study for people diagnosed with a complex health condition such as cancer, diabetes or an autoimmune disorder

Researchers are conducting a study to better understand how people make important health decisions and how they feel about those decisions over time. The goal of this study is to learn what factors help patients feel confident and satisfied with their health-related decisions, as well as what may lead to regret or uncertainty later on.

NePtune: Using PARP Inhibitors Before Surgery in Localized Prostate Cancer

https://www.facingourrisk.org/research-clinical-trials/study/314 /neptune-using-parp-inhibitors-before-surgery-in-localized-prostate-cancer

Treatment
Treatment study for people with intermediate- or high-risk prostate cancer with certain tumor mutations

This research study is enrolling prostate cancer patients who plan to undergo surgery to have their prostate removed (radical prostatectomy) and whose cancer has one of the listed gene mutations: ATM, BRCA1, BRCA2, CHEK2, PALB2, RAD51B, RAD51C, RAD51D, RAD54L2, BARD1, FANCA or BRIP1.

Improving Support for Families with Genetic Conditions: A Study on Trauma-Informed Medical Care

https://www.facingourrisk.org/research-clinical-trials/study/383 /improving-support-for-families-with-genetic-conditions-a-study-on-trauma-informed-medical-care

Surveys, Registries, Interviews
Survey of parents and caregivers of children with genetic conditions

This study explores how medical stress affects families with genetic conditions and their relationships with healthcare providers to improve future support.

Vaccine for People at High Risk for Pancreatic Cancer

https://www.facingourrisk.org/research-clinical-trials/study/365 /vaccine-for-those-at-high-risk-of-developing-pancreatic-cancer

Prevention
Phase 1 pancreatic cancer prevention study for people at high risk

This study is testing an experimental vaccine that helps the immune system recognize changes in a protein called KRAS, which is commonly involved in pancreatic cancer. The vaccine is given with an immune-boosting medicine that helps improve the body’s response.

Comparing an Investigational Targeted Drug AZD5335 to Standard Treatments in People With Platinum‑Resistant Ovarian Cancer (TREVI‑OC‑01)

https://www.facingourrisk.org/research-clinical-trials/study/371 /comparing-an-investigational-targeted-drug-azd5335-to-standard-treatments-in-people-with-platinumresistant-ovarian-cancer-trevioc01

Treatment
Phase 3 treatment study for platinum-resistant ovarian cancer

This study is testing whether a new targeted therapy called AZD5335 works better than currently used treatments for people with platinum‑resistant ovarian, fallopian tube, or primary peritoneal cancer.The study is looking at how long people live without their cancer getting worse while taking AZD5335 compared with standard treatments. 

Using a Blood Test to Detect Early Cancer Recurrence After Treatment (ORACLE)

https://www.facingourrisk.org/research-clinical-trials/study/372 /using-a-blood-test-to-detect-early-cancer-recurrence-after-treatment-oracle

Treatment
Post-treatment study to monitor for recurrence

This study is testing whether a type of blood test called a liquid biopsy can find very small amounts of cancer left in the body after treatment—before cancer shows up on scans or causes symptoms.The blood test looks for circulating tumor DNA (ctDNA), tiny pieces of cancer DNA that may be present in the bloodstream. Researchers want to learn how well this test can:

Treating Advanced or Metastatic Breast Cancer with a Type of Immunotherapy Called CAR-T

https://www.facingourrisk.org/research-clinical-trials/study/364 /treating-advanced-or-metastatic-breast-cancer-with-a-type-of-immunotherapy-called-car-t

Treatment
Phase 1 treatment study for people with advanced solid tumors

CAR-T therapy is a type of immunotherapy that uses the patient's own immune cells in order to treat their cancer. With CAR-T therapy, the immune cells are removed from the blood and enhanced in the lab to improve their ability to kill cancer cells. The goal of this clinical trial is to learn the safety and effectiveness of an experimental CAR-T combination known as CLBR001+ABBV-461 for treating people with metastatic breast cancer. Another goal is to learn the best dose of this combination for treating metastatic breast cancer. 

Pfizer Clinical Trials for Metastatic Prostate Cancer are Now Enrolling

https://www.facingourrisk.org/research-clinical-trials/study/321 /pfizer-clinical-trials-for-metastatic-prostate-cancer-are-now-enrolling


Men aged 18 years or older with metastatic prostate cancer

The study will determine whether the study medicine mevrometostat can delay or stop the growth of metastatic prostate cancer. Mevrometostat is thought to work by blocking the abnormal EZH2 activity in cells, which may help prevent or delay hormone therapy resistance and cancer growth and progression.

Comparing an Experimental Drug Puxi-Sam to Standard Chemotherapy for Metastatic Endometrial Cancer (Bluestar‑Endometrial01)

https://www.facingourrisk.org/research-clinical-trials/study/370 /comparing-an-experimental-drug-puxi-sam-with-standard-chemotherapy-for-metastatic-endometrial-cancer-bluestarendometrial01

Treatment
Phase 3 treatment study for metastatic endometrial cancer

This study is testing whether a new targeted drug called puxitatug samrotecan (Puxi-Sam) works better than standard chemotherapy for treating advanced or metastatic endometrial cancer whose cancer has grown or returned after prior treatment with platinum chemotherapy and immunotherapy. 

Cancer Patients: Share Your Experience Talking With Surgeons About Treatment Decisions

https://www.facingourrisk.org/research-clinical-trials/study/374 /cancer-patients-share-your-experience-talking-with-surgeons-about-treatment-decisions

Surveys, Registries, Interviews
Survey for adults with cancer who discussed possible surgery with a surgeon

Anonymous online survey enrolling adults with cancer who have met with a surgeon about possible cancer surgery

Testing a Combination of Immunotherapy and a Vaccine in People With Advanced Pancreatic or Lung Cancer

https://www.facingourrisk.org/research-clinical-trials/study/373 /testing-a-combination-treatment-with-an-anti-cd38-antibody-kras-vaccine-and-anti-pd-1-antibody-in-people-with-advanced-pancreatic-or-lung-cancer

Treatment
Phase 2 treatment study for advanced pancreatic and lung cancer

This is a Phase 2 treatment trial enrolling adults with advanced pancreatic cancer or advanced non-small cell lung cancer that has continued to grow despite standard immunotherapy.

For Adults With Advanced HR+ HER2- Breast Cancer, Not Yet Treated: Join the FourLight-3 Study

https://www.facingourrisk.org/research-clinical-trials/study/366 /this-study-is-for-adults-with-advanced-hr-positive-her2-negative-breast-cancer-who-have-not-yet-received-treatment-for-their-advanced-disease


Phase 3 study for adults with advanced HR-positive, HER2-negative breast cancer who have not yet received treatment for their advanced disease

The FourLight-3 clinical trial tests a study treatment, atrimociclib, plus letrozole against standard approved treatments plus letrozole. The clinical trial is for adults with advanced or metastatic HR-positive, HER2-negative breast cancer who have not received prior treatment for advanced disease.

Treating Recurrent dMMR or MSI-High Endometrial Cancer with the Immunotherapy Drug, Nivolumab with or without the Immunotherapy Drug, Ipilimumab

https://www.facingourrisk.org/research-clinical-trials/study/362 /testing-an-immunotherapy-drug-nivolumab-with-or-without-the-immunotherapy-drug-ipilimumab-for-recurrent-dmmr-endometrial-cancer

Treatment
Phase 2 treatment study for recurrent endometrial cancer with dMMR or MSI-High biomarker

This clinical trial is studying two different immunotherapy approaches for people with endometrial cancer that has come back after treatment (recurrent). It focuses on tumors that have a biomarker called mismatch repair deficiency, (dMMR or MMR-D) or microsite instability high (MSI-High). These biomarkers are often found in cancers that respond to immunotherapy.

 

Using a Shorter Type of MRI as a Screening Tool for People at High Risk for Prostate Cancer

https://www.facingourrisk.org/research-clinical-trials/study/353 /using-biparametric-magnetic-resonance-imaging-mri-as-a-screening-tool-for-those-at-high-risk-for-prostate-cancer

Prevention
Screening for people at high risk for prostate cancer

This study is looking at whether using a shorter type of MRI known as bpMRI (biparametric MRI) in combination with PSA tests in men who are at high risk of developing prostate cancer will improve prostate cancer screening and lead to earlier detection. 

The Prostate Cancer, Genetic Risk, and Equitable Screening Study (ProGRESS)

https://www.facingourrisk.org/research-clinical-trials/study/360 /the-prostate-cancer-genetic-risk-and-equitable-screening-study-progress

Prevention
Prostate cancer screening study for male US veterans age 55–69

Prostate cancer is very common among male Veterans. Current screening tests, like the PSA blood test, can find cancer early but can also lead to unnecessary testing and treatment. This study will use genetic testing to see if they can determine which men are at higher risk for serious prostate cancer and which men are at low risk and can avoid unnecessary biopsies. Participants will have testing that looks for gene mutations that may increase the risk for prostate cancer.

Understanding Access to Genetic Services for Latina Women with Breast Cancer

https://www.facingourrisk.org/research-clinical-trials/study/367 /understanding-access-to-genetic-services-for-latina-women-with-breast-cancer

Surveys, Registries, Interviews
A phone survey for Latina breast cancer survivors diagnosed within the past five years in California

Researchers are surveying Latina breast cancer survivors and patients who were diagnosed with breast cancer within the past five years, lived in California at the time of diagnosis, and are between the ages of 20 and 79 years old.

Treating Advanced Breast Cancer or Other Solid Cancers Using a Combination of a New Targeted Therapy, ZEN003694, With The Targeted Therapy Abemaciclib (Verzenio)

https://www.facingourrisk.org/research-clinical-trials/study/363 /testing-a-new-drug-zen003694-with-chemotherapy-abemaciclib-for-people-with-advanced-or-inoperable-breast-cancer-and-other-solid-tumors

Treatment
Phase 1 treatment study for advanced breast cancer and other solid tumors

This clinical trial is studying whether the combination of two targeted therapies, abemaciclib (Verzenio) and a new targeted therapy  ZEN003694 (also known as ZEN-3694) can be given together safely and what dose should be used in future studies.

Study of an Investigational Drug, E7386 Plus Lenvatinib in People with Endometrial Cancer after Chemotherapy and Immunotherapy

https://www.facingourrisk.org/research-clinical-trials/study/355 /study-of-a-new-drug-e7386-in-combination-with-lenvatinib-in-people-with-previously-treated-endometrial-cancer


Treatment study for people with previously treated endometrial cancer

This trial will evaluate the optimal dose, safety and effectiveness of an investigational drug called E7386 given together with a targeted therapy called lenvatinib.

Study of a New Drug, Sacituzumab Tirumotecan, Given Alone or in Combination with an Immunotherapy for Metastatic, Triple-Negative Breast Cancer (TroFuse-011)

https://www.facingourrisk.org/research-clinical-trials/study/359 /study-of-a-new-drug-sacituzumab-tirumotecan-given-alone-or-in-combination-with-an-immunotherapy-for-people-with-triple-negative-breast-cancer

Treatment
Phase 3 treatment study for people with metastatic, triple-negative breast cancer

This study is testing a new targeted therapy, sacituzumab tirumotecan, given alone or with the immunotherapy Keytruda (pembrolizumab) to treat metastatic, triple-negative breast cancer (TNBC). Keytruda is an immunotherapy that is FDA approved to treat TNBC. The goal of the study is to learn how well sacituzumab tirumotecan can cause tumors to shrink or disappear and how long that response lasts.

Study of a New Investigational Inhibitor to Treat People with Advanced Solid Tumors

https://www.facingourrisk.org/research-clinical-trials/study/300 /study-of-a-new-investigationai-inhibitor-to-treat-people-with-advanced-solid-tumors

Treatment
Treatment study for people with advanced solid tumors

The study will test if an investigational treatment, XL309, is safe and works when used alone or in combination with a PARP inhibitor to treat people with some advanced solid tumors. The study is enrolling people with BRCA1 or BRCA2 inherited mutations and have HER2-negative breast cancer, prostate cancer, pancreatic cancer, high grade ovarian, fallopian tube or primary peritoneal cancer; or other solid tumors with certain genetic mutations. 

Using a PARP Inhibitor and Oral Chemotherapy to Treat Advanced Solid Tumors with a Mutation in BRCA1, BRCA2, PALB2, ATM or CHEK2

https://www.facingourrisk.org/research-clinical-trials/study/376 /using-a-parp-inhibitor-and-oral-chemotherapy-to-treat-advanced-solid-tumors-with-a-mutation-in-brca1-brca2-palb2-atm-or-chek2

Treatment
Phase 1 treatment study for metastatic solid tumors

This study is testing a new combination of two oral drugs to see if they are safe and show signs of helping people with advanced cancer whose tumors have mutations in one of these genes: BRCA1, BRCA2, PALB2, ATM, and CHEK2. 

Immunotherapy (Toripalimab) for Reducing Recurrence Risk After Surgery for MMR-D or MSI-H Stage IIB - III Colon Cancer

https://www.facingourrisk.org/research-clinical-trials/study/358 /post-surgery-immunotherapy-toripalimab-for-mmr-d-msi-h-stage-iib-iii-colon-cancer

Treatment
Study for people who have had surgery to remove the Stage IIB-III MMR-D / MSI-H colon cancer

This phase II trial evaluates how well immunotherapy (toripalimab) works for reducing the risk of cancer recurrence after surgery in patients with mismatch repair deficient stage IIB, IIC, or III colon cancer.

Maintenance Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer in People with a BRCA Mutation or a Biomarker Called HRD

https://www.facingourrisk.org/research-clinical-trials/study/361 /testing-olaparib-for-one-or-two-years-with-or-without-bevacizumab-to-treat-ovarian-cancer-with-a-brca-mutation-or-a-biomarker-called-hrd

Treatment
Phase 3 ovarian cancer treatment study for people with BRCA mutation or HRD

This study is looking at whether people with ovarian cancer do better when they take the drug olaparib (also called Lynparza) for one year or for two years after finishing chemotherapy. Some participants in the study may also get another medicine called bevacizumab (Avastin) along with olaparib. You may be able to join this study if you have stage 3 or 4 ovarian cancer and either a BRCA1 or BRCA2 gene change, or a certain tumor marker called HRD.

Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer (LAP100)

https://www.facingourrisk.org/research-clinical-trials/study/347 /testing-higher-dose-radiation-therapy-for-locally-advanced-pancreatic-cancer

Treatment
Radiation treatment study for people with locally advanced pancreatic cancer

This research study will test whether higher doses of radiation therapy are safe and effective for people with locally advanced pancreatic cancer. 

A Study of the PARP Inhibitor Saruparib Added to Standard Treatment for High Risk BRCA-Positive Prostate Cancer (EvoPAR PR02)

https://www.facingourrisk.org/research-clinical-trials/study/369 /a-study-of-the-parp-inhibitor-saruparib-added-to-standard-treatment-for-high-risk-brca1-positive-prostate-cancer

Treatment
Phase 3 treatment study for BRCA-positive high-risk prostate cancer

This study is testing a new medication called saruparib (AZD5305) to see if it can help people with prostate cancer that is high risk for getting worse or spreading to other parts of the body. Saruparib is a type of targeted therapy known as a PARP inhibitor. The study is open to people with a BRCA1 or BRCA2 mutation in their tumor. The goal of this study is to find out if adding saruparib after radiation treatment can lower the chances of the cancer coming back or spreading.

A New Targeted Therapy CX‑5461 to Treat Advanced Breast, Ovarian, Pancreatic or Prostate Cancer with an ATM, BRCA1/2, CHEK2, PALB2 or Other Mutation

https://www.facingourrisk.org/research-clinical-trials/study/377 /an-new-targeted-therapy-cx5461-to-treat-advanced-breast-ovarian-pancreatic-or-prostate-cancer-with-inherited-or-tumor-mutations

Treatment
Phase 1 treatment study for advanced or metastatic breast, ovarian, pancreatic or prostate cancer

This research study is testing the safety and effectiveness of an investigational targeted therapy called CX‑5461. The goal is to find a safe dose and learn more about how well the drug works to treat advanced breast, ovarian, pancreatic or prostate cancers in people with certain inherited or tumor‑related gene mutations, including ATM, BARD1, BRCA1, BRCA2, BRIP1, CHEK2, NBN, PALB2, RAD51C, RAD51D or other mutations related to DNA repair.

Pancreatic Cancer Screening Study for People with ATM, BRCA1, BRCA2 or PALB2 Mutations

https://www.facingourrisk.org/research-clinical-trials/study/330 /screening-study-for-pancreatic-cancer

Prevention
Pancreatic cancer screening study for people with ATM, BRCA1, BRCA2 or PALB2 mutations

This study will look at how often routine MRI scans detect abnormal findings in people with inherited mutations in BRCA1, BRCA2, ATM, and PALB2, who are undergoing pancreatic cancer screening. Researchers want to learn how often MRI and endoscopic ultrasound (EUS) yield abnormal results, and how frequently they find pancreatic cancer or precancer. The study will also review the rate of procedures like biopsies and surgeries among participants. 

Learning about the Needs of Autistic People Related to Breast Cancer Screening and Testing

https://www.facingourrisk.org/research-clinical-trials/study/341 /learning-about-the-needs-of-autistic-people-related-to-breast-cancer-screening-and-testing


Online survey for autistic people with or at high risk for breast cancer

This survey is now closed. 

The nonprofit organization, Facing Our Risk of Cancer Empowered (FORCE) is working with the Autistic Self Advocacy Network (ASAN) to learn about people’s needs for information, support and services related to breast health, breast cancer risk and screening. The information will be collected through an online survey. There are two parts to this survey; 1) a short eligibility questionnaire, and 2) a full survey. 

PREVAIL Study: A Genetic Education and Genetic Testing Study for African American Men with Prostate Cancer or with a Strong Family History of Cancer

https://www.facingourrisk.org/research-clinical-trials/study/351 /prevail-study-a-genetic-education-and-genetic-testing-study-for-african-american-men-with-prostate-cancer-or-with-a-strong-family-history-of-cancer

Surveys, Registries, Interviews
Study for African American men with prostate cancer or with a strong family history of cancer

PREVAIL is a patient-choice study where African American men with prostate cancer or with a strong family history of cancer can choose to either view a pretest genetic education video before having genetic testing or meet with a genetic counselor before genetic testing.

Understanding the Cancer Journey: A Survey of Patient Experiences and Emotional Impact

https://www.facingourrisk.org/research-clinical-trials/study/357 /understanding-the-cancer-journey-a-survey-of-patient-experiences-and-emotional-impact

Surveys, Registries, Interviews
Survey for people diagnosed with lung, liver, pancreatic or thyroid cancer

Survey for people diagnosed with cancer

Hormone Replacement Therapy After Risk-Reducing Surgery in Individuals at Increased Risk for Breast Cancer: The Patient Perspective

https://www.facingourrisk.org/research-clinical-trials/study/337 /hrt-after-risk-reducing-surgery-in-women-at-increased-risk-for-breast-cancer-the-patient-perspective


Survey for individuals with a BRCA1, BRCA2, PALB2, RAD51C, RAD51D mutation

This study will explore the decision making surrounding hormone replacement therapy (HRT) in individuals aged 35-50 with a BRCA1, BRCA2, PALB2, RAD51C, RAD51D genetic mutation who have undergone risk-reducing bilateral salpingo-oophorectomy (removed both tubes and ovaries) to lower cancer risk.

Studying a New PARP Inhibitor and Hormonal Therapy to Treat HER2-negative, HR-positive Metastatic Breast Cancer with a BRCA1, BRCA2, or PALB2 Mutation (EvoPAR BR01)

https://www.facingourrisk.org/research-clinical-trials/study/349 /studying-a-new-parp-inhibitor-and-hormonal-therapy-to-treat-her2-negative-hr-positive-metastatic-breast-cancer-with-a-brca1-brca2-or-palb2-mutation-evopar-br01

Treatment
Phase 3 treatment study for HER2-negative, HR-positive metastatic breast cancer with a BRCA1, BRCA2 or PALB2 mutation

EvoPAR-BR01 is studying two investigational drugs as first-line treatment for HER2-negative, HR-positive, metastatic breast cancer in people with an inherited or tumor mutation in BRCA1, BRCA2 or PALB2. Saruparib is a new PARP1 inhibitor (a type of targeted therapy). Camizestrant is an estrogen receptor degrader (a type of hormonal therapy). The study will look at different combinations of treatments to learn which combination leads to the best survival and fewest side effects. 

An Online Program to Help Asian American Breast Cancer Survivors Manage Pain and Depression

https://www.facingourrisk.org/research-clinical-trials/study/352 /an-online-program-to-help-asian-american-breast-cancer-survivors-manage-pain-and-depression

Quality of Life
An online program to help Asian American breast cancer survivors manage pain and depression

This study is looking at the effectiveness of a technology-based information and coaching and support program for Asian American women who have been diagnosed with breast cancer.

Treating Advanced or Metastatic Cancers with a New PARP1 Inhibitor (GS-0201) Alone or Combined with Other Drugs

https://www.facingourrisk.org/research-clinical-trials/study/350 /treating-advanced-or-metastatic-cancers-with-the-new-parp-inhibitor-alone-or-combined-with-other-drugs

Treatment
Treatment study for people with advanced or metastatic solid tumors

The goal of this treatment study is to learn if the new drug GS-0201 is safe and can help treat people with different types of metastatic or advanced cancer. GS-0201 is a new drug that has not yet been approved for treatment of cancer. GS-0201 is a type of targeted therapy known as a PARP1 inhibitor. 

A Study to Compare Two Surgical Procedures in Women with BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer (SOROCk)

https://www.facingourrisk.org/research-clinical-trials/study/101 /a-study-to-compare-two-surgical-procedures-in-women-with-brca1-mutations-to-assess-reduced-risk-of-ovarian-cancer-sorock

Prevention
Ovarian cancer prevention for women with a BRCA1 mutation who still have their ovaries

SOROCk [NRG-CC008] is a clinical trial studying if removal of just the fallopian tubes can reduce the risk of ovarian cancer nearly as much as removing both the ovaries and fallopian tubes among women with an inherited BRCA1 mutation. The main benefit of removing only the fallopian tubes and not the ovaries is to prevent surgically-induced menopause. The study will also examine various patient-reported quality of life outcomes. Researchers believe that most ovarian cancers first begin in the fallopian tubes, suggesting that removing the fallopian tubes only may prevent the development of ovarian cancer. This concept has never been formally testing in a clinical trial.

Understanding the Needs of LGBTQIA+ Caregivers Supporting People with Cancer

https://www.facingourrisk.org/research-clinical-trials/study/346 /understanding-the-needs-of-lgbtqia-caregivers-supporting-people-with-cancer

Surveys, Registries, Interviews
Survey and interview for LGBTQIA+ caregivers supporting people with cancer

This study team wants to understand the experiences of LGBTQIA+ caregivers supporting people with cancer, and what interventions or services could fill their needs and support their health.

HEAL-ABC Study: Harnessing E-Mindfulness Approaches for Living-After Breast Cancer

https://www.facingourrisk.org/research-clinical-trials/study/342 /heal-abc-study-harnessing-e-mindfulness-approaches-for-living-after-breast-cancer

Quality of Life
Quality of life study for young breast cancer survivors who have symptoms associated with depression

This study will examine mindfulness training to improve mental health and well-being in younger breast cancer survivors, also known as “HEAL-ABC.” This trial is currently enrolling young breast cancer survivors who have elevated symptoms associated with depression.

Clinical and Molecular Studies of Li-Fraumeni Syndrome and TP53-Associated Disorders

https://www.facingourrisk.org/research-clinical-trials/study/340 /clinical-and-molecular-studies-of-li-fraumeni-syndrome-and-tp53-associated-disorders

Surveys, Registries, Interviews
This study will enroll Li-Fraumeni Syndrome patients, family members, and household members. Patients and family/household members may be enrolled with informed consent

The Li-Fraumeni Syndrome Biobank (LFSBB) study is a biobank that collects specimens such as blood and other biomedical samples for individuals who have Li-Fraumeni Syndrome (LFS), unaffected relatives, and household members.

Using the Drug eRapa to Prevent the Growth of Polyps in People with Familial Adenomatous Polyposis (SERENTA)

https://www.facingourrisk.org/research-clinical-trials/study/348 /study-of-the-drug-erapa-in-people-with-familial-adenomatous-polyposis-serenta

Prevention
Prevention study for people with Familial Adenomatous Polyposis (FAP) who have polyps in the colon or rectum

The purpose of this study is to find out if a medication called eRapa can help slow down the formation of polyps in people with Familial Adenomatous Polyposis (FAP).

Exploring the Experience of Asian Patients Receiving Results from Cancer Genetic Testing

https://www.facingourrisk.org/research-clinical-trials/study/354 /exploring-the-experience-of-asian-patients-receiving-results-from-cancer-genetic-testing


Interview for Asian people who have received genetic testing

This study's goal is to understand the experience of Asian patients at least 18 years of age who received genetic test results within the past two years.

Treating HER2-negative, Metastatic Breast Cancer with a BRCA or PALB2 Mutation Using a New Drug, Axatilimab, Combined with Olaparib

https://www.facingourrisk.org/research-clinical-trials/study/345 /treating-her2-negative-brca12-or-palb2-positive-metastatic-breast-cancer-using-a-new-drug-combined-with-olaparib

Treatment
Treatment study for HER2-negative, metastatic breast cancer with a BRCA1/2 or PALB2 mutation

This clinical trial is studying a new combination of drugs to treat metastatic, HER2-negative or HER2-low breast cancer in people with an inherited mutation in BRCA1, BRCA2 or PALB2 or a tumor mutation in BRCA1 or BRCA2. The study is looking at whether adding a new targeted therapy drug called axatilimab to treatment with the PARP inhibitor olaparib (Lynparza) will improve outcomes in people with metastatic breast cancer. 

Looking at Tumor DNA Before Chemotherapy to Predict Cancer Recurrence in People with High-Risk, Early-Stage Breast Cancer

https://www.facingourrisk.org/research-clinical-trials/study/344 /study-looking-at-tumor-dna-to-predict-cancer-recurrence-for-those-planning-to-undergo-chemotherapy-for-high-risk-early-breast-cancer

Treatment
Biomarker study for people with early-stage breast cancer

This is a study looking at biomarkers to predict recurrence in people with high-risk, early-stage breast cancer who are planning to undergo chemotherapy. This study will follow patients forward over a period of time to see how well the test cancer predict outcomes.

PROMISE Registry: A Prostate Cancer Registry of Outcomes and Germline Mutations for Improved Survival and Treatment Effectiveness

https://www.facingourrisk.org/research-clinical-trials/study/149 /promise-registry-a-prostate-cancer-registry-of-outcomes-and-germline-mutations-for-improved-survival-and-treatment-effectiveness

Surveys, Registries, Interviews
A screening registry for people diagnosed with prostate cancer

PROMISE is a nationwide registry of prostate cancer patients with inherited mutations; screening approximately 5,000 participants with a prostate cancer diagnosis. The PROMISE team is studying how these mutations affect patient outcomes and hope to help patients learn more about their disease, the treatments that they may benefit most from, and any research studies that they may be eligible for.

Testing a Shorter Course of Chemo- and Immunotherapy (Without Anthracycline Drugs) for People With Early-Stage Triple-Negative Breast Cancer

https://www.facingourrisk.org/research-clinical-trials/study/343 /a-study-testing-shorter-safer-chemo-immunotherapy-without-anthracycline-drugs-for-people-with-early-stage-triple-negative-breast-cancer

Treatment
Treatment study for early-stage triple-negative breast cancer

This study is testing whether a shorter course of combined chemotherapy and immunotherapy treatment—without a type of chemotherapy known as an anthracycline—works as well as the standard, longer treatment for people with early-stage triple-negative breast cancer at high risk for recurrence.

Sexual Health and Rehabilitation Online (SHAREonline): An Educational Intervention for Young Women after Cancer

https://www.facingourrisk.org/research-clinical-trials/study/323 /sexual-health-and-rehabilitation-online-shareonline-an-educational-intervention-for-young-women-after-cancer


An online study comparing two educational interventions for female cancer survivors experiencing sexual health changes

SHAREonline compares two brief educational interventions conducted by videoconference to learn if they help women age 19-49 manage sexual function changes after cancer treatment.

What Happens to Tissue or Blood Samples you Donate as Part of Research?

https://www.facingourrisk.org/research-clinical-trials/study/327 /what-happens-to-tissue-or-blood-samples-you-donate-as-part-of-research

Surveys, Registries, Interviews
Survey to share your views on a new method to track research specimens

Survey to share your views on a new method to track research specimens, like tissue or blood, you or your loved ones may have donated for science

Pancreatic Cancer Screening Study (CAPS5)

https://www.facingourrisk.org/research-clinical-trials/study/222 /pancreatic-cancer-screening-studycaps5

Prevention
Screening study for people at high risk for pancreatic cancer

CAPS5 is a study looking at screening for early cancer in people with an elevated lifetime risk of developing pancreatic cancer. The goal is to study biomarkers derived from images and tissue samples (blood, pancreas fluid, duodenal fluid) for the early detection of pancreatic cancer and precancerous lesions.

 

Registry for People at Increased Risk for Pancreatic Cancer

https://www.facingourrisk.org/research-clinical-trials/study/331 /registry-for-people-at-increased-risk-for-pancreatic-cancer

Surveys, Registries, Interviews
Study collecting blood samples and imaging records of people at high risk of developing pancreatic cancer

This study will collect blood samples and MRI images from people at an increased risk of developing pancreatic cancer in order to improve early-stage detection methods in the future. 

Study of the Drug Olvi-Vec in Women with Ovarian Cancer

https://www.facingourrisk.org/research-clinical-trials/study/334 /study-of-the-drug-olvi-vec-in-women-with-ovarian-cancer

Treatment
Treatment for women diagnosed with platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer or whose cancer did not respond to prior chemotherapy

This study will test how safe and effective the immunotherapy drug Olvi-Vec is, when it is followed by further chemotherapy and the drug bevacizumab in women diagnosed with platinum-resistant or platinum-refractory ovarian, fallopian tube or primary peritoneal cancer.

Testing the Safety And Action of the Investigational Drug REC-4881 in People With Familial Adenomatous Polyposis (FAP) (TUPELO Study)

https://www.facingourrisk.org/research-clinical-trials/study/288 /testing-the-safety-and-action-of-the-investigational-drug-rec-4881-in-people-with-familial-adenomatous-polyposis-fap

Prevention
Prevention study for people with an APC mutation and FAP who have had colectomy surgery

This study is looking at how safe and effective the research drug REC-4881 is for treating polyps in people with Familial Adenomatous Polyposis (FAP). Participants will receive the oral drug REC-4881. A participant's dose will depend on when they join the study. 

Study of the drug TNG260 and an Immunotherapy in Advanced Solid Tumors With a STK11 Mutation

https://www.facingourrisk.org/research-clinical-trials/study/333 /study-of-the-drug-tng260-and-an-immunotherapy-in-advanced-solid-tumors-with-a-stk11-mutation

Treatment
This is a treatment study enrolling people with advanced or metastatic solid tumors with known STK11 mutations

The study is designed to find the safest dose of a drug called TNG260, given along with a standard dose of the immunotherapy drug pembrolizumab, in people with advanced or metastatic solid tumors and have a STK11 genetic mutation.

Lynch Syndrome Vaccine Study

https://www.facingourrisk.org/research-clinical-trials/study/273 /testing-a-combination-of-vaccines-for-cancer-prevention-in-lynch-syndrome


Testing a combination of vaccines for cancer prevention in Lynch syndrome

This study is being done to assess the safety and effectiveness of a series of vaccines (Tri-Ad5), together with another drug (N-803) that magnifies the body’s response to vaccines, to see if there is an effect on the risk of developing colon and other cancers in LS patients.

The American Cancer Society’s “VOICES of Black Women” Observational Study

https://www.facingourrisk.org/research-clinical-trials/study/336 /the-american-cancer-societys-voices-of-black-women-observational-study

Surveys, Registries, Interviews
Survey for Black women who have never been diagnosed with cancer

VOICES of Black Women is a research survey to better understand cancer and other health conditions among Black women. VOICES is enrolling Black women ages 25-55 in the United States who have never been diagnosed with cancer.

Olaparib with Cediranib or Ceralasertib for People with Advanced or Metastatic Breast Cancer and with a BRCA1 or BRCA2 Mutation

https://www.facingourrisk.org/research-clinical-trials/study/304 /olaparib-with-cediranib-or-ceralasertib-for-people-with-advanced-or-metastatic-breast-cancer-and-with-a-brca1-or-brca2-mutation

Treatment
Treatment study for people with advanced breast cancer who have a BRCA1 or BRCA2 genetic mutation and who were previously treated with a PARP inhibitor

This study is for people with advanced or metastatic breast cancer, have a BRCA1 or BRCA2 genetic mutation and were previously treated with a PARP inhibitor. The study will examine how effective  Olaparib in combination with Cediranib or Ceralasertib is in reducing the size of cancer and determining the length of time patients respond well to the treatment.

Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents (EvoPAR-PR01)

https://www.facingourrisk.org/research-clinical-trials/study/339 /studying-the-effectiveness-of-new-parp-inhibitor-saruparib-compared-to-current-treatment-options-for-metastatic-prostate-cancer-evopar-pro1

Treatment
Treatment study for metastatic, castration-sensitive prostate cancer

This study will evaluate an investigational PARP inhibitor drug called Saruparib in combination with new hormonal agents in the treatment of metastatic prostate cancer, compared to the current standard treatment available. The study will enroll people whose tumors have mutations in the following genes: BRCA1, BRCA2, ATM, BARD1, CDK12, PALB2, RAD51B, RAD51C, RAD51D

Acting on Cancer Testing Together (ACT-Together)

https://www.facingourrisk.org/research-clinical-trials/study/326 /acting-on-cancer-testing-together-act-together


This is a study for women diagnosed with BRCA 1 or BRCA2 focused on increasing education on options for reducing cancer risk associated with their diagnosis

The goal of this research study is to develop a new education program, called the ACT-Together intervention, to educate and support women who test positive for the BRCA1 or BRCA2 mutation on how they can reduce their risk of cancer in an online group setting.

Understanding Risk Factors for Stomach Cancer in People with Inherited Mutations

https://www.facingourrisk.org/research-clinical-trials/study/332 /understanding-risk-factors-for-stomach-cancer-in-people-with-inherited-mutations

Surveys, Registries, Interviews
Online survey on stomach cancer risk for people with an inherited mutation in genes that are linked to an increased risk of certain cancers

The purpose of this study is to understand gastric (stomach) cancer risk among people with an inherited (germline) mutation in genes that are linked to an increased risk of certain cancers, including APC, ATM, BRCA1, BRCA2, CDH1, CHEK2, PALB2, Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM), MUTYH, STK11, and other genes linked to increased cancer risk. 

Understanding the Emotional and Social Experiences of Individuals Diagnosed with Ovarian Cancer

https://www.facingourrisk.org/research-clinical-trials/study/335 /understanding-the-emotional-and-social-experiences-of-individuals-living-with-ovarian-cancer

Surveys, Registries, Interviews
Survey for people diagnosed with ovarian cancer

A survey for people diagnosed with ovarian cancer to share your experiences, social support, and self-compassion following your diagnosis. 

CHANCES: Studying the Connection Between Chemotherapy Exposure and Secondary Cancers of the Blood in Ovarian and other Cancer Survivors

https://www.facingourrisk.org/research-clinical-trials/study/325 /chances-studying-the-connection-between-chemotherapy-exposure-and-secondary-cancers-of-the-blood-in-ovarian-cancer-survivors

Surveys, Registries, Interviews
Registry for people who completed treatment for ovarian cancer

The primary goal of the study is to identify risk factors for developing secondary blood cancers and to understand how chemotherapy and PARP inhibitor exposure influence clonal changes in the blood that may predispose to later development of a blood cancer.

Cognitive Training for Breast Cancer Survivors with Memory and Thinking Problems

https://www.facingourrisk.org/research-clinical-trials/study/312 /cognitive-training-for-breast-cancer-survivors-with-memory-and-thinking-problems

Quality of Life
How well cognitive training helps breast cancer survivors with their memory and thinking problems

This study will explore how well cognitive training helps breast cancer survivors with their memory and thinking problems caused by cancer.

PATROL Study: Prostate Cancer Screening for People AT Genetic Risk FOr Aggressive Disease

https://www.facingourrisk.org/research-clinical-trials/study/291 /patrol-study-prostate-cancer-screening-for-people-at-genetic-risk-for-aggressive-disease

Prevention
Screening study for people with a mutation linked to prostate cancer risk

The PATROL (Prostate Cancer Screening for People AT Genetic Risk FOr Aggressive Disease) study is for people at risk for prostate cancer because they carry one or more genes that are known or suspected to increase prostate cancer risk: BRCA2, HOXB13, ATM, BRCA1, MLH1, MSH2, MSH6, PALB2, PMS2, CHEK2, RAD51D, or TP53.

Social Support and Coping Strategies Among LGBTQIA+ Cancer Patients

https://www.facingourrisk.org/research-clinical-trials/study/303 /social-support-and-coping-strategies-among-lgbtqia-cancer-patients

Surveys, Registries, Interviews
Survey for LGBTQIA+ cancer patients who reside in the United States

This study explores how different levels of support systems influence coping strategies among LGBTQIA+ cancer patients.

The DETECT Study: Detecting Endometrial Cancer in Tampons

https://www.facingourrisk.org/research-clinical-trials/study/306 /the-detect-study-detecting-endometrial-cancer-in-tampons

Prevention
Early detection of endometrial cancer in women undergoing hysterectomy surgery at the University of Alabama

This study will test whether endometrial samples from tampons can be used for early detection of endometrial cancer and is open to women over 45 years of age who are undergoing hysterectomy surgery (surgery to remove the uterus)

Treating Metastatic Pancreatic Cancer Using a New Combination of Chemotherapy Drugs in People with a BRCA1, BRCA2 or PALB2 genetic or tumor mutation (The PLATINUM Trial)

https://www.facingourrisk.org/research-clinical-trials/study/338 /treating-metastatic-brca1-brca2-or-palb2-pancreatic-cancer-using-a-new-combination-of-chemotherapy-drugs


Treatment study for people with metastatic pancreatic cancer and a BRCA1, BRCA2 or PALB2 mutation

This study will compare a 3-drug chemotherapy combination (NABPLAGEM; gemcitabine, cisplatin, nab-paclitaxel) to a 2-drug chemotherapy combination (gemcitabine/nab-paclitaxel) to treat people with an inherited and/or tumor-associated BRCA1, BRCA2 or PALB2 mutation who have pancreatic cancer that has progressed on front-line treatment with FOLFIRINOX/NALIRIFOX (fluorouracil, irinotecan, leucovorin and oxaliplatin). 

Effectiveness of Lymph Node Mapping to Reduce the Risk of Swelling in the Legs in Patients with Stage I Endometrial Cancer

https://www.facingourrisk.org/research-clinical-trials/study/310 /effectiveness-of-lymph-node-mapping-to-reduce-the-risk-of-swelling-in-the-legs-in-patients-with-stage-i-endometrial-cancer

Treatment
People with stage I endometrial cancer who are having a hysterectomy

This study compares the effect of sentinel lymph node mapping to standard lymph node dissection in reducing the risk of swelling in the legs (lymphedema) in patients undergoing a hysterectomy for stage I endometrial cancer.

The LiFT UP Li-Fraumeni & TP53: Understanding & Progress Study

https://www.facingourrisk.org/research-clinical-trials/study/307 /the-lift-up-study

Surveys, Registries, Interviews
Study looking at cancer risk for people with Li-Fraumeni syndrome

The LiFT UP Study is a research project for individuals and families from around the world. The goal is to learn more about adults and children who have a change in the TP53 gene in their blood to better predict their specific cancer risks. 

Registry to Discover New Treatments and Developmental Processes of Colorectal and Endometrial Cancer in Patients with Hereditary Cancer

https://www.facingourrisk.org/research-clinical-trials/study/301 /registry-to-discover-new-treatments-and-developmental-processes-of-colorectal-and-endometrial-cancer-in-patients-with-hereditary-cancer

Surveys, Registries, Interviews
Registry for people who screen for colorectal endometrial cancer

This research registry will collect and save data, cancer samples and family health history information to discover new ways cancer develops. It will look to find new genes that could be used for treatments and preventing cancer for people with hereditary cancer.

Study of a New Treatment Called ONM-501 Alone and in Combination with Immunotherapy for Triple Negative Breast Cancer, Advanced Solid Tumors and Lymphomas

https://www.facingourrisk.org/research-clinical-trials/study/311 /study-of-a-new-treatment-called-onm-501-alone-and-in-combination-with-cemiplimab-in-people-with-triple-negative-breast-cancer-advanced-solid-tumors-and-lymphomas

Treatment
Treatment study for people with triple negative breast cancer, advanced solid tumors or lymphomas

This study is looking at the safety and best dose for treatment with the drug ONM-501 alone or in combination with immunotherapy for treating advanced solid tumors or lymphomas. 

Understanding the Cancer Journey: A Survey of Patient Experiences and Emotional Impact

https://www.facingourrisk.org/research-clinical-trials/study/319 /understanding-the-cancer-journey-a-survey-of-patient-experiences-and-emotional-impact


Online survey for people diagnosed with breast, colorectal, gastric or prostate cancer within the past twenty years

Researchers are conducting a survey of cancer patients who were diagnosed with breast, colorectal, gastric or prostate cancer within the past twenty years. The aim is to gather information about their diagnosis, treatment, and personal experiences of battling cancer. The survey will collect data on the type of cancer, diagnosis, treatment plan, medications used, and personal stories throughout the journey to help gain a better understanding of the emotional and psychological impact of cancer on patients.

Treating Metastatic Prostate Cancer with a New PARP Inhibitor AZD5305 in Combination With Hormone Therapy (PETRANHA)

https://www.facingourrisk.org/research-clinical-trials/study/329 /treating-metastatic-prostate-cancer-with-a-new-parp-inhibitor-azd5305-combined-with-hormone-therapy


Treatment study for metastatic prostate cancer

This study will look at the effectiveness of a new PARP inhibitor drug called AZD5305 in combination with different hormone therapies to treat metastatic prostate cancer, compared to the current standard treatment.

The Phoenix Trial: Cemiplimab for Patients with Localized dMMR Colon Cancer

https://www.facingourrisk.org/research-clinical-trials/study/299 /the-phoenix-trial-cemiplimab-for-patients-with-localized-dmmr-colon-cancer

Treatment
Treatment study for people with localized colon cancer who have dMMR

This study will examine the effectiveness and safety of cemiplimab, a treatment given prior to surgery. Participants will undergo endoscopy after the therapy and take CT scans to assess the effects of the therapy. The study also will compare genes of pretreatment cancer samples between patients who responded well to the therapy and patients who did not.

ShareForCures®: Susan G. Komen's People-Powered, Data-Driven Breast Cancer Research Registry

https://www.facingourrisk.org/research-clinical-trials/study/295 /shareforcures-susan-g-komens-people-powered-data-driven-breast-cancer-research-registry

Surveys, Registries, Interviews
Registry for anyone diagnosed with breast cancer

Today, researchers are learning about breast cancer from a small subset of patients, who are not representative of all breast cancer patients. ShareForCures® is an online registry that offers people who have been diagnosed with breast cancer a way to participate in research by connecting information about themselves with their breast cancer diagnosis, medical records, genomics. Participation is open to anyone adult, living in the United States, and who has been diagnosed with breast cancer.

The Risk Factor Analysis of Hereditary Breast and Ovarian Cancer In Women with BRCA1, BRCA2 or PALB2 Mutations

https://www.facingourrisk.org/research-clinical-trials/study/120 /the-risk-factor-analysis-of-hereditary-breast-and-ovarian-cancer-in-women-with-brca1-brca2-or-palb2-mutations

Surveys, Registries, Interviews
Study for people who have a BRCA1, BRCA2, or PALB2 genetic mutation

Those who carry the BRCA1, BRCA2 or PALB2 gene mutations experience a higher lifetime risk of developing breast and ovarian cancer, but we need to know more about the other genetic and non-genetic factors that may also influence risk. This study follows women with these gene mutations over time, striving to build the evidence we need to help them and others make better decisions to protect their health.

Cancer Risk Perception and Management of Individuals With a BRCA1 or BRCA2 Mutation Who Were Assigned Male at Birth (AMAB)

https://www.facingourrisk.org/research-clinical-trials/study/324 /cancer-risk-perception-and-management-in-brca12-carriers-assigned-male-at-birth-amab


Research study enrolling individuals assigned male at birth (AMAB) who have a BRCA1 and/or BRCA2 mutation

This study seeks to explore the experiences of individuals with BRCA1 or BRCA2 mutations who were assigned male at birth. We aim to understand your journey to genetic testing and how you perceive and manage your cancer risks.

High Dose Testosterone Treatment for People with Metastatic Prostate Cancer and an ATM, CDK12 or CHEK2 Mutation

https://www.facingourrisk.org/research-clinical-trials/study/294 /high-dose-testosterone-treatment-for-people-with-metastatic-prostate-cancer-and-an-atm-cdk12-or-chek2mutation

Treatment
People who have metastatic castration-resistant prostate cancer with an ATM, CDK12, or CHEK2 mutation

This study will examine how well an increased dose of testosterone treatment works for people with metastatic castration-resistant prostate cancer (mCRPC) with an ATM, CDK12, or CHEK2 genetic mutation. Participants will continue to receive the medication as long as their cancer doesn’t get worse and they do not experience severe side effects.

Cancer Previvorship and Survivorship and Gender-Affirming Hormones in Transgender Individuals

https://www.facingourrisk.org/research-clinical-trials/study/320 /cancer-previvorship-and-survivorship-and-gender-affirming-hormones-in-transgender-individuals


Survey and interview for people who are transgender with a predisposition to cancer who are interested in or taking gender-affirming hormones

We are recruiting transgender, non-binary, and gender expansive people to join a research study. We want to learn how to better provide cancer prevention and gender affirming care. If you are at risk for cancer, we want to hear about your experiences talking to your doctor about gender-affirming hormones and cancer risk.

Exploring Awareness of Fertility Preservation Options in Patients at Risk of Iatrogenic Infertility. Role of Genetic Counselors

https://www.facingourrisk.org/research-clinical-trials/study/322 /awareness-of-fertility-preservation-options-in-patients-affected-by-cancer


Online anonymous survey for adults treated in the US for cancer

To explore patients' awareness of how medical treatments may affect fertility and identify helpful resources for future patients through a 10-15 minutes anonymous online survey. Enrollment ends on February 28,2025. Eligibility: Adults treated in the US for cancer, thalassemia, or sickle cell disease.

Screening Study for Men at High Genetic Risk for Prostate Cancer

https://www.facingourrisk.org/research-clinical-trials/study/72 /men-at-high-genetic-risk-for-prostate-cancer

Prevention
Prostate screening with MRI for men with Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM) or a BRCA1, BRCA2, HOXB13, ATM, NBN, TP53, BRIP1, CHEK2, PALB2, RAD51C, RAD51D, or other mutation

The National Institutes of Health has a clinical trial for men at high genetic risk for prostate cancer. This is trial is for men without prostate cancer, ages 30 to 75, who have tested positive for Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM) or BRCA1, BRCA2, HOXB13, ATM, NBN, TP53, BRIP1, CHEK2, PALB2, RAD51C, RAD51D, or FANC (FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, and FANCM). The trial involves screening MRI of the prostate every two years and biopsy of the prostate if the MRI is abnormal. There is no cost for travel or study-related tests. 

Vaccines for Pancreatic Cancer After Chemotherapy

https://www.facingourrisk.org/research-clinical-trials/study/318 /vaccines-for-pancreatic-cancer-after-chemotherapy-and-prior-to-surgery


Treatment study for people with pancreatic cancer

This study is looking at the safety of, and the immune system response to a vaccine in people diagnosed with pancreatic cancer. The vaccine will  be administered after chemotherapy. The vaccine will incorporate proteins that can trigger an immune response and will be given along with a drug called poly-ICLC which can also activate immune cells.

Denosumab for Breast Cancer Risk Reduction in Women With an Inherited BRCA1 Mutation (The Breast Cancer Prevention Study)

https://www.facingourrisk.org/research-clinical-trials/study/196 /denosumab-for-breast-cancer-risk-reduction-in-women-with-an-inherited-brca1-mutation-the-breast-cancer-prevention-study


Prevention study enrolling women ages 25-55 with a BRCA1 mutation

This is a study to test the effectiveness of a drug (denosumab) on preventing the development of breast cancer in women with an inherited BRCA1 mutation.

Denosumab is a drug that is currently used to treat bone loss in order to reduce the risk of broken bones in healthy people, and is also used to reduce new bone growths in cancer patients whose cancer has spread to their bones. Research has shown that denosumab may also reduce the risk of developing breast cancer in women with an inherited BRCA1 mutation.

Carboplatin Chemotherapy before Surgery for Patients with High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation

https://www.facingourrisk.org/research-clinical-trials/study/286 /swog-s2210-carboplatin-chemotherapy-before-surgery-for-patients-with-high-risk-prostate-cancer-and-an-inherited-brca1-or-brca2-gene-mutation

Treatment
Treatment before surgery for people with high-risk prostate cancer and an inherited BRCA1 or BRCA2 gene mutation

This study tests how well carboplatin before surgery works in treating patients with high-risk prostate cancer who have inherited BRCA1 or BRCA2 gene mutations. The purpose of the study is to treat men with BRCA1 or BRCA2 mutations who are at higher risk of prostate cancer after surgery (removal of the prostate) compared to patients without these mutations.

Validating a Blood Test for Early Ovarian Cancer Detection in High-risk Women and Families: MicroRNA Detection Study (MiDE)

https://www.facingourrisk.org/research-clinical-trials/study/138 /validating-a-blood-test-for-early-ovarian-cancer-detection-in-high-risk-women-and-families

Prevention
Screening study for women with a BRCA1, BRCA2, BRIP1, PALB2, RAD51C, RAD51D, PMS2, MLH1, MSH2, MSH6, or EPCAM mutation

The goal of MiDe is to develop a clinical diagnostic test to detect early onset ovarian cancer, as currently, there are no good screening or early detection tests available. Participants can be expected to provide up to 4 tubes of blood every 6 months for up to 5 years. We can collect these samples through mobile phlebotomy all around the US. The study is enrolling people with an inherited mutation with a gene linked to ovarian cancer, such as BRCA1, BRCA2, BRIP1, PALB2, RAD51C, RAD51D, PMS2, MLH1, MSH2, MSH6, or EPCAM. Participants can be expected to provide up to 4 tubes of blood every 6 months for up to 5 years. We can collect these samples through mobile phlebotomy all around the US.

Using ctDNA Blood Test for Earlier Detection and Treatment of Recurrence or Spread after Treatment for Stage 3 Colon Cancer

https://www.facingourrisk.org/research-clinical-trials/study/283 /using-ctdna-for-earlier-detection-and-treatment-of-recurrence-or-spread-after-treatment-for-stage-3-colon-cancer

Treatment
Monitoring and treatment study for people who completed treatment for stage 3 colon cancer

The usual care after a person with stage 3 colon cancer has had surgery and chemotherapy is to begin active surveillance. This is a time when no additional treatment is given, but instead patients have frequent imaging scans to see if their cancer has come back.

This study is looking at whether a blood test known as circulating tumor DNA (ctDNA) can find signs of remaining cancer or recurrence after treatment earlier than standard active surveillance. People in the study who have evidence of cancer in their ctDNA test may receive additional treatment based on their test results. The goal of this study is to learn if using ctDNA and additional treatment improves outcomes in people after treatment for stage 3 colon cancer. Currently, testing with ctDNA is not part of standard of care to determine if colon cancer treatment was successful or if there is a recurrence. 

Combining the Immunotherapy Dostarlimab and PARP Inhibitor Niraparib for Advanced or Metastatic Breast, Ovarian or Pancreatic Cancer with an Inherited or Tumor BRCA Mutation

https://www.facingourrisk.org/research-clinical-trials/study/231 /immunotherapy-and-parp-inhibitor-for-advanced-or-metastatic-breast-ovarian-or-pancreatic-cancer-with-a-brca-mutation


Treatment study for people with advanced breast, ovarian or pancreatic cancer and an inherited or tumor BRCA mutation

This study is looking at the effectiveness of combining a PARP inhibitor called niraparib and an immunotherapy called dostarlimab for treating people with an inherited BRCA mutation (found with genetic testing) or a tumor mutation (found through tumor testing) who have breast, pancreatic, ovarian, fallopian tube or primary peritoneal cancer that is metastatic or advanced and cannot be removed by surgery (unresectable).

Comparing a Combination of Drugs for Treatment of HER2-positive Colorectal Cancer as First Line Treatment in the Metastatic Setting

https://www.facingourrisk.org/research-clinical-trials/study/274 /treatment-of-her2-positive-colorectal-cancer-as-first-line-treatment-in-the-metastatic-setting

Treatment
People with HER2-positive colorectal cancer who have not yet received treatment in the metastatic setting

This study is being done to decide if the drug Tukysa (Tucatinib) combined with other cancer drugs works better than the standard of care, which is chemotherapy treatment for people with a specific type of colorectal cancer called HER2 positive colorectal cancer. The study also aims to understand the side effects of the combination of these drugs in treatment. The combination of drugs being used are Tukysa (Tucatinib), Herceptin (Trastuzumab), and mFOLFOX6, which is a combination of Oxaliplatin, Leucovorin, Levoleucovorin, and Fluorouracil.

Ethical Challenges in Genetic Testing for Terminally Ill People and their Families

https://www.facingourrisk.org/research-clinical-trials/study/315 /a-study-on-ethical-challenges-in-genetic-testing-for-terminally-ill-patients-and-their-families


Interview of palliative care patients and/or their adult family members who have been offered and involved in genetic testing or counseling

This study will interview palliative care patients and/or their adult family members (spouse, parents, children, siblings) who have been offered and involved in genetic testing or counseling related to the condition for which the patients are receiving palliative care.

Study of Colorectal Cancer and Genetics in Hispanic and Latino People (ENLACE Study)

https://www.facingourrisk.org/research-clinical-trials/study/276 /study-of-colorectal-cancer-and-genetics-in-hispanic-and-latino-people-enlace-study

Treatment
Hispanic and Latino people diagnosed with colorectal cancer

The ENLACE study will learn more about colorectal cancer in Hispanic people so that treatment can be improved. Results may help your doctor choose your treatment and help you find out if you are eligible for a clinical trial. Your results may also help family members understand their cancer risks. People will have blood drawn and complete a questionnaire to join the study. Genetic testing will be done on your blood and the tissue from your tumor biopsy or surgery to test the genes that you inherited. You do not have to pay for the genetic testing. You will receive the results of your test from your oncologist and genetic counseling may be recommended. Two weeks and one year after talking with your doctor about your test results, you will complete follow-up questionnaires either in person or over the phone. 

Pancreatic Cancer Early Detection for People at High Risk

https://www.facingourrisk.org/research-clinical-trials/study/227 /pancreatic-cancer-early-detection-for-people-at-high-risk

Prevention
Registry and biobank for high risk people undergoing pancreatic cancer screening

The study will collect clinical information, family history, and samples (blood, saliva or cheek swab) from people and families at risk for pancreatic cancer. Collecting this information and samples will create a resource to drive research necessary for early detection and prevention of pancreatic ductal adenocarcinoma (PDAC).

Roadmap to Parenthood: A Study about Fertility and Family-Building After Cancer

https://www.facingourrisk.org/research-clinical-trials/study/302 /roadmap-to-parenthood-a-study-about-fertility-and-family-building-after-cancer


A survey for people aged 18-45, assigned female at birth, and history of a cancer diagnosis

Roadmap to Parenthood is a remote, survey-based study. Eligible participants must be aged 18-45, assigned female at birth, and history of a cancer diagnosis. this study to evaluate an online tool developed to educate and provide support to women and people assigned female at birth who are interested in family building after cancer. This study involves the completion of four online surveys. All study procedures are done remotely.

Collecting Blood and Stool Samples to Detect Colorectal Cancer or Precancerous Polyps in Lynch Syndrome Patients (CORAL Study)

https://www.facingourrisk.org/research-clinical-trials/study/256 /early-detection-of-colorectal-cancer-for-people-with-lynch-syndrome

Prevention
People with Lynch Syndrome at risk for colon cancer

This study will colect blood and stool samples to detect colorectal cancer or precancerous polyps in people with Lynch syndrome and those diagnosed with early onset colorectal cancer, diagnosed younger than 50 years old. 

Study of the PARP inhibitor AZD9574 Alone and Combined with Other Cancer Medicines to Treat People with Advanced Solid Cancers (CERTIS1 Study)

https://www.facingourrisk.org/research-clinical-trials/study/282 /study-of-the-parp-inhibitor-azd9574-alone-and-combined-with-other-cancer-medicines-to-treat-people-with-advanced-solid-cancers-certis1-study

Treatment
Treatment study for people with advanced breast, ovarian, pancreatic or prostate cancer or gliomas

This research involves studying a drug called AZD9574 on its own and in combination with other anti-cancer drugs in people with advanced cancer that has come back or progressed. AZD9574 is a type of targeted therapy known as a PARP inhibitor. The study aims to understand the safety, tolerance, how the drug moves in the body, how it affects the body, and its initial effectiveness.

Study of the Drug Sovilnesib in People with Ovarian Cancer

https://www.facingourrisk.org/research-clinical-trials/study/308 /study-of-the-drug-sovilnesib-in-people-with-ovarian-cancer


Treatment study for people with platinum-resistant ovarian cancer

This study will test the safety and effectiveness of the drug sovilnesib in patients with ovarian cancer.

Mastectomy Decision Support Study

https://www.facingourrisk.org/research-clinical-trials/study/313 /mastectomy-decision-support-study


Individual interviews with women who had or are considering a bilateral mastectomy to receive feedback on materials that inform about the emotional implications of the surgery

The purpose of this study is to get participants’ opinions on the content, format, and design of educational materials that inform about the emotional consequences of undergoing a bilateral mastectomy.

The WISDOM Study: Women Informed to Screen Depending on Measures of Risk

https://www.facingourrisk.org/research-clinical-trials/study/45 /wisdom-study

Prevention
Genetic testing and breast cancer screening

The goal of the Wisdom Study is to determine if breast cancer screening can be made better by personalizing each woman’s mammogram schedule, compared to the current one-size-fits-all, annual approach. The Wisdom Study is designed to end the confusion about when to start and how often to have a mammogram. 

MRI Screening in Men at High Risk of Developing Prostate Cancer

https://www.facingourrisk.org/research-clinical-trials/study/260 /screening-in-men-at-high-risk-of-developing-prostate-cancer

Prevention
Screening using MRI for men at risk of developing prostate cancer

This study will determine if prostate magnetic resonance imaging (MRI) will find prostate cancer in men at high risk of developing prostate cancer.

Studying People and Families Affected by Li-Fraumeni Syndrome (TP53 Mutation )

https://www.facingourrisk.org/research-clinical-trials/study/267 /observing-people-who-have-li-fraumeni-syndrome-tp53-genetic-mutation

Surveys, Registries, Interviews
Registry for people with Li-Fraumeni syndrome (LFS) or from LFS families

The goal of this study is to identify whether Li-Fraumini syndrome (LFS), which has a high lifetime cancer risk, has any other causes besides the TP53 mutation. The study involves people with Li-Fraumeni syndrome and people from families with Li-Fraumeni syndrome filling out questionnaires with their medical information.

Studies for People with ER-Positive, HER2-Negative Advanced or Metastatic Breast Cancer (TACTIVE-U)

https://www.facingourrisk.org/research-clinical-trials/study/279 /treatment-studies-for-people-with-er-positive-her2-negative-advanced-or-metastatic-breast-cancer-tactive-u


Treatment for ER-positive, HER2-negative metastatic breast cancer

Researchers at Pfizer and Arvinas are conducting the TACTIVE-U studies for people with ER-positive, HER2-negative advanced or metastatic breast cancer who have received at least one prior round of treatment and no more than two prior rounds of treatments for advanced or metastatic disease. One of these rounds of treatment must have included a CDK4/6 inhibitor (e.g., Kisqali, Verzenio, Ibrance). The TACTIVE-U studies are looking at the safety of an oral study medicine, ARV-471 (also known as vepdegestrant), and how well it works when combined with other breast cancer medicines.

A Surveillance Program for Women at High Risk for Breast Cancer (CAPSBRACA)

https://www.facingourrisk.org/research-clinical-trials/study/271 /a-surveillance-program-for-women-at-high-risk-for-breast-cancer-capsbraca

Surveys, Registries, Interviews
Screening study for women at risk for breast cancer due to an inherited mutation or other risk factor

Screening study for women at risk for breast cancer due to an inherited mutation or other risk factor. The study will create a registry of women at high risk of breast cancer. A registry collects data about specific populations to understand them better. This study will also look at whether an abbreviated MRI works as well as a full MRI for screening women at high risk of breast cancer.

Testing a Vaccine for Treating or Preventing Triple-Negative Breast Cancer

https://www.facingourrisk.org/research-clinical-trials/study/285 /treatment-study-for-people-with-stage-2-or-3-triple-negative-breast-cancer-at-high-risk-for-recurrence


Treatment study for people with stage 2 or 3 triple-negative breast cancer at high risk for recurrence

Researchers are studying the affects of this breast cancer vaccine on the immune system in two groups of people:

UPLIFT: Cancer Caregivers Study

https://www.facingourrisk.org/research-clinical-trials/study/309 /uplift-cancer-caregivers-study


Survey for cancer caregivers of an LGBTQIA+ family member or friend

Survey for cancer caregivers of an LGBTQIA+ family member or friend to understand the impact of caregiving on the mental, physical, and financial well-being of LGBTQ+ people providing unpaid care

Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High-Risk Women (TUBA/WISP II)

https://www.facingourrisk.org/research-clinical-trials/study/205 /risk-reducing-salpingectomy-with-delayed-oophorectomy-as-an-alternative-to-risk-reducing-salpingo-oophorectomy-in-high-risk-women

Prevention
Prevention study for women at high risk for ovarian cancer

This study is looking at whether removal of the fallopian tubes (salpingectomy) followed by removal of the ovaries (oophorectomy) at a later date closer to the time of natural menopause may reduce the risk of ovarian cancer nearly as much as removing both the ovaries and fallopian tubes at the same time (salpingo-oophorectomy) among women with an inherited BRCA1, BRCA2, BRIP1, RAD51C or RAD51D mutation. Removing the fallopian tubes only first and the ovaries at a later time closer to natural menopause may lessen menopausal symptoms while still lowering the risk for ovarian cancer.

 

Young, Empowered & Strong: Web-Based Symptom Monitoring and Self-Management for Young Adult Breast Cancer Survivors (YES Study)

https://www.facingourrisk.org/research-clinical-trials/study/199 /young-empowered-strong-web-based-symptom-monitoring-and-self-management-for-young-adult-breast-cancer-survivors


Women diagnosed with breast cancer between the ages of 15-39

The goal of this study is to measure whether a web-based patient-reported symptom monitoring and self management portal, Young, Empowered & Strong (YES), improves the quality of life of young breast cancer survivors when compared to standard of care symptom management. 

A Study of Targeted Therapies for Patients With Recurrent Endometrial Cancer

https://www.facingourrisk.org/research-clinical-trials/study/245 /a-study-of-different-targeted-therapies-for-patients-with-recurrent-or-persistent-endometrial-cancer

Treatment
Phase 2 treatment study for recurrent endometrial cancer

This study is to test the safety and effectiveness of different kinds of targeted therapy with or without atezolizumab (or Tecentriq) in individuals with recurrent or persistent endometrial cancer. Participants will be placed into study groups based on their tumor.

 

FORCE Survey for People at Increased Risk for Colorectal, Pancreatic or Prostate Cancer

https://www.facingourrisk.org/research-clinical-trials/study/287 /survey-for-people-at-increased-risk-for-breast-or-gynecologic-cancer-due-to-an-inherited-mutation


Survey for people at high risk for Colorectal, Pancreatic or Prostate Cancer

FORCE is conducting a short survey to better understand the unmet needs of people who are at high risk for colorectal, pancreatic or prostate cancer. You can take the survey here. 

A Study Comparing Two Anti-inflammatory Medications Naproxen or Aspirin for Cancer Prevention in Lynch Syndrome

https://www.facingourrisk.org/research-clinical-trials/study/281 /studying-the-use-of-naproxen-and-aspirin-for-cancer-prevention-in-people-with-lynch-syndrome

Prevention
Prevention study for people with Lynch syndrome

The trial is enrolling people with Lynch syndrome. On average, the length of this study will last one year from the start of enrollment to completion. The study will measure  the effect of naproxen or aspirin on the immune cells in the gastrointestinal tract of people with Lynch syndrome. The trial will also evaluate any symptoms from the medications and any other changes of the colon and rectum.

Kindred Study

https://www.facingourrisk.org/research-clinical-trials/study/255 /kindred

Surveys, Registries, Interviews
Interviews with African American people who tested positive for a genetic mutation

We are talking with African American adults about cancer genetic testing, including those that have received a positive cancer genetic testing result and people with a family member who received testing. We are learning about new and improved ways to support African American individuals and families before, during and after they participate in cancer genetic testing.

TAPUR Study: Testing FDA Approved Drugs Targeting Tumor Biomarkers in People with Advanced Stage Cancer

https://www.facingourrisk.org/research-clinical-trials/study/262 /tapur-study-testing-fda-approved-drugs-targeting-tumor-gene-abnormalities-in-people-with-advanced-stage-cancer

Treatment
Cancer treatment study for people with advanced solid tumors

The TAPUR Study aims to describe the safety and efficacy of Food and Drug Administration (FDA)-approved, targeted anticancer drugs prescribed for treatment of patients with advanced cancer that has a potentially actionable genomic alteration.

Self -Perception and Intimacy After the Cancer Experience (SPICE)

https://www.facingourrisk.org/research-clinical-trials/study/247 /self-perception-and-intimacy-after-the-cancer-experience-spice

Surveys, Registries, Interviews
Online survey for cancer survivors ages 18-39 years old about sexual health

SPICE is an online survey that asks questions about your sexuality, sexual health knowledge, interpersonal relationships, and body image. Participants will be asked questions about their body image, impact of cancer, relationships, and how they feel about their sexuality.

PreCharge: Digital Program for People Affected by Hereditary Cancer

https://www.facingourrisk.org/research-clinical-trials/study/292 /precharge-digital-program-for-people-with-hereditary-cancer-syndromes


Study to help people affected by hereditary cancer and who have not been diagnosed with cancer improve their mental and emotional well-being

PreCharge is an IRB approved, nationwide study funded by the National Cancer Institute. The purpose of this study is to test a digital program designed to help people affected by hereditary cancer and who have not been diagnosed with cancer improve their mental and emotional well-being.

Metastatic Castration Resistant Prostate Cancer Clinical Trial

https://www.facingourrisk.org/research-clinical-trials/study/240 /metastatic-castration-resistant-prostate-cancer-clinical-trial

Treatment
Treatment study for men with metastatic castration resistant prostate cancer

Metastatic prostate cancer that no longer responds to hormone therapy is called metastatic castration resistant prostate cancer (mCRPC). This clinical trial may be an option for you if you have been diagnosed with mCRPC that has spread or gotten worse since your last treatment. Participants will be randomly assigned to receive the current standard of care medicine, enzalutamide, or PF-06821497 (study medicine) orally in combination with enzalutamide.

Exploring the Attitudes of Those Who Tested Positive for an Adult-Onset Cancer Predisposition as a Minor

https://www.facingourrisk.org/research-clinical-trials/study/316 /exploring-the-attitudes-of-those-who-tested-positive-for-an-adult-onset-cancer-predisposition-as-a-minor


Survey and interview for people who tested positive for an adult-onset cancer predisposition as a minor

This study aims to interview those who tested positive for an adult-onset cancer predisposition as a minor to highlight their attitudes regarding predispositional genetic testing in childhood. Results may help guide clinicians in how they approach and navigate conversations about genetic testing in presymptomatic minors.

My Best GI Eating Study

https://www.facingourrisk.org/research-clinical-trials/study/258 /my-best-gi-eating-study


Diet and weight loss study for people who are overweight and at increased risk of colorectal cancer

This study will test three different diets in people who are overweight and who have an increased risk of colorectal cancer. The study will look at whether these diets improve eating and possibly lead to weight loss. 

 

Treating Metastatic Solid Tumors with an Inherited or Acquired Gene Mutation Using the PARP Inhibitor Talazoparib

https://www.facingourrisk.org/research-clinical-trials/study/230 /treating-metastatic-solid-tumors-with-an-inherited-or-acquired-gene-mutation-using-the-parp-inhibitor-talazoparib

Treatment
Treatment study for people with advanced solid tumors

This study is looking whether the drug Talazoparib (also known as Talzenna) is safe and effective for treating people with advanced solid cancers (including breast, gastric, ovarian, pancreatic, prostate or other solid tumors) in people with an inherited mutation (found through genetic testing) or an acquired mutation (found with biomarker testing) in ATM, ATR, BRCA1, BRCA2, BRIP1, BAP1, BARD1, CDK12, CHEK1, CHEK2, IDH1, IDH2, MRE11A, NBN, PALB2, RAD50, RAD51, RAD51B, RAD51C, RAD51D, RAD54L or other genes.

A clinical trial for people with ER-positive, HER2-negative advanced (locally advanced or metastatic) breast cancer: VERITAC-2

https://www.facingourrisk.org/research-clinical-trials/study/269 /studies-for-people-with-er-positive-her2-negative-advanced-or-metastatic-breast-cancer-veritac-studies


A clinical trial for ER-positive, HER2-negative advanced breast cancer

Researchers at Pfizer and Arvinas are conducting the VERITAC-2 cinical trial for people with ER-positive, HER2-negative advanced (locally advanced or metastatic) breast cancer that has profressed after previous treatment. This clinical trial is specifically for people who have already been treated with CDK4/6 inhibitor* therapy in combination with hormone therapy for their locoregional recurrent/metastatic disease.

* CDK4/6 inhibitors include medications called palbociclib (IBRANCE®), ribociclib (KISQALI®), and abemaciclib (Verzenio®).

A Randomized Study of Olaparib or Placebo in Patients with Surgically Removed Pancreatic Cancer who have a BRCA1, BRCA2 or PALB2 Mutation (APOLLO)

https://www.facingourrisk.org/research-clinical-trials/study/140 /olaparib-or-placebo-in-patients-with-surgically-removed-pancreatic-cancer-who-have-a-brca1-brca2-or-palb2-mutation

Treatment
Treatment study for pancreatic cancer in people with a BRCA1, BRCA2, or PALB2 mutation

The usual approach for patients with curable (i.e., non-metastatic) pancreatic cancer is a combination of surgery, FDA-approved chemotherapy, radiation (in select cases), then surveillance monitoring. This means that patients are typically monitored by their oncologist for evidence that the cancer has returned (recurrence), but they receive no additional treatment after the completion of surgery and chemotherapy.

The purpose of EA2192 / APOLLO is to compare the usual approach (observation) to treatment for one year with a drug called olaparib, in patients with BRCA1, BRCA2 or PALB2 mutation. EA2192 / APOLLO will help the study doctors find out if this different approach is better, the same, or worse than the usual approach. To decide if it is better, the study doctors will be looking to see if olaparib delays cancer recurrence compared to the usual approach of surveillance. 

Cancer Prevention Vaccine (Nous-209) for People with Lynch Syndrome

https://www.facingourrisk.org/research-clinical-trials/study/278 /cancer-prevention-vaccine-nous-209-for-people-with-lynch-syndrome


Prevention study for people with Lynch syndrome

This study is testing a vaccine, known as the Nous-209 vaccine, which is intended to decrease the chances that people with Lynch syndrome will develop polyps that can turn into cancer.

Testing a Vaccine for Preventing or Treating Triple-Negative Breast Cancer

https://www.facingourrisk.org/research-clinical-trials/study/284 /testing-a-vaccine-for-treating-or-preventing-triple-negative-breast-cancer


Prevention study for people with a BRCA1, BRCA2 or PALB2 inherited mutation who are planning to undergo risk-reducing mastectomy

Researchers are studying the affects of this breast cancer vaccine on the immune system in two groups of people:

Tools To Be Fit: Tools to Improve Nutrition and Physical Activity for Cancer Survivors

https://www.facingourrisk.org/research-clinical-trials/study/171 /tools-to-be-fit-tools-to-improve-nutrition-and-physical-activity-for-colorectal-cancer-survivors

Quality of Life
Bladder, breast, colon, endometrial, kidney (renal cell carcinoma), ovarian, prostate, or rectal cancer

Eating well and being physically active may help prevent cancer recurrence. Tools To Be Fit is a study to figure out what tools work best for helping cancer survivors improve their diet and exercise. Participants will get access to a combination of tools such as text messages, a wearable physical activity tracker, apps, health coaching, and coaching for a support person in the participant’s life.

Prostate Cancer Genetic Risk Evaluation and Screening Study (PROGRESS)

https://www.facingourrisk.org/research-clinical-trials/study/180 /prostate-cancer-genetic-risk-evaluation-and-screening-study-progress

Prevention
People at high risk for prostate cancer due to an inherited mutation

This study will look at how enhanced prostate cancer screening using MRI will improve early detection rates and further understanding of how inherited mutations can lead to development of prostate cancer.

A Study on Options for Managing Cancer Risk Among Women with a BRCA1 or BRCA2 Mutation

https://www.facingourrisk.org/research-clinical-trials/study/119 /a-survey-on-options-for-managing-cancer-risk-among-women-with-a-brca1-or-brca2-mutation

Surveys, Registries, Interviews
A survey for women with a BRCA1 or BRCA2 mutation

Women with a BRCA1 or BRCA2 mutation are at higher risk of developing breast and/or ovarian cancer compared to women in the general population. There are various options available to these women to help reduce or manage these risks, including preventive surgery. We are conducting an important new study to examine and understand cancer prevention decisions and outcomes in these women.

Treating Metastatic Prostate Cancer with Chemotherapy or PARP Inhibitor in People with Mutations (COBRA)

https://www.facingourrisk.org/research-clinical-trials/study/210 /treating-metastatic-prostate-cancer-with-chemotherapy-or-parp-inhibitor-in-people-with-mutations-cobra

Treatment
Treatment study for mCRPC with an inherited or tumor mutation in BARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2, RAD51B, RAD51C, RAD51D or RAD54L

This study is comparing carboplatin chemotherapy to the drug, olaparib (a type of targeted therapy) as first-line treatment for metastatic castration-resistant prostate cancer in people with a BARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2, RAD51B, RAD51C, RAD51D or RAD54L inherited mutation found through genetic testing, or tumor mutation found through biomarker testing.

A Randomized Study of Robotic-Assisted Nipple Sparing Mastectomy vs. Standard Surgery Nipple Sparing Mastectomy for Early Stage Breast Cancer

https://www.facingourrisk.org/research-clinical-trials/study/263 /a-randomized-study-of-robotic-assisted-nipple-sparing-mastectomy-vs-open-surgery-nipple-sparing-mastectomy-for-early-stage-breast-cancer


Nipple sparing mastectomy with reconstruction for women with early-stage breast cancer

This study will compare robotic-assisted nipple sparing mastectomy (NSM) to standard surgery NSM for women with early-stage breast cancer. Eligible women will be randomly placed into one of two groups and either undergo the robotic-assisted procedure or undergo the standard of care open surgery for NSM. Participants will be followed for 5 years.

Blood Markers of Early Pancreas Cancer

https://www.facingourrisk.org/research-clinical-trials/study/141 /blood-markers-of-early-pancreas-cancer

Prevention
Observational study for people with family history of pancreas cancer or an inherited mutation linked to pancreatic cancer risk

The purpose of this study is to try to find markers of early pancreatic cancer for individuals at higher-than-average risk, expedite the diagnosis in individuals with symptoms, and substantially improve an individual's chance of surviving the disease.

Helping Latinas Understand Their Risk for Breast Cancer and Get Breast Cancer Care

https://www.facingourrisk.org/research-clinical-trials/study/250 /helping-latinas-understand-their-risk-for-breast-cancer-and-get-breast-cancer-care

Prevention
Latinas with a high risk of breast cancer

This study will teach Latinas with a high risk of breast cancer about how diet, exercise, ethnicity, genetics and screening and prevention guidelines may impact their likelihood for developing breast cancer. The study will test ways of teaching participants about breast cancer and risk factors, comparing the current standard of care to new personal educational sessions. Bilingual and bicultural staff are available for the phone study to make the study open to both English and Spanish speakers.

Exploring How People of Caribbean Descent Share Information About Their Genetic Mutations with Family Members

https://www.facingourrisk.org/research-clinical-trials/study/275 /exploring-how-people-of-caribbean-descent-share-information-about-their-genetic-mutations-with-their-family-members


Survey and interview for people of Caribbean descent who tested positive for a genetic mutation linked to cancer.

We're looking into how families share information among Caribbean individuals who have a genetic mutation linked to an increased risk of cancer. The goal is to understand the experiences of Caribbean people dealing with a higher chance of developing cancer. This study will help us figure out how genetic counselors can better support Caribbean patients and their family members in handling this genetic information. If you're interested, you can participate by filling out a survey. If you're eligible, we might reach out to you for a 45-60 minute interview. 

The Experience of Genetic Testing Among Latinas with a BRCA1 or BRCA2 Mutation

https://www.facingourrisk.org/research-clinical-trials/study/305 /the-experience-of-genetic-testing-among-latinas-with-a-brca1-or-brca2-mutation


Interviews with Latinas who have a BRCA1 or BRCA2 mutation

This goal of this study is to interview Latinas, who have been diagnosed with BRCA1 or BRCA2 mutation, and explore their experience with genetic testing

Upright MRI for Prostate Cancer Screening

https://www.facingourrisk.org/research-clinical-trials/study/259 /upright-mri-for-prostate-cancer-screening

Prevention
Screening for prostate cancer using upright MRI

This study will compare the effectiveness of an upright magnetic resonance imaging (MRI) compared to prostate specific antigen (PSA) and current MRI imaging for prostate cancer screening.

A Pilot Study Investigating the Views of Key Stakeholders on Somatic and Germline Cancer Testing

https://www.facingourrisk.org/research-clinical-trials/study/298 /individuals-views-on-somatic-and-germline-testing


This is a survey research study enrolling people with a history of cancer, cancer genetic testing, and an inherited mutation or variant of uncertain significance (VUS) in a hereditary cancer gene

This is a survey research study enrolling people with a history of cancer, cancer genetic testing, and an inherited mutation or variant of uncertain significance (VUS) in a hereditary cancer gene (e.g., APC, ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CDKN2A, CDK4, CHEK2, EPCAM, HOXB13, MLH1, MSH2, MSH6, MUTYH, NBN, PALB2, PMS2, PTEN, RAD51C, RAD51D, STK11, TP53).

BRCA 1 and BRCA 2: Interviews on Genetic Testing and Individual Experiences

https://www.facingourrisk.org/research-clinical-trials/study/169 /brca-1-and-2-interviews-on-genetic-testing-and-individual-experiences

Surveys, Registries, Interviews
People with or without cancer who have had or are considering BRCA testing

This study seeks to interview individuals who come from families with high cancer risk and/or who have tested positive for a BRCA1 or BRCA2 genetic mutation. We are also interested in individuals who may be contemplating BRCA 1/2 genetic testing; those who feel they lack access to genetic testing or who feel they lack information and social and medical support with regard to getting access to genetic testing; those who have been diagnosed with breast cancer who may be at high risk for a range of hereditary cancer. We are especially hoping to reach racially and ethnically diverse males and females whose experiences are often left out of research studies.

Testing the Drug Obeticholic Acid for Familial Adenomatous Polyposis

https://www.facingourrisk.org/research-clinical-trials/study/289 /testing-the-drug-obeticholic-acid-for-familial-adenomatous-polyposis


Prevention study for people with an APC mutation and FAP or AFAP who have polyps in remaining tissue after colectomy surgery

This study is no longer enrolling patients. 

Cancer Experience Registry

https://www.facingourrisk.org/research-clinical-trials/study/248 /cancer-experience-registry

Surveys, Registries, Interviews
Online survey for patients and caregivers focusing on multiple aspects of cancer

Online survey for patients and caregivers focusing on multiple aspects of cancer to understand its emotional, physical, practical, and financial impact, so we can identify and address gaps in care and support.

Study of a New Immunotherapy Treatment Called NC410 in People with Different Types of Advanced or Metastatic Cancers

https://www.facingourrisk.org/research-clinical-trials/study/251 /study-of-an-immunotherapy-treatment-in-individuals-with-advanced-or-metastatic-solid-tumors


People with advanced or metastatic colorectal, endometrial, ovarian, stomach, esophageal or other cancers

This study will test the safety and effectiveness of using a new immunotherapy drug called NC410 to treat people with different types of metastatic or advanced cancers that cannot be removed by surgery. The study is open to people with colorectal, endometrial, ovarian, stomach, esophageal, head and neck and other cancers that:

A Study of the Drug REC-4881 For Treating People with Advanced Cancers with an APC or AXIN1 Mutation

https://www.facingourrisk.org/research-clinical-trials/study/290 /a-study-of-the-drug-rec-4881-for-treating-people-with-advanced-cancers-with-an-apc-or-axin1-mutation


Treatment study for people with advanced cancer with an APC or AXIN1 mutation

This study is looking at how well the research drug REC-4881 works and how safe it is for the treatment of people with advanced or metastatic cancers with an APC or AXIN1 mutation.

Treating Metastatic Breast or Pancreatic Cancer in People with an Inherited BRCA or PALB2 Mutation Using Chemotherapy and Patients’ Stem Cells

https://www.facingourrisk.org/research-clinical-trials/study/117 /sharon-a-clinical-trial-for-metastatic-cancer-with-an-inherited-brca-or-palb2-mutation-using-chemotherapy-and-patients-own-stem-cells

Treatment
Treatment study for metastatic breast or pancreatic cancer in people with an inherited BRCA1 or BRCA2 mutation

The purpose of this study is to see whether the combination of melphalan, BCNU, hydroxocobalamin, ascorbic acid, and autologous (self) bone marrow stem cell infusion, is safe and effective for treating patients with advanced pancreatic cancer or Stage IV, HER2-negative breast cancer who have a BRCA1, BRCA2 or PALB2 inherited mutation. All of these treatments are given intravenously (by vein). This study is open to people who have already received a PARP inhibitor, as well as those who have not. There are no restrictions on the number of prior treatments a patient has received before enrolling.

Studying a Combination of Three Drugs to Treat Previously Untreated Metastatic Colorectal Cancer which Is MSI-High and Has a BRAF V600E Mutation

https://www.facingourrisk.org/research-clinical-trials/study/252 /comparing-three-drugs-in-patients-with-metastatic-colorectal-cancer-who-have-not-had-prior-treatment


Study for metastatic colorectal cancer that has not yet been treated

This study is being done to learn about the effects of using three study medicines together as treatment for metastatic colorectal cancer that has been previously untreated.

Comparing Screening Methods for Detection of Early-Stage Gastric Cancer in People with a CHD1 Genetic Mutation

https://www.facingourrisk.org/research-clinical-trials/study/293 /comparing-screening-methods-for-detection-of-early-stage-gastric-cancer-in-people-with-a-chd1-genetic-mutation


Gastric cancer screening study for people with a CHD1 inherited mutation

This study will compare a new technique of screening for a type of inherited gastric cancer known as diffuse hereditary gastric cancer (DHGC) to see if it can identify cancer better than the current recommended screening. 

All of Us Research Program

https://www.facingourrisk.org/research-clinical-trials/study/197 /all-of-us-research-program

Surveys, Registries, Interviews
Anyone age 18 or over can participate in this research study

The All of Us Research Program is seeking one million people from across the U.S. to help build one of the most diverse health databases in history. We welcome participants from all backgrounds. People who join will share information about their health, habits, and what it’s like where they live. By looking for patterns, researchers may learn more about what affects people’s health.

Coaching for Family Caregivers of People with Advanced Cancer from Rural and Minority Communities

https://www.facingourrisk.org/research-clinical-trials/study/272 /quality-of-life-study-for-caregivers-involving-in-person-or-telephone-coaching-sessions


Quality of life study for caregivers involving in-person or telephone coaching sessions

This study is for families with patients who have newly-diagnosed advanced cancer. African American family caregivers and family caregivers living in rural communities will be eligible. Navigators working with an outpatient palliative care team, provide six health coaching sessions either in person or over the phone to help with managing stress and coping, getting and asking for help, improving caregiving skills, and decision-making/advance care planning Monthly follow-up is also provided from diagnosis through early bereavement.

Interviews with Young Women with a BRCA Mutation About Their Breast Cancer Risk Management Experiences

https://www.facingourrisk.org/research-clinical-trials/study/297 /interviews-with-young-women-with-a-brca-mutation-about-their-breast-cancer-risk-management-experiences


Young women with a BRCA mutation

This research study focuses on young women’s emotional experiences when considering or engaging in strategies to manage increased breast cancer risk.

Inherited Cancer Registry (ICARE): Contribute to Research While Staying Informed

https://www.facingourrisk.org/research-clinical-trials/study/195 /inherited-cancer-registry-icare-contribute-to-research-while-staying-informed

Surveys, Registries, Interviews
Registry for with an inherited mutation or cancer in the family

ICARE is a registry of individuals interested in participating in inherited cancer research, through which data and samples are collected to contribute to research. Participants are also provided with ongoing research and clinical updates and informed about other research opportunities for which they might be eligible. Participants are recruited across the United States and beyond. There is no cost to participate, and all materials can be completed online.

Treatment with an ATR Inhibitor for Advanced or Metastatic Solid Tumors

https://www.facingourrisk.org/research-clinical-trials/study/157 /treatment-with-atr-inhibitor-for-advanced-or-metastatic-solid-tumors

Treatment
Advanced solid tumors

This study will look at how well a new oral targeted therapy known as an ATR inhibitor works on advanced or metastatic solid tumors with mutations in genes linked to DNA damage repair. The study will look at response to treatment with the drug ART0380 in combination with the chemotherapy agent, gemcitabine. 

Testing an Immunotherapy, Pembrolizumab, in Patients With Advanced Solid Tumors

https://www.facingourrisk.org/research-clinical-trials/study/234 /testing-an-immunotherapy-in-patients-with-advanced-solid-tumors


Treatment study for people with advanced cancers

This study is no longer enrolling.

Study of a New Treatment Called TNG348 in People with Advanced or Metastatic Cancer and with a BRCA1 or BRCA2 Mutation or HRD Positive Tumor

https://www.facingourrisk.org/research-clinical-trials/study/296 /study-of-a-new-treatment-called-tng348-in-people-with-advanced-or-metastatic-cancer-and-with-a-brca1-or-brca2-mutation-or-hrd-positive-tumor


Treatment for patients who have advanced breast, ovarian, pancreatic, and prostate cancer and a BRCA1 or BRCA2 mutation or have an HRD positive tumor

The study will test the safety and effectiveness of a new drug called TNG348 used alone or in combination with Olaparib (a PARP inhibitor.) The study is for patients who have advanced breast, ovarian, pancreatic, and prostate cancer and a BRCA1 or BRCA2 mutation or have an HRD positive tumor.

Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient (dMMR/MSI-High) Cancers Resistant to Prior PD-L1 Inhibitor

https://www.facingourrisk.org/research-clinical-trials/study/151 /nivolumab-and-relatlimab-in-advanced-msi-h-cancers-resistant-to-prior-pd-l1-inhibitor

Treatment
Solid tumors that are MSI-High and resistant to prior immunotherapy

The purpose of this study is to evaluate the safety, effectiveness, and tolerability of using the immunotherapy drugs nivolumab and relatlimab in patients with microsatellite instability high (MSI-H) solid tumors resistant to prior PD-L1 therapy.

Both nivolumab and relatlimab are a type of immunotherapy known as immune checkpoint inhibitors. Immune checkpoint inhibitors are drugs that prevent cancer cells from switching off immune cells. This allows the immune system to find, unmask and destroy cancer cells.

Serum Biomarkers to Characterize the Effects of Therapy on Ovarian Reserve in Premenopausal Women With Early-stage Breast Cancer or BRCA Mutations

https://www.facingourrisk.org/research-clinical-trials/study/109 /blood-tests-to-measure-ovarian-reserves-in-women-with-a-brca-mutation-or-women-treated-for-early-stage-breast-cancer

Prevention
Study for premenopausal women with early-stage breast cancer and high-risk women with BRCA mutations and no evidence of breast or ovarian cancer

The purpose of this study is to see how cancer treatment affects the ovaries, such as the impact on conceiving a child or the early onset of menopause. Comparatively, the study will also look at high-risk women with BRCA1/2 mutations (and no evidence of breast or ovarian cancer).

The study will check blood levels of hormones that the ovaries produce and will use questionnaires to gather information about participant menstrual cycles, health, and pregnancies. 

Talazoparib for People with Metastatic Breast Cancer Who Have Acquired (Somatic) BRCA Mutations

https://www.facingourrisk.org/research-clinical-trials/study/100 /talazoparib-for-people-with-metastatic-breast-cancer-who-have-acquired-somatic-brca-mutations

Treatment
Treatment study for people with metastatic breast cancer without a known mutation in BRCA1 or BRCA2, who learn they have a BRCA1 or BRCA2 acquired tumor mutation (somatic mutation)

This is a study for patients with metastatic breast cancer who do not have an inherited mutation in BRCA1 or BRCA2 but who are are found to have a BRCA1 or BRCA2 acquired tumor mutation (somatic mutation) found through liquid biopsy. Patients are treated with talazoparib, a well-tolerated oral PARP inhibitor that targets the BRCA1and BRCA2 mutation to determine whether this treatment (which is already approved for germline BRCA1 and BRCA2 carriers) is effective in this population.

A Pancreatic Cancer Screening Study for High Risk Individuals

https://www.facingourrisk.org/research-clinical-trials/study/95 /pancreatic-cancer-screening-study-for-high-risk-people

Prevention
Screening study to detect pancreatic cancer and precancer

The purpose of this study is to screen and detect pancreatic cancer and precancer in people with either a strong family history of pancreatic cancer, or an inherited mutation associated with pancreatic cancer risk.

Magnetic Resonance Imaging (MRI) will be used to screen for early stage pancreatic cancer. Participants will also be asked to donate a blood sample at specific intervals for the creation of a blood bank necessary for the development of a blood-based screening test for pancreatic cancer. 

Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects

https://www.facingourrisk.org/research-clinical-trials/study/175 /niraparib-before-surgery-in-treating-patients-with-high-risk-localized-prostate-cancer-and-dna-damage-response-defects


High-risk localized prostate cancer

This study will look at how well the PARP Inhibitor niraparib works, when given before a radical prostatectomy, for people with high-risk prostate cancer that has not spread to other parts of the body, and who have a tumor mutation in any of the following genes:BRCA1/2, ATM, CDK12, CHEK1/2 FANCA, FANCD2, FANCL, GEN1, NBN, PALB2, RAD51, RAD51c, and BRIP1.

.

LIVING WELL: A Web-Based Program to Improve Quality of Life in Ovarian Cancer Survivors

https://www.facingourrisk.org/research-clinical-trials/study/270 /living-well-a-web-based-program-to-improve-quality-of-life-in-ovarian-cancer-survivors


A research program offering mindfulness, coping, and healthy lifestyle skills for ovarian cancer survivors

A free research program offering mindfulness, coping, and healthy lifestyle skills for ovarian cancer survivors. The goal of the study is to determine if the program can improve quality of life. You can participate from your home!

Connect My Variant

https://www.facingourrisk.org/research-clinical-trials/study/90 /connect-my-variant

Surveys, Registries, Interviews
Study for people with an inherited mutation to help them talk with relatives about their family history and genetic test results, connect them to others with the same variant and to their family trees

Researchers at the University of Washington (UW) are recruiting participants with known inherited mutation.  We aim to help participants talk to relatives (both immediate and distant) about their family history and genetic test results, to connect them with others who have the same variant, and to their family trees together.  The study provides tools and resources to help at-risk relatives get genetic testing through their own local doctors.

Genomic Services Research Program Study for People with Unexpected Genetic Results

https://www.facingourrisk.org/research-clinical-trials/study/89 /study-for-people-with-unexpected-genetic-results

Prevention
Study for people who received unexpected genetic test results about their cancer risk after having genetic testing done for some other reason

A new study is recruiting people who received unexpected genetic test results about their cancer risk after having genetic testing done for some other reason.

This is a study of people with "secondary results” from genetic testing. Secondary results are unexpected. They are not related to the reason the person had the genetic test but are shared because they may be very important to the person’s health. Most secondary results have to do with high risks for health problems that can be treated or prevented. Many of these results are related to cancer risk. If you think you have received a secondary result, you may be eligible to join this study.

Study of Oral Drug Bazedoxifene Plus Conjugated Estrogens for Treating Hot Flashes in Women at High Risk for Breast Cancer

https://www.facingourrisk.org/research-clinical-trials/study/218 /bazedoxifene-plus-conjugated-estrogens-for-hot-flashes-in-women-at-high-risk-for-breast-cancer


Women at high risk for breast cancer due to ATM, CDH1, CHEK2, NBN, NF1, PALB2, PTEN, STK11, P53 or PTEN mutation who have hot flashes

Bazedoxifene is a type of drug known as a selective estrogen receptor modulator (SERM) that is similar to the drug tamoxifen. A combination of bazedoxifene and estrogen taken orally has been used to control hot flashes. This study will look at hot-flashes, quality of life and breast changes in high-risk women taking the combination of drugs compared with women not taking the combination of drugs. Women will be selected at random to participate in the group receiving the drug and the group not receiving the drug. The study will involve breast imaging, blood tests and small sampling of breast tissue at the beginning and end of the study. 

Talking to Employers and Medical Staff About Breast Cancer Treatment and Your Job (TEAMWork Study)

https://www.facingourrisk.org/research-clinical-trials/study/86 /talking-to-employers-and-medical-staff-about-breast-cancer-treatment-and-your-job

Quality of Life
Study for people diagnosed with cancer to help them navigate wok-related issues

The goal of this study is to improve a tool that helps cancer patients navigate work-related issues. Researchers are testing an early version of a mobile app designed to help breast cancer patients keep their jobs. The app – called TEAMWork (Talking to Employers And Medical staff about Work) – provides advice for patients who need to talk to their employers about treatment or their medical team about work. Researchers want patient feedback on what aspects of the app work well and what can be better.  

Hereditary Breast Cancer Treatment Study (Treatment Study)

https://www.facingourrisk.org/research-clinical-trials/study/85 /breast-cancer-treatment-in-women-with-palb2-mutations

Surveys, Registries, Interviews
Treatment Study to better understand breast cancer treatment among people with ATM, CHEK2 and PALB2 genetic mutations

The Treatment Study is an international research study to better understand breast cancer treatment among individuals with ATM, CHEK2 and PALB2 gene mutations. Participants are asked to complete online or paper study questionnaires (every two years for 10 years) and share their family history, medical, and genetics records.

 

Registry to Promote Health Equity for People of African Ancestry with Breast or Prostate Cancer

https://www.facingourrisk.org/research-clinical-trials/study/277 /registry-to-promote-health-equity-for-people-of-african-ancestry-with-breast-or-prostate-cancer


This is a registry for people of African ancestry who have breast or prostate cancer

The purpose of this research is to study and understand the genetic and molecular causes of breast and prostate cancer in people with African ancestry. People in this study will complete a questionnaire about their environments and lifestyles. You will also give a blood sample and permission for the study team to access a piece of your cancer tissue from the center where you were treated. These blood and tissue samples will be used for molecular and genetic testing to look for changes that are only seen in the tumor as well as look for genetic changes that a person may have been born with, known as inherited gene mutations. Results of these tests will be provided to you. You will be followed by the study team for one year.

Energetics and Lifestyle in Inherited Syndromes (ELLIE’s Study)

https://www.facingourrisk.org/research-clinical-trials/study/84 /ellies-project

Quality of Life
A survey for people with a hereditary cancer genetic mutation

ELLIE’s Project is designed to look at factors that may affect cancer risk in people with inherited mutations linked to cancer. The study will look at weight, Body Mass Index, metabolism, dietary habits and activity level over the course of people’s life-time. ELLIE’s Project aims to gain a better understanding of the baseline lifestyle factors related to nutrition and physical activity in people with a hereditary cancer gene mutation.

Identification and Analysis of Families With Genetic Susceptibility To Cancer Registry

https://www.facingourrisk.org/research-clinical-trials/study/33 /identification-and-analysis-of-families-with-genetic-susceptibility-to-cancer-registry

Surveys, Registries, Interviews
Registry for people with an inherited mutation or variant of uncertain significance

The research laboratory at the Abramson Cancer Center is studying genetic sources of cancer risk and currently has one of the largest collections (also called a registry) of families with known or suspected risk in the world. A number of research projects are performed in collaboration with this registry. Research participants receive a numerical identification number that protects their privacy. Collaborating centers do not have access to personal identifiers such as names and dates of birth because only the numerical identifiers are shared.

 

Survey for People Diagnosed with Breast Cancer to Provide Feedback on a New Type of Clinical Trial

https://www.facingourrisk.org/research-clinical-trials/study/226 /survey-for-people-diagnosed-with-breast-cancer-to-provide-feedback-on-a-new-type-of-clinical-trial


Survey for people diagnosed with stage 0 - stage 3 breast cancer

Stanford researchers invite people diagnosed with stage 0 to stage 3 breast cancer to take this 15 minute survey to share your thoughts about the advantages and disadvantages of participating in a new type of clinical trial called “a window opportunity” trial. will use this information to help design future clinical trials.

Opening the Conversation

https://www.facingourrisk.org/research-clinical-trials/study/228 /opening-the-conversation

Quality of Life
Online communication program for breast and gynecologic cancer survivors and their partners

This is a clinical trial sponsored by the American Cancer Society that will test the helpfulness of two programs designed to teach breast and gynecological cancer survivors and their partners to communicate and cope with physical, emotional, and relationship challenges after cancer. The programs are conducted entirely via Zoom videoconference, so travel is not required to participate.

Preferences Survey for Women With an Inherited BRCA Mutation and Without a Cancer Diagnosis

https://www.facingourrisk.org/research-clinical-trials/study/239 /preferences-survey-for-women-with-an-inherited-brca-mutation-and-without-a-cancer-diagnosis


Online survey for women with a BRCA1 or BRCA2 inherited mutation and no personal history of cancer.

We hope to understand women’s preferences about the benefits and effects of cancer-preventing surgeries. In this survey of women ages 25-50 with an inherited BRCA1 or BRCA2 mutation and no personal history of cancer, we present scenarios and ask participants to make hypothetical choices. Your responses will help us to design educational tools for people who are at high risk of breast and ovarian cancer who face personal decisions about cancer prevention.

Restoring Sensation after DIEP Flap Reconstruction

https://www.facingourrisk.org/research-clinical-trials/study/217 /restoring-sensation-after-diep-flap-reconstruction


Study for people undergoing DIEP flap reconstruction

The goal of this study is to look at how well a nerve graft works for improving sensation to the reconstructed breast after mastectomy in people undergoing DIEP flap reconstruction (deep inferior epigastric perforator flap). 

 

Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations

https://www.facingourrisk.org/research-clinical-trials/study/129 /olaparib-in-treating-patients-with-metastatic-biliary-tract-cancer-with-aberrant-dna-repair-gene-mutations


Treatment study for people with metastatic biliary tract (bile duct) cancer and who have an inherited or tumor mutation

This study will look at how well the drug olaparib works in treating people who have been diagnosed with biliary tract (bile duct) cancer that has spread to other places in the body and who also have an inherited or tumor mutation in certain genes, including ATM, BRCA 1/2, BRIP1, CHEK2, RAD51C, RAD51D, PALB2, PTEN, NBN and others.  

Testing a Vaccine for Cancer Prevention in People with a BRCA1 or BRCA2 Mutation

https://www.facingourrisk.org/research-clinical-trials/study/172 /testing-a-vaccine-for-cancer-prevention-in-people-with-a-brca1-or-brca2-mutation


People with a BRCA1 or BRCA2 mutation

This study will look at a new vaccine known as INO-5401 used alone or combined with a second vaccine called INO-9012. The study will test if the vaccine is safe (without large side effects) and test a new way of giving vaccines. It will also test whether the vaccine activates the immune system. A goal of this research is to reduce cancer risk in people with a BRCA1 or BRCA2 mutation. Additional studies will be needed to learn if this vaccine approach lowers cancer risk in mutation carriers. 

Adding Pembrolizumab to Olaparib to Treat Pancreatic Cancer in People with an Inherited BRCA Mutation

https://www.facingourrisk.org/research-clinical-trials/study/164 /adding-pembrolizumab-to-olaparib-to-treat-pancreatic-cancer-in-people-with-an-inherited-brca-mutation

Treatment
Metastatic pancreatic cancer and a BRCA1 or BRCA2 mutation

This study is researching whether adding the immunotherapy drug Pembrolizumab (Keytruda) to the PARP inhibitor Olaparib (Lynparza) works better than olaparib alone in treating people with metastatic pancreatic cancer who also have an inherited BRCA1 or BRCA2 mutation.  

Investigational PARP Inhibitor AZD5305 Alone or Combined With Other Anti-cancer Agents in People With Advanced Solid Tumors (PETRA)

https://www.facingourrisk.org/research-clinical-trials/study/176 /investigational-parp-inhibitor-azd5305-alone-or-combined-with-other-anti-cancer-agents-in-people-with-advanced-solid-tumors-petra


Advanced ovarian, breast, prostate or pancreatic cancer

PETRA is studying a new PARP inhibitor AZD5305 taken either alone or combined with other treatments in people with advanced ovarian, breast, prostate or pancreatic cancer with an inherited or tumor mutation in: BRCA1/2, PALB2, RAD51C or RAD51D. The treaments participants receive will depend on their cancer type, mutation and when they join the study.

Survey about Motivations and Barriers to Talking with Family Members about Inherited Cancer Risk

https://www.facingourrisk.org/research-clinical-trials/study/280 /survey-about-goals-of-inherited-cancer-risk-disclosure-in-families-with-an-inherited-gene-mutation


Survey for people with an inherited gene mutation

This study aims to understand the different goals and motivations individuals with an inherited gene mutation have when talking about their genetic cancer risk with family members in a conversation.

Study for Women at Increased Risk of Developing Breast Cancer

https://www.facingourrisk.org/research-clinical-trials/study/257 /study-for-women-at-increased-risk-of-developing-breast-cancer


This study will create a system to assess an individual’s risk of breast cancer

This study will create a system to assess an individual’s risk of breast cancer based on random sampling of normal breast tissue as well as determine new and help understand previously identified risk biomarkers.

Intimacy and Self-Esteem Among Sexual and Gender Minority Cancer Survivors (RISE-SGM)

https://www.facingourrisk.org/research-clinical-trials/study/265 /an-interview-about-intimacy-and-self-esteem-for-sexual-and-gender-minority-cancer-survivors


A one-time interview study to explore experiences with sexual functioning, sexual relationships, sexual self-concept, and self-esteem of 18-39-year-old sexual and/or gender minority cancer survivors

Relationships, Intimacy, and Self-Esteem among Sexual and Gender Minority Cancer Survivors (RISE) is a research study that focuses on the experiences of 18-39-year-old sexual and/or gender minority cancer survivors. Participants will be asked to complete an interview on relationships, self-esteem, and intimacy.

Factors Influencing Disparities in Quality of Life among People of Color Affected by Cancer

https://www.facingourrisk.org/research-clinical-trials/study/223 /factors-influencing-disparities-in-quality-of-life-among-people-of-color-affected-by-cancer


Survey for people of color who have completed treatment for cancer

This study focuses on cancer survivors’ needs during the transition into a new normal life after the completion of cancer treatment. The goal is to explore ways in which we can improve physical activity and diet among cancer survivors and address their challenges to develop and maintain an active and healthy lifestyle.

We specifically would like to work with and for cancer survivors who self-describe as people of color to understand how social structures, stress and environmental factors impact health behaviors and subsequent quality of life.

Breastfeeding and Breast Cancer Screening in People at High Risk: Knowledge and Perspectives

https://www.facingourrisk.org/research-clinical-trials/study/238 /survey-for-women-at-high-risk-for-breast-cancer-on-knowledge-and-perspectives-about-breast-cancer-risk-factors-and-screening


Online survey for women with an ATM, BARD1, BRCA1, BRCA2, CDH1, CHEK2, PALB2, PTEN, RAD51C, RAD51D, STK11 or TP53 inherited mutation.

Researchers at the Mayo Clinic and McGill University are partnering with FORCE on a survey of women who have inherited mutations in BRCA1, BRCA2 or other genes (including PALB2, ATM, CHEK2, and others) related to increased breast cancer risk. We are interested in the effects of testing positive for an inherited mutation on decisions about the timing of pregnancy, breastfeeding, breast cancer screening and risk-reducing surgery. 

NUV-868 Alone and in Combination With PARP Inhibitors in Patients With Advanced Solid Tumors

https://www.facingourrisk.org/research-clinical-trials/study/204 /nuv-868-alone-and-in-combination-with-parp-inhibitors-in-patients-with-advanced-solid-tumors


Treatment study for people with advanced solid tumors, including triple-negative breast, ovarian, pancreatic and prostate cancer

This study will test how safe and effective the experimental drug NUV-868 is by itself and in combination with a PARP inhibitor in people with advanced solid tumors. The first part of the study will include people with any solid tumor type, and the second part will include people with triple-negative breast, ovarian, pancreatic or prostate cancers only. 

Effect of Acupuncture on Memory and Thinking Difficulties after Breast Cancer

https://www.facingourrisk.org/research-clinical-trials/study/219 /effect-of-acupuncture-on-memory-and-thinking-difficulties-after-breast-cancer


Acupuncture study for people with memory issues who completed treatment for stage 0-3 breast cancer

Ths study is closed

Treating Early-Stage HER2-Negative Breast Cancer with a PARP Inhibitor (Niraparib) and Immunotherapy (Dostarlimab) in People with a BRCA or PALB2 Mutation

https://www.facingourrisk.org/research-clinical-trials/study/158 /treating-early-stage-breast-cancer-with-a-parp-inhibitor-niraparib-and-immunotherapy-dostarlimab-in-people-with-a-brca-or-palb2-mutation


Treatment before surgery for people with early-stage breast cancer & a BRCA1, BRCA2 or PALB2 mutation

This study will look at how well the drugs Niraparib (a PARP inhibitor) and Dostarlimab (an immunotherapy) treat early-stage breast cancer in people with an inherited BRCA1, BRCA2 or PALB2 mutation.  

Survey For Individuals With A Hereditary Cancer Genetic Testing Result That Was Later Reclassified

https://www.facingourrisk.org/research-clinical-trials/study/261 /survey-for-individuals-with-a-hereditary-cancer-genetic-testing-result-that-was-later-reclassified


Survey for people whose genetic test results were reclassified

Researchers are conducting an online survey to look into the personal experiences of people who received reclassfied genetic testing results for hereditary cancer gene mutations. 

Developing a Test for the Detection of Ovarian Cancer

https://www.facingourrisk.org/research-clinical-trials/study/137 /developing-a-test-for-the-detection-of-ovarian-cancer


Prevention study for women with a BRCA1 or BRCA2 mutation who are scheduled for risk-reducing salpingo-oophorectomy

The purpose of this study is to develop a test for early detection of ovarian cancer. Two patient populations are included in this study: women scheduled for surgery or testing for suspected but undiagnosed ovarian/fallopian tube cancer, and women with a BRCA1 or BRCA2 mutation who are scheduled for a risk-reducing salpingo-oophorectomy. The study will examine DNA from a washing of the uterus (womb) and proteins found in the blood to see if they can detect ovarian cancer.

Research Opportunity for Previvors and their Romantic Partners

https://www.facingourrisk.org/research-clinical-trials/study/207 /research-opportunity-for-previvors-and-their-romantic-partners


Interview for people with inherited mutations who had risk-reducing mastectomy and their partners

Researchers at the University of Kentucky are hoping to learn more about the relational experiences of individuals with hereditary breast cancer mutations who have navigated a double mastectomy while in a committed romantic relationship. They are particularly interested in the couples’ experience related to sexual intimacy before and after prophylactic surgical procedures. You do not have to live in Kentucky to participate. 

Cancer Screening for People With Intellectual Disability: Exploring Parent and Caregiver Perspectives

https://www.facingourrisk.org/research-clinical-trials/study/268 /parent-and-caregiver-perspectives-on-cancer-screening-for-people-with-intellectual-disabilities


Survey for parents and caregivers to share perspectives on cancer screening for people with intellectual disabilities

Our goal is to understand the experiences of people with intellectual disability in regard to screening for cancer, for example colonoscopies for colon cancer and mammograms for breast cancer. For people not being screened, we hope to learn about any barriers faced.

Comparing the Safety and Effectiveness of a New Hormonal Therapy in Patients with HER2-Negative, ER-Positive Early Breast Cancer

https://www.facingourrisk.org/research-clinical-trials/study/254 /comparing-the-safety-and-effectiveness-of-secondary-treatments-in-patients-with-her2-negative-early-breast-cancer


Treatment study for people with early-stage breast cancer

This study is comparing safety and effectiveness of a new drug called giredestrant compared to standard hormone therapy in people with early-stage, ER-positive breast cancer. 

What Factors Influence Survivors’ Guilt in Individuals Who Tested Negative for a Known Hereditary Cancer Syndrome?

https://www.facingourrisk.org/research-clinical-trials/study/264 /survey-for-people-who-received-a-negative-genetic-test-result-for-a-known-mutation-in-the-family


People who received a negative genetic test result

This study is to understand the experiences of people who have received a negative genetic test result for a known familial hereditary cancer mutation (i.e., a “true negative” result) and determine what factors influence the presence of survivors’ guilt in these individuals.

A Randomized Study of an eHealth Delivery Alternative for Cancer Genetic Testing for Hereditary Predisposition in Metastatic Breast, Ovarian, Prostate and Pancreatic Cancer Patients

https://www.facingourrisk.org/research-clinical-trials/study/102 /a-randomized-study-of-an-ehealth-delivery-alternative-for-cancer-genetic-testing-for-hereditary-predisposition-in-metastatic-breast-ovarian-prostate-and-pancreatic-cancer-patients-e-reach


A study looking at using web options to increase access to testing AND patients in this study can get genetic counseling and testing in their home

Genetic testing can be helpful to identify potential targeted treatments for some patients with metastatic cancer. But some patients have a hard time getting easy and fast testing. This study is looking at using web options to increase access to testing AND patients in this study can get genetic counseling and testing in their home! 

Comparing Three Drugs as Late-Stage Treatment for Individuals with Metastatic Colorectal Cancer

https://www.facingourrisk.org/research-clinical-trials/study/246 /comparing-the-drugs-opdualag-and-stivarga-as-late-stage-treatment-for-individuals-with-metastatic-colorectal-cancer


treatment study for people with metastatic colorectal cancer

This study is being done to look at how well a combination of three drugs works for the treatment of metastatic colorectal cancer in patients who have had their cancer come back or get worse after treatment. The study is open to people who have had at least one, but no more than four courses of treatment in the metastatic setting. 

Comparing an Immunotherapy Drug, Pembrolizumab With Chemotherapy in Advanced or Recurrent Endometrial Cancer

https://www.facingourrisk.org/research-clinical-trials/study/244 /treatment-for-advanced-or-recurrent-endometrial-cancer


Comparing an Immunotherapy Drug, Pembrolizumab With Chemotherapy in Advanced or Recurrent Endometrial Cancer

This study is to test the safety and effectiveness of treatment with pembrolizumab, also known as Keytruda, compared to a combination of chemotherapy treatments in women with deficient mismatch repair (dMMR) advanced or recurrent endometrial cancer who had not previously been treated with prior chemotherapy treatments. The study is being conducted to determine if  pembrolizumab is better than the combined chemotherapy in terms of Progression Free Survival (PFS).

 

Testing Immunotherapy Treatments for Recurrent Endometrial Cancer

https://www.facingourrisk.org/research-clinical-trials/study/253 /testing-cancer-treatments-in-recurrent-endometrial-cancer


Treatment study for people with endometrial cancer that has returned

This study tests the combination of two immunotherapy drugs compared to one immunotherapy drug to shrink tumors in patients with endometrial cancer that has returned after not being detected for a period of time (recurrent). The study is enrolling people with a biomarker known as dMMR.

Investigating the Use of Self-Acupressure for Fatigue in Ovarian Cancer Survivors

https://www.facingourrisk.org/research-clinical-trials/study/242 /investigating-the-use-of-self-acupressure-for-fatigue-in-ovarian-cancer-survivors


University of Michigan researchers are investigating the use of self-acupressure for fatigue in ovarian cancer survivors.

Study using acupressure for people experiencing fatigue after ovarian cancer treatment.

Study of Physical Activity at Home for Relief from Neuropathy Caused by Taxanes in People with Breast Cancer

https://www.facingourrisk.org/research-clinical-trials/study/220 /physical-activity-at-home-for-relief-from-neuropathy-caused-by-taxanes-in-people-with-breast-cancer


Quality of life study for breast cancer patients experiencing neuropathy from chemotherapy

Chemotherapy-induced peripheral neuropathy (CIPN) symptoms include numbness combined with tingling sensations, persistent shooting, stabbing, or burning pain even in the absence of an obvious cause, lower extremity muscle weakness, and impaired balance. Resistance exercise has shown promising results; however, the effect of exercise on CIPN remains understudied. This study will look at the effects of gain and balance training and resistance exercise (using bands) on gait, balance, and lower extremity muscle strength after a 16-week home-based exercise program compared to educational materials without an exercise program.

 

Chemotherapy, Bevacizumab, and/or Atezolizumab for Patients With Deficient DNA Mismatch Repair (dMMR or MSI-H) Metastatic Colorectal Cancer, the COMMIT Study

https://www.facingourrisk.org/research-clinical-trials/study/126 /chemotherapy-bevacizumab-andor-atezolizumab-for-dmmr-msi-h-metastatic-colorectal-cancer-commit-study


This is a treatment study is for people with metastatic colorectal cancer

This study is for people with metastatic colorectal cancer. The study will compare how well treatment with a combination of chemotherapy agents and an immunotherapy agent works compared with treatment using an immunotherapy agent alone. This study is focused on patients who are determined to be mismatch-repair deficient (dMMR) or have an MSI-H diagnosis, which are commonly seen in people with Lynch syndrome.

Women's Sexuality After Gynecological Cancer Treatments

https://www.facingourrisk.org/research-clinical-trials/study/243 /womens-sexuality-after-gynecological-cancer-treatments


Virtual or in-person interview to share personal experiences of sexuality after gynecological cancer treatment(s).

Explore women's lived experiences of sexuality after gynecological cancer treatment(s).

Combined Pembrolizumab & Quavonlimab (MK-1308A) Versus Other Treatments in People With MSI-High or dMMR Stage IV Colorectal Cancer

https://www.facingourrisk.org/research-clinical-trials/study/181 /combined-pembrolizumab-quavonlimab-mk-1308a-versus-other-treatments-in-people-with-msi-high-or-dmmr-stage-iv-colorectal-cancer


Stage 4 colorectal cancer

The purpose of this study is to assess the efficacy and safety of co-formulated pembrolizumab/quavonlimab versus four other treatments in patients with Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Metastatic (stage IV) Colorectal Cancer.

Combination ATR inhibitor and PARP Inhibitor in Recurrent Ovarian Cancer (CAPRI)

https://www.facingourrisk.org/research-clinical-trials/study/156 /combination-atr-inhibitor-and-parp-inhibitor-in-recurrent-ovarian-cancer-capri


Recurrent ovarian cancer

This study will look at how well patients with recurrent ovarian, primary peritoneal or fallopian tube cancer respond to treatment with a targeted therapy known as an ATR inhibitor when combined with the PARP inhibitor Olaparib.

IGNITE-TX - Identifying Individuals for Genetic Testing for Familial Cancer

https://www.facingourrisk.org/research-clinical-trials/study/266 /helping-people-with-a-genetic-mutation-in-brca1-brca2-or-lynch-syndrome-talk-to-their-family-members-about-their-risk-for-cancer-and-find-the-best-way-to-get-family-members-tested


People with a genetic mutation in BRCA1, BRCA2 or Lynch syndrome who have relatives who have not been tested

The IGNITE-TX study is all about helping people with a genetic mutation in BRCA1, BRCA2 or Lynch syndrome talk to their family members about their risk for cancer and find the best way to get family members tested.

TALAPRO-3: A Clinical Trial in Men with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) and DNA Damage Repair (DDR) Gene Alteration

https://www.facingourrisk.org/research-clinical-trials/study/153 /talapro-3-a-clinical-trial-in-men-with-metastatic-castration-sensitive-prostate-cancer-mcspc-and-dna-damage-repair-ddr-gene-alteration


Metastatic castration-sensitive prostate cancer

The TALAPRO-3 trial is assessing whether the study drug, talazoparib, is effective and safe when given in combination with enzalutamide as a treatment option for men with metastatic castration-sensitive prostate cancer and a DDR gene alteration.

Study of Two Drugs in ER+ and/or PR+ Cancers With PI3K and/or PTEN Tumor or Inherited Mutations

https://www.facingourrisk.org/research-clinical-trials/study/249 /study-of-two-drugs-in-er-andor-pr-cancers-with-pi3k-andor-pten-tumor-or-inherited-mutations


People with advanced breast or endometrial or ovarian cancer

This study is investigating if the study drug copanlisib, when used in combination with fulvestrant, is safe and effective for people with certain advanced ER-positive and/or PR-positive cancers.  People with PI3K and/or PTEN changes in tumor tissue or inherited mutations are eligible.

Paid Research Interview Opportunity: Stage III or IV Ovarian Cancer Patients

https://www.facingourrisk.org/research-clinical-trials/study/237 /paid-research-interview-opportunity-patients-receiving-neoadjuvant-or-first-line-treatment-for-ovarian-cancer


Interview for people with stage III or IV ovarian cancer

Modus Outcomes is seeking patients with stage III or IV ovarian cancer to participate in online interviews. We will ask you questions about your symptoms and how ovarian cancer impacts your life. Then, we will ask for feedback on questionnaires used in ovarian cancer studies.

A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC) (CheckMate 8HW)

https://www.facingourrisk.org/research-clinical-trials/study/112 /nivolumab-nivolumab-plus-ipilimumab-or-chemotherapy-for-microsatellite-instability-high-msi-h-metastatic-colorectal-cancer-checkmate-8hw


People with metastatic colorectal cancer that is MSI-High

The purpose of this study is to compare the benefit of the combination of immunotherapy agents Nivolumab plus Ipilimumab in patients who have Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) metastatic colorectal cancer versus using Nivolumab as a single therapy or chemotherapy. 

Testing the Targeted Therapy Elimusertib in Combination with Chemotherapy for Advanced Cancers

https://www.facingourrisk.org/research-clinical-trials/study/232 /testing-a-targeted-therapy-in-combination-with-chemotherapy-for-advanced-solid-tumors


Treatment study for people with advanced cancers

This study is looking at how well the drug elimusertib (a type of targeted therapy known as an ATR inhibitor) works when combined with chemotherapy for treating people with advanced cancers, including urothelial, ovarian, gastric, endometrial, triple-negative breast cancer and others.

Effects of Occupational Therapy Telehealth Intervention on Cancer-Related Cognitive Impairment in Breast Cancer Survivors

https://www.facingourrisk.org/research-clinical-trials/study/225 /effects-of-occupational-therapy-telehealth-intervention-on-cancer-related-cognitive-impairment-in-breast-cancer-survivors


Telehealth study for breast cancer survivors with memory issues

The purpose of this study is to look at the effects and ease of use of occupational therapy delivered by telehealth on activity performance, memory and quality of life in breast cancer survivors. Participants will complete all sessions from home via Zoom videoconferencing. This is a 2-arm randomized control trial, which means that each participant will be randomly assigned to one of two groups. Participants will complete the same number of sessions regardless of which group they are assigned to.

Perceptions of an Online Platform to Facilitate Sharing of Family Health History

https://www.facingourrisk.org/research-clinical-trials/study/241 /perceptions-of-an-online-platform-to-facilitate-sharing-of-family-health-history


Online survey for people with an ATM, BARD1, BRCA1, BRCA2, CDH1, CHEK2, PALB2, PMS2, PTEN, RAD51C, RAD51D, STK11, TP53 inherited mutation or Lynch syndrome.

Online survey for people with a family history of hereditary breast and ovarian cancer and Lynch syndrome about online health history-sharing.

Androgen Suppression With Abiraterone, Leuprolide, PARP Inhibitor and Stereotactic Radiotherapy in Prostate Cancer (ASCLEPIuS)

https://www.facingourrisk.org/research-clinical-trials/study/177 /androgen-suppression-with-abiraterone-leuprolide-parp-inhibitor-and-stereotactic-radiotherapy-in-prostate-cancer-asclepius


Newly diagnosed prostate cancer grade group 3-5

This study will look at treating men with high risk prostate cancer using the PARP inhibitor, niraparib combined with prostate stereotactic body radiotherapy (SBRT), abiraterone, leuprolide, and prednisone. Phase 1 of this study will look at the best dose of niraparib for this treatment combination. The phase 2 portion of this study will look at the 3-year PSA recurrence free-survival rate of the patients who received this combined therapy.

PARP Inhibitor (Niraparib) in Patients with Inherited or Tumor PALB2 Mutations in Advanced Solid Tumors (PAVO)

https://www.facingourrisk.org/research-clinical-trials/study/183 /parp-inhibitor-niraparib-in-patients-with-inherited-or-tumor-palb2-mutations-in-advanced-solid-tumors-pavo


Any advanced or metastatic solid tumor except ovarian or prostate

PAVO is an open-label Phase II study investigating if the study drug, a PARP inhibitor called niraparib (Zejula), is safe and effective for certain people who have been diagnosed with an
advanced solid tumor with either an inherited or tumor PALB2 mutation.

Opening the Conversation Study

https://www.facingourrisk.org/research-clinical-trials/study/214 /opening-the-conversation-study


Videoconference sessions that address cancer related concerns for couples

This study will adapt and evaluate an intervention designed to help young couples cope with and communicate about cancer-related reproductive and sexual health concerns.

 

Project MTFM: Medical Tattooing Following Mastectomy

https://www.facingourrisk.org/research-clinical-trials/study/233 /project-mtfm-medical-tattooing-following-mastectomy


Survey for breast cancer survivors following mastectomy

This study aims to better understand how breast cancer surgery can impact mental health and wellness. We will also explore how breast cancer survivors view breast cancer surgery and medical tattooing following. Participation includes an optional information session and consultation with a medical tattoo artist. 

Preliminary Evaluation of Screening for Pancreatic Cancer in Patients with an Inherited Genetic Risk Due to a BRCA1, BRCA2, PALB2 or ATM Mutation

https://www.facingourrisk.org/research-clinical-trials/study/121 /screening-for-pancreatic-cancer-in-patients-with-an-inherited-brca1-brca2-palb2-or-atm-mutation


Pancreatic cancer screening for people at high risk and with an inherited BRCA1, BRCA2, ATM, or PALB2 mutation

Improved screening for pancreatic cancer in high-risk groups, such as people with an inherited BRCA1, BRCA2, ATM, or PALB2 mutation, may help find cancer early and improve survival rates. People enrolled in this study will undergo screening using endoscopic ultrasound or MRI of the abdomen.

Metastatic Prostate Cancer Project

https://www.facingourrisk.org/research-clinical-trials/study/70 /metastatic-prostate-cancer-project


A nationwide genomic research study for men with advanced and/or metastatic prostate cancer

The Metastatic Prostate Cancer Project is a nationwide genomic research study for men with advanced and/or metastatic prostate cancer. Patients can join online and participate by sharing their medical information and samples. The goal of the project is to generate a comprehensive database that will be shared with the entire research community to accelerate discoveries in prostate cancer.

Retifanlimab (Immunotherapy) Alone or Combined with Other Therapies for Advanced Endometrial Cancer that Progressed on or after Platinum Chemotherapy (POD1UM-204)

https://www.facingourrisk.org/research-clinical-trials/study/165 /retifanlimab-alone-or-with-other-agents-for-advanced-endometrial-cancer-that-progressed-with-platinum


Advanced endometrial cancer

This study is for people with advanced or metastatic endometrial cancer that has progressed on or after platinum-based chemotherapy. Participants will receive retifanlimab (a type of immunotherapy) alone or in combination with other immunotherapies or targeted therapies.

A New Risk Measurement Tool for Those at High Risk for Ovarian Cancer

https://www.facingourrisk.org/research-clinical-trials/study/236 /a-new-risk-measurement-tool-for-those-at-high-risk-for-ovarian-cancer


This study is using a new type of genetic test to measure ovarian cancer risk

This study is using a new type of genetic test to measure ovarian cancer risk in women who have inherited genetic mutations that increase their risk for ovarian cancer or women who have an ovarian cyst or other non-cancerous masses (adnexal mass). NOTE: This study is no longer enrolling patients. 

The Metastatic Breast Cancer Project

https://www.facingourrisk.org/research-clinical-trials/study/60 /the-metastatic-breast-cancer-project


A nationwide genomic research study for people with advanced and/or metastatic breast cancer

The Metastatic Breast Cancer Project is a patient-partnered initiative that directly engages patients across the US & Canada to transform our understanding of metastatic breast cancer. Patients participate by sharing their medical information, tumor samples, and their voices, partnering with the project team to accelerate discoveries. There is no cost to participate and only minimal effort is required to have a major impact.
 

Exploring the Psychosocial Implications of Individuals with a Genetic Test Result that was Later Reclassified

https://www.facingourrisk.org/research-clinical-trials/study/229 /exploring-the-psychosocial-implications-of-individuals-with-a-genetic-test-result-that-was-later-reclassified


Interview for people who's genetic test results were reclassified

Researchers at Bay Path University are conducting virtual/phone interviews with individuals who have received a reclassified genetic test result to cancer related genes. This study will help researchers learn the psychosocial implications and experiences of those who have received a reclassified genetic test result when undergoing hereditary cancer gene testing, (for example, your original genetic test results showed a variant of uncertain significance that was later found to be harmful or harmless). 

Pembrolizumab and Olaparib for People With Metastatic Pancreatic Cancer with Homologous Recombination Deficiency or Exceptional Response to Platinum Chemotherapy

https://www.facingourrisk.org/research-clinical-trials/study/127 /pembrolizumab-and-olaparib-for-metastatic-pancreatic-cancer-with-homologous-recombination-deficiency-or-exceptional-response-to-platinum-chemotherapy


Treatment study for people diagnosed with metastatic pancreatic cancer with Homologous Recombination Deficiency, or whose disease has responded well to first-line or second-line platinum therapy

This is a study for people diagnosed with metastatic pancreatic cancer with Homologous Recombination Deficiency, or whose disease has responded well to first-line or second-line platinum therapy. The goal of this study is to look at whether combining the immunotherapy drug, pembrolizumab and the PARP inhibitor, olaparib is a more effective treatment for this cancer than taking olaparib alone.

 

Treating Recurrent or Metastatic Endometrial Cancer with an Immunotherapy in Combination with a PARP Inhibitor or a Chemotherapy Drug

https://www.facingourrisk.org/research-clinical-trials/study/235 /treating-recurrent-or-metastatic-endometrial-cancer-with-an-immunotherapy-in-combination-with-a-parp-inhibitor-or-a-chemotherapy-drug


Treatment study for metastatic endometrial cancer

This study will determine the effectiveness of an immunotherapy called Avelumab, in treating recurrent or metastatic endometrial cancer. One group of participants will receive Avelumab, a second group of participants will receive the combination of Avelumab and Talazoparib, and a third group of participants will receive the combination of Avelumab and Axitinib. The effectiveness of the study drugs will be measured through tumor biopsies. NOTE: This study is no longer enrolling patients.

Studying the Targeted Therapy Olaparib Given with Radium-223 for Advanced Prostate Cancer with Bone Metastasis

https://www.facingourrisk.org/research-clinical-trials/study/198 /studying-the-medication-olaparib-given-with-radium-223-for-advanced-prostate-cancer-with-bone-metastasis


People with castration-resistant prostate cancer with bone spread

This study is measuring the best dosage for and side effects of the drug combination Olaparib and radium-223 to treat men with metastatic, castration-resistant prostate cancer that has spread to the bones. 

Chemotherapy, Immunotherapy and PARP Inhibitor for the Treatment of Metastatic Aggressive Variant Prostate Cancer

https://www.facingourrisk.org/research-clinical-trials/study/200 /chemotherapy-immunotherapy-and-parp-inhibitor-for-the-treatment-of-metastatic-aggressive-variant-prostate-cancer-avpc


Treatment in people with aggressive metastatic prostate cancer

This study will look at how well the combination of chemotherapy drugs (such as cabazitaxel and carboplatin), a PARP inhibitors (niraparib), and an immunotherapy agents (cetrelimab) works for treating people with a rare type of prostate cancer known as aggressive variant prostate cancer (AVPC). The research will compare the benefits of giving niraparib with or without cetrelimab, after treatment with chemotherapy.

Interview Study: Exploring Gender Diverse Experiences of Hereditary Cancer Risk

https://www.facingourrisk.org/research-clinical-trials/study/186 /interview-study-exploring-gender-diverse-experiences-of-hereditary-cancer-risk


People with elevated cancer risk who identify as trans* or nonbinary

Are you a gender diverse previvor or patient who would like to share your story? A Johns Hopkins genetic counseling student is conducting an interview study exploring gender diverse folks’ experiences of hereditary cancer care, with the aim of better educating providers about LGBTQ+ needs and concerns. We are conducting interviews over Zoom with individuals who qualify. If you are interested in participating, contact Sarah Roth at [email protected]. NOTE: This study is no longer enrolling people.

Differences in Family Communication about Positive Genetic Test Results Between Asian Americans

https://www.facingourrisk.org/research-clinical-trials/study/208 /differences-in-family-communication-about-positive-genetic-test-results-between-asian-americans


Interview for Asian Americans with a mutation in BRCA1, BRCA2, ATM, CHEK2, PALB2 or other gene linked to breast or ovarian cancer risk

This study aims to explore family communication differences across Asian American families  about testing positive for an inherited mutation in BRCA1, BRCA2, ATM, BARD1, BRIP1, CHEK2, PALB2, PTEN, RAD51C, RAD51D, TP53 or another gene linked to hereditary breast and/or ovarian cancer. Participants will complete a 10–15-minute initial intake survey to confirm eligibility. Eligible participants will then be contacted to schedule a 30-45-minute-long interview over Zoom to explore these topics. After completion of the interview, participants will be entered into a raffle for two $50 Visa gift cards. There are no costs associated with participation. NOTE: This study is closed. 

Physical Activity Promotion for Breast and Endometrial Cancer Survivors

https://www.facingourrisk.org/research-clinical-trials/study/202 /physical-activity-promotion-for-breast-and-endometrial-cancer-survivors


Exercise study for breast or endometrial cancer survivors

This study is looking at whether messaging and coaching can increase activity level and how moderate-to-vigorous activity improves symptoms and quality-of-life in women diagnosed with breast or endometrial cancer. NOTE: This study is no longer enrolling. 

Survey about Endometrial Cancer Risk and Risk-Reducing Surgery for Women with a BRCA1/2 Mutation or Mutation in the Family

https://www.facingourrisk.org/research-clinical-trials/study/185 /survey-about-endometrial-cancer-risk-and-risk-reducing-surgery-for-women-with-a-brca12-mutation-or-mutation-in-the-family


Women with a BRCA mutation or from a family with a BRCA mutation

Researchers at the Mayo Clinic, McGill University and FORCE are conducting a survey of women with a BRCA1/2 mutation, or who come from a family with a known BRCA mutation but tested negative, or have not had testing. Our goal is to learn about the information needs and decisions made related to endometrial cancer risk. https://tinyurl.com/BRCAMUTATION. NOTE: This study is closed for enrollment. 

Testing the New Targeted Therapy CYH33 in Combination With the PARP Inhibitor Olaparib in People With Advanced Solid Tumors and DNA Damage Repair Mutations

https://www.facingourrisk.org/research-clinical-trials/study/168 /cyh33-in-combination-with-olaparib-in-patients-with-advanced-solid-tumors-and-dna-damage-repair-mutations


Advanced solid tumors

This study will look at safety and effectiveness of the targeted therapy CYH33 combined with the PARP inhibitor olaparib in people with advanced cancers and a DNA damage repair (DDR) gene mutation whose cancer got worse on, or after receiving a PARP inhibitor. The study will also enroll people with recurrent, platinum resistant ovarian cancer. In addition to safety and efficacy, the study will test whether the combination of CYH33 and olaparib can block tumor growth and overcome a patient’s resistance to PARP inhibitor treatment.

RANKL Inhibition With Denosumab on Mammographic Density in Premenopausal Women With Dense Breasts (TRIDENT)

https://www.facingourrisk.org/research-clinical-trials/study/93 /denosumab-and-mammographic-density-in-premenopausal-women-with-dense-breasts-trident

Prevention

The purpose of this study is to evaluate if denosumab can reduce the breast density of premenopausal women who have dense breasts. Denosumab is an FDA-approved injectable medication that is used to treat osteoporosis and to prevent fractures in cancer patients with bone metastases. This study could help us identify novel ways to prevent breast cancer in younger women. NOTE: This study is no longer enrolling people

Atorvastatin ± Aspirin for Colorectal Cancer Prevention for People with Lynch Syndrome

https://www.facingourrisk.org/research-clinical-trials/study/144 /atorvastatin-aspirin-for-colorectal-cancer-prevention-for-people-with-lynch-syndrome


This study will look at how well atorvastatin (a cholesterol lowering agent) works with or without aspirin in preventing colorectal cancer in people with Lynch syndrome. Atorvastatin may lower the risk of developing cancers in the colon and rectum. Aspirin may reduce the risk of colon polyps and colon cancers. Giving atorvastatin and aspirin may work better at reducing the risk of colorectal cancer (CRC) in high-risk individuals with Lynch syndrome.

A Study of the Investigational Targeted Therapy ART4215 to Treat Advanced or Metastatic Solid Tumors

https://www.facingourrisk.org/research-clinical-trials/study/178 /a-study-of-the-investigational-targeted-therapy-art4215-to-treat-advanced-or-metastatic-solid-tumors


Advanced solid tumors

This study is looking at how well a drug called ART4215 works either alone or when combined with the PARP inhibitor talazoparib in people with different types of advanced cancers. ART4215 is an oral targeted therapy that is designed to keep cancer cells from repairing DNA damage. 

Assessing Decisions about Uterine and Ovarian Cancer Prevention by People with Lynch Syndrome

https://www.facingourrisk.org/research-clinical-trials/study/224 /assessing-decisions-about-uterine-and-ovarian-cancer-prevention-by-people-with-lynch-syndrome


Online survey for people with Lynch syndrome

This study is seeking information about the personal experiences of uterine and ovarian cancer prevention and screening for people with Lynch syndrome. An online survey will allow participants to share their experiences which will ultimately help medical practitioners be more aware about the wants, needs, and decision-making strategies used by people with Lynch syndrome to preserve their gynecological health.

EnergyPoints: A Mobile App Guiding Use of Acupressure for Cancer-related Fatigue and Sleep Disturbances

https://www.facingourrisk.org/research-clinical-trials/study/184 /energypoints-a-mobile-app-guiding-use-of-acupressure-for-cancer-related-fatigue-and-sleep-disturbances


Anyone diagnosed with cancer experiencing fatigue

This study is looking at the use of acupressure to manage cancer-related fatigue and sleep disturbances. EnergyPoints is an app that teaches users how to self-administer acupressure, to manage fatigue and sleep disturbances related to cancer. The purpose of this research study is to learn from participants’ experiences using EnergyPoints, while they wear a fitness tracker to measure activity and sleep.

Adding PARP Inhibitor to Enzalutamide to Treat Men with Metastatic Prostate Cancer that is Resistant to Anti-androgen Therapy

https://www.facingourrisk.org/research-clinical-trials/study/221 /adding-parp-inhibitor-to-enzalutamide-to-treat-men-with-metastatic-prostate-cancer-that-is-resistant-to-anti-androgen-therapy


Treatment study for men with metastatic prostate cancer

This study is testing the effectiveness of adding a type of targeted therapy known as a PARP inhibitor to androgen-deprivation therapy for men with metastatic prostate cancer that has become resistant to standard androgen deprivation therapy.

 

Studying Types of Therapy for Coping With Fear of Recurrence Among Breast Cancer Survivors

https://www.facingourrisk.org/research-clinical-trials/study/216 /studying-types-of-therapy-for-coping-with-fear-of-recurrence-among-breast-cancer-survivors


People with stage 1-3 breast cancer who completed treatment within 5 years of enrollment

Fear of cancer recurrence (FCR) is a common problem for breast cancer survivors. This study will test the effectiveness of three types of online, group therapy for breast cancer survivors with FCR. 

Nivolumab vs Placebo Combined with Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy for High-risk ER+, HER2-Negative Breast Cancer (CheckMate 7FL)

https://www.facingourrisk.org/research-clinical-trials/study/143 /nivolumab-vs-placebo-combined-with-neoadjuvant-chemotherapy-adjuvant-endocrine-therapy-for-high-risk-er-her2-negative-breast-cancer-checkmate-7fl


Newly-diagnosed, non-metastatic, ER-positive, HER2-negative breast cancer

CA209-7FL: The purpose of a clinical trial is to look at whether the study drug, nivolumab, works in combination with neoadjuvant chemotherapy and adjuvant endocrine (hormone) therapy. The study will look at the safety profile of these study drug combinations and how well your body tolerates them. NOTE: This study is no longer enrolling patients. 

Diagnosis of Breast Cancer in Young Women - Share Your Story

https://www.facingourrisk.org/research-clinical-trials/study/113 /diagnosis-of-breast-cancer-in-young-women-share-your-story


Researchers from the University of Illinois, Chicago Cancer Center invite breast cancer survivors who were diagnosed under the age of 45 to share their diagnosis stories. You will be asked to use your own words to share your experience on an online questionnaire. 

Abiraterone/Prednisone and Olaparib Alone or In Combination for Treatment of Metastatic Castration-Resistant Prostate Cancer With Mutations Related to DNA Repair

https://www.facingourrisk.org/research-clinical-trials/study/203 /abirateroneprednisone-and-olaparib-alone-or-in-combination-for-treatment-of-metastatic-castration-resistant-prostate-cancer-with-mutations-related-to-dna-repair


Men with mCRPC with an inherited mutation or a tumor mutation in a DNA damage repair gene

This study is comparing three different treatments for men with metastatic castration-resistant prostate cancer, (mCRPC) who also have an inherited mutation or a tumor mutation in a gene that affects DNA damage repair. The study is open to men with inherited mutations found on genetic testing or tumor mutations in one of the following genes: ATM, BRCA1, BRCA2, FANCA, PALB2, RAD51, ERCC3, MRE11, NBN, MLH3, CDK12, CHEK2, HDAC2, ATR, PMS2, GEN1, MSH2, MSH6, BRIP1, or FAM175A.

A Phase 2 Study of Olaparib Monotherapy in Metastatic Breast Cancer Patients with Germline or Somatic Mutations in DNA Repair Genes (Olaparib Expanded)

https://www.facingourrisk.org/research-clinical-trials/study/68 /olaparib-expanded-treating-metastatic-breast-cancer-in-people-without-gbrca-mutations


Olaparib Expanded is a study looking at whether the drug Olaparib is effective treatment for people with certain types of metastatic breast cancer.  Olaparib belongs to a class of drugs known as PARP inhibitors. PARP inhibitors are particularly effective for treating tumors in people with an inherited BRCA mutation. This study is looking at whether olaparib is also effective for treating metastatic breast cancer in people who do not have an inherited BRCA mutation. Currently the study is only recruiting people with an inherited PALB2 mutation or people who test negative for an inherited mutation in BRCA1 or BRCA2 but have an acquired (somatic) BRCA1 or BRCA2 mutation found on tumor testing. 

Treatment for Metastatic Castration-Sensitive Prostate Cancer and Inherited or Tumor Mutations in DNA Damage Repair Genes (Amplitude)

https://www.facingourrisk.org/research-clinical-trials/study/209 /treatment-for-metastatic-castration-sensitive-prostate-cancer-and-inherited-or-tumor-mutations-in-dna-damage-repair-genes-amplitude


Treatment for metastatic castration-sensitive prostate cancer and a tumor or inherited mutation in BRCA1, BRCA2, ATM, BRIP1, CHEK2, PALB2 or related gene

The goal of AMPLITUDE is to see if adding the PARP inhibitor niraparib to standard of care hormone therapy (Abiraterone Acetate, prednisone and androgen deprivation therapy (ADT) is safe and more effective than standard of care alone. The study is enrolling people who have metastatic castration-sensitive prostate cancer and have an inherited or tumor mutation in one of the following genes involved in DNA damage repair: BRCA2, BRCA1, BRIP1, CHEK2, FANCA, PALB2, RAD51B and RAD54L. NOTE: This study is no longer enrolling patients. 

Exploring the Fertility Preservation Needs of Individuals with Positive Genetic Test Results

https://www.facingourrisk.org/research-clinical-trials/study/211 /exploring-the-fertility-preservation-needs-of-individuals-with-positive-genetic-test-results


Survey and video interview for people who tested positive for an inherited mutation

The goal of this study is to identify if there is a need for more specialized providers, specifically genetic counselors, to meet the needs of patients regarding fertility preservation and family planning prior to cancer treatment or preventative surgery. We hope to identify the appropriate setting and timeline for these services to streamline and enhance comprehensive patient care for patients with a hereditary breast or gynecologic cancer variant.

Factors Influencing Reproductive Decision-Making in Individuals with a BRCA1 or BRCA2 Gene Mutation

https://www.facingourrisk.org/research-clinical-trials/study/215 /factors-influencing-reproductive-decision-making-in-individuals-with-a-brca1-or-brca2-gene-mutation


Survey for people with a BRCA1 or BRCA2 mutation

This study will survey individuals with a mutation in the BRCA1 or BRCA2 gene. We are seeking experiences and opinions of individuals regarding childbearing and reproductive choices. This will allow healthcare professionals, especially genetic counselors, to learn about what information is needed due to psychosocial and medical factors. The survey is approximately 25 minutes long to complete and is available online.

Interview Study about Barriers to Genetic Testing of Family Members in Latin America

https://www.facingourrisk.org/research-clinical-trials/study/212 /interview-study-about-barriers-to-genetic-testing-of-family-members-in-latin-america


People with a hereditary cancer gene mutation and relatives living in Latin America

We are interviewing people who identify as Hispanic/Latinx/e with a genetic mutation associated with hereditary cancer and close family members who live in Latin America. This research study will describe genetic testing barriers and the communication of genetic risk to family members living in a Latin American country. The goal of this study is to improve the support that cancer genetic counselors can offer to individuals and their international family members. NOTE: This study is no longer enrolling. 

GENTleMEN Study: Genetic Testing for Men with Metastatic Prostate Cancer

https://www.facingourrisk.org/research-clinical-trials/study/63 /genetic-testing-for-men-with-metastatic-prostate-cancer-gentlemen-study


The goal of this research study is to determine if online genetic education and testing with online telephone genetic counseling is an acceptable method of delivering genetic testing to men with metastatic prostate cancer.

This study involves undergoing genetic counseling and genetic testing for inherited cancer risk.

 

Pancreatic Cancer Early Detection Program

https://www.facingourrisk.org/research-clinical-trials/study/20 /pancreatic-cancer-early-detection


This is a study looking at esophageal ultrasound and Magnetic Resonance Imaging (MRI) as a screening for pancreatic cancer in high risk individuals. 

Combination Drugs for Treating Metastatic Castration-Resistant Prostate Cancer with Tumor Mutation that Affect DNA Repair

https://www.facingourrisk.org/research-clinical-trials/study/206 /combination-drugs-for-treating-metastatic-castration-resistant-prostate-cancer-with-tumor-mutation-that-affect-dna-repair


Treatment study for men with metastatic castration-resistant prostate cancer

The goal of this study is to compare the effectiveness of three different drug combinations to treat men with metastatic castration-resistant prostate cancer (mCRPR), who also have a mutation in a gene that affects DNA repair found through tumor testing. 

 

Pragmatic Randomized Trial of Proton vs. Photon Therapy for Patients with Non-Metastatic Breast Cancer Receiving Comprehensive nodal Radiation: A Radiotherapy Comparative Effectiveness Trial

https://www.facingourrisk.org/research-clinical-trials/study/56 /radcomp-a-study-at-the-heart-of-breast-cancer-treatment


The RadComp Study, short for Radiotherapy Comparative Effectiveness, is a nationwide clinical study comparing two FDA approved radiation therapies for the treatment of breast cancer, PHoton Therapy vs. PRoton Therapy. With any radiation treatment to the breast, the heart may be exposed to radiation potentially resulting in heart problems in the future. Both Photon and Proton therapies are FDA approved; however, to date doctors do not know which therapy is better or worse in terms of reducing side effects and promoting length and quality of life after radiation.

We hope to learn: The effectiveness of proton vs. photon therapy in reducing major cardiovascular events and how treatment affects patient’s quality of life, such as financial burden, fatigue, and anxiety. These objectives were chosen as study priorities by breast cancer patients themselves.

Zoom Interviews to Explore Ideas about Long-Term Follow-Up Cancer Genetic Counseling

https://www.facingourrisk.org/research-clinical-trials/study/213 /zoom-interviews-to-explore-ideas-about-long-term-follow-up-cancer-genetic-counseling


Interviews with adults that have recently met with a cancer genetic counselor in the U.S., regardless of genetic testing outcome

This study aims to explore perceptions of patients and genetic counselors about long-term follow-up in cancer genetic counseling, including if and how patients would like additional follow-up with a genetic counselor beyond the pre- and post-test counseling session. If you wish to participate, email the student investigator to schedule a voluntary 30–60-minute Zoom interview. All information will be de-identified. There are no costs associated with participation. NOTE: This study is no longer enrolling. 

UCLA Research Study: Zoom Interviews to Learn from Asian Americans Living with Metastatic Cancer

https://www.facingourrisk.org/research-clinical-trials/study/174 /ucla-research-study-zoom-interviews-to-learn-from-asian-americans-living-with-metastatic-cancer


Asian Americans with metastatic cancer of any type

We would like to invite you to share your experiences to help improve the quality of life for Asian Americans diagnosed with metastatic cancer. NOTE: This study is no longer enrolling. 

Metastatic Pancreatic Cancer in US

https://www.facingourrisk.org/research-clinical-trials/study/194 /metastatic-pancreatic-cancer-in-us


People with metastatic pancreatic cancer and their caregivers

Global Patients along with IQVIATM, a worldwide healthcare consulting firm, is currently conducting a research study, to better understand the experience of patients and/or caregivers of patients living with metastatic pancreatic cancer.

Interviews for People With a Genetic Test Result That was Later Reclassified

https://www.facingourrisk.org/research-clinical-trials/study/193 /interviews-for-people-with-a-genetic-test-result-that-was-later-reclassified


People with a genetic test result that was later reclassified

Researchers at MD Anderson Cancer Center are conducting telephone interviews with individuals who have received modified (also known as reclassified or amended) genetic test results in any cancer related gene. We are interested in learning about the experience of receiving a modified test result and decisions made. 

Studying Crowdfunding for Cancer

https://www.facingourrisk.org/research-clinical-trials/study/187 /studying-crowdfunding-for-cancer


Cancer survivors who have used crowdfunding to help cover cancer-related costs

This is a study on how the practice of crowdfunding affects the experience of having cancer. With the support of the National Science Foundation (NSF award #2021152), the researcher is interviewing cancer patients/survivors and their supporters about their use of crowdfunding platforms like GoFundMe. earcher is interviewing cancer patients/survivors and their supporters about their use of crowdfunding platforms like GoFundMe. 

Survey: Making Decisions about Genetic Testing

https://www.facingourrisk.org/research-clinical-trials/study/189 /survey-making-decisions-about-genetic-testing


Survey for adults who have had genetic testing for inherited cancer risk through a doctor

You are invited to participate in an anonymous online survey about your decision to do genetic testing and how you dealt with the uncertainty of the outcome. The online survey includes a newly developed Uncertainty Management Scale (UMS) based on our years of prior uncertainty research. Knowing more about how people manage uncertainty may be helpful to society. You will be compensated $10 for completing the survey. This study is no longer enrolling. 

Interview Study about Hispanic/Latino Community Experiences Accessing Genetic Testing for Hereditary Cancer Risk

https://www.facingourrisk.org/research-clinical-trials/study/191 /interview-about-hispaniclatino-community-experiences-accessing-genetic-testing-for-hereditary-cancer-risk


Hispanic/Latino people with a personal diagnosis of cancer or a family history of cancer

This study is looking at how to improve access to genetic testing among Hispanic/Latino populations in the U.S. We are conducting interviews with people in the Hispanic/Latino community who have either received genetic testing for hereditary cancer risk, or who have a family history of hereditary cancer and/or cancer diagnosis. This study could help develop policy options to inform how to improve access to genetic testing. Email Amanda Gutierrez at [email protected] if you are interested in participating. NOTE: This study is no longer enrolling.

Targeted Therapy RP-3500 Alone or in Combination with Talazoparib or Gemcitabine in Advanced Solid Tumors with DNA Damage Repair Mutations (TRESR Study)

https://www.facingourrisk.org/research-clinical-trials/study/179 /targeted-therapy-rp-3500-alone-or-in-combination-with-talazoparib-or-gemcitabine-in-advanced-solid-tumors-with-dna-damage-repair-mutations-tresr-study


Advanced solid tumors

This study is looking at how well a drug called RP-3500 works either alone or when combined with other cancer treatments in people with different types of advanced cancers with a mutation in one of the following genes: BRCA1, BRCA2, ATM, RAD51B, RAD51C, RAD51D, ATRIP, CHTF8, FZR1, MRE11, NBN, RAD17, RAD50, REV3L, SETD2 or RNASEH2. RP-3500 is a type of oral, targeted therapy known as an ATR inhibitor. The combination prescribed will depend on cancer type and mutation and when people join the study.

ATR Inhibitor BAY 1895344 Plus Niraparib Phase 1b Study in Advanced Solid Tumors and Ovarian Cancer

https://www.facingourrisk.org/research-clinical-trials/study/155 /atr-inhibitor-plus-niraparib-study-in-advanced-solid-tumors-and-ovarian-cancer


Advanced ovarian cancer or other solid tumors

This study will look at how well how well people with advanced ovarian, fallopian tube or primary peritoneal cancer or other solid tumors respond to treatment with the targeted therapy BAY1895344 in combination with the PARP inhibitor niraparib.

A Survey on Health Behaviors for Women with BRCA1/2 Mutations

https://www.facingourrisk.org/research-clinical-trials/study/190 /a-survey-on-health-behaviors-for-women-with-brca12-mutations


Survey for women with a BRCA1 or BRCA2 mutation

Researchers in the National University of Ireland, Galway are looking for people to take part in a survey on BRCA1/2 alteration carriers and health behaviours. The once-off survey asks questions about how you cope and what you think about health behaviours. Note: This study is closed to enrollment.

Survey: Medical Records to Save After a Cancer Diagnosis

https://www.facingourrisk.org/research-clinical-trials/study/162 /survey-medical-records-to-save-after-a-cancer-diagnosis


Adults with cancer

In less than 5 minutes, learn which medical records are important to keep after a cancer diagnosis, why they are important to save, and ideas of how to keep them for you and your family.  The study has been IRB-approved by UC Irvine and is available in English and Spanish!  Note: This study is now closed to enrollment.

Investigating BRCA Previvors’ Utilization of Social Media for Health Decision Making and Social Support

https://www.facingourrisk.org/research-clinical-trials/study/173 /investigating-brca-previvors-utilization-of-social-media-for-health-decision-making-and-social-support


Women with a BRCA1 or BRCA2 mutation who have never had cancer

This study investigates why women share aspects of their previvorship identity on social media platforms. We are interviewing women above 18 years old, who carry known pathogenic variants in BRCA1 or BRCA2, and share their previvor journey on social media platforms like Instagram, Facebook, Twitter, and TikTok at least once every other week. We are conducting anonymous interviews over Zoom with women who qualify. If you are interested, contact Mariah Wellman at [email protected]. NOTE: This study is no longer enrolling people. 

Survey: How Willing are You to Participate in Different Types of Clinical Trials for the Prevention of Breast Cancer?

https://www.facingourrisk.org/research-clinical-trials/study/188 /survey-how-willing-are-you-to-participate-in-different-types-of-clinical-trials-for-the-prevention-of-breast-cancer


This study looks at why women at an increased risk of developing breast cancer are interested or uninterested in participating in breast cancer prevention clinical trials. The study consists of a 10-15 minute (max) anonymous questionnaire that asks hypothetical questions about participating in clinical trials with various study designs. This study’s findings may be used to better inform how to best design clinical trials aimed at the prevention of a breast cancer in the future. NOTE: This study is no longer enrolling.

Survey for Caregivers of Relatives in Families with an Inherited Mutation Linked to Cancer

https://www.facingourrisk.org/research-clinical-trials/study/150 /survey-for-caregivers-of-relatives-in-families-with-an-inherited-mutation-linked-to-cancer


This anonymous survey is being conducted by researchers at the National Human Genome Research Institute of the National Institutes of Health, in collaboration with Facing Our Risk of Cancer Empowered (FORCE). The goal of this survey is to help researchers understand the caregiving experiences of families affected by hereditary cancer. By sharing your experience with us, you can help us develop more resources to improve the experience of future family caregivers.  NOTE: THIS STUDY IS NO LONGER ENROLLING.

 

Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer (MOUNTAINEER)

https://www.facingourrisk.org/research-clinical-trials/study/115 /tucatinib-plus-trastuzumab-in-patients-with-her2-colorectal-cancer-mountaineer


This is a study for people who have been diagnosed with HER2-positive (HER2+) metastatic colorectal cancer (mCRC).  The goal of this study is to look at how well the drug tucatinib (Tukysa) works to improve outcomes when given with trastuzumab (Herceptin), versus how well tucatinib works when administered by itself. NOTE: This study is no longer enrolling patients. 

Using ctDNA Blood Test to Screen for Cancer DNA after Treatment for Early-Stage TNBC and/or an Inherited or Tumor BRCA Mutation; Followed by Study Comparing Niraparib with Placebo for People with Cancer DNA found in their Blood (ZEST)

https://www.facingourrisk.org/research-clinical-trials/study/170 /screening-for-cancer-dna-in-the-blood-after-treatment-for-early-stage-tnbc-andor-a-brca-mutation-followed-by-study-comparing-niraparib-with-placebo-for-people-with-cancer-dna-found-in-their-blood-zest


Early-stage TNBC or early-stage breast cancer with a BRCA mutation

This study will enroll people with early-stage triple negative breast cancer or people with an inherited or acquired BRCA1 or BRCA2 mutation who have completed treatment (or are still in treatment with hormone therapy) for screening using a blood test known as circulating tumor DNA (ctDNA). Individuals who test positive for ctDNA may be eligible to participate in a randomized study to receive the PARP inhibitor, niraparib or a placebo and undergo close monitoring with imaging (CT scans). The study will look at the safety and efficacy of niraparib plus monitoring compared with placebo plus monitoring for people who test positive for cancer cells in their blood but who have no evidence of cancer recurrence. NOTE: This study is no longer enrolling. 

A National Survey to Share the Voices of Ovarian Cancer Caregivers

https://www.facingourrisk.org/research-clinical-trials/study/167 /a-national-survey-to-share-the-voices-of-ovarian-cancer-caregivers


Caregivers to people with ovarian cancer

We would like to invite you to make your views heard as to the real-world burden and impact of ovarian cancer.  The research hopes to identify areas for improvement in supporting the lives of people who care for patients living with ovarian cancer. By taking part in the survey your views, alongside those of other caregivers of women living with ovarian cancer will be heard. This will help generate the scientific evidence required to ensure healthcare professionals and other healthcare supporting bodies have a deep understanding about what it is like to live with advanced ovarian cancer and can help provide them with the tools to support patients, caregivers, and their families. NOTE: This survey is closed to enrollment.

Treating Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer with Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib

https://www.facingourrisk.org/research-clinical-trials/study/133 /treating-metastatic-pancreatic-colorectal-gastroesophageal-or-biliary-cancer-with-chemotherapy-and-rucaparib


Metastatic colorectal, pancreatic, gastroesophageal or biliary tract cancer

This study is focused on patients with pancreatic, colorectal, gastroesophageal, or biliary (bile duct) cancer that has spread to other places in the body (metastasized). NOTE: This study is no longer enrolling patients. 

Talazoparib in Treating Patients With Recurrent, Advanced, or Metastatic Cancers and Inherited or Acquired Gene Mutations

https://www.facingourrisk.org/research-clinical-trials/study/152 /talazoparib-in-treating-patients-with-recurrent-advanced-or-metastatic-cancers-and-inherited-or-acquired-gene-mutations


This study will look at how well the PARP inhibitor talazoparib works in treating patients with cancers that have returned after a period of improvement, do not respond to treatment, or have spread to other parts of the body, and have inherited mutations or tumor mutations in BRCA or other specific genes. NOTE: This study is no longer enrolling patients. 

Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel for Recurrent or Primary Advanced Endometrial Cancer (RUBY)

https://www.facingourrisk.org/research-clinical-trials/study/166 /dostarlimab-plus-carboplatin-paclitaxel-versus-placebo-plus-carboplatin-paclitaxel-for-recurrent-or-primary-advanced-endometrial-cancer-ruby


Metastatic endometrial cancer

This study for people with Stage III or Stage IV endometrial cancer will look at how well the combination of an immunotherapy plus targeted therapy and chemotherapy works compared with chemotherapy alone.  NOTE: This study is no longer enrolling people. 

TALAPRO-2: A study Assessing the Study Drug + Enzalutamide vs. Placebo + Enzalutamide in Men with Metastatic Castration Resistant Prostate Cancer (mCRPC) and DNA Damage Repair (DDR) Deficiency

https://www.facingourrisk.org/research-clinical-trials/study/98 /talapro-2-a-study-assessing-the-study-drug-enzalutamide-vs-placebo-enzalutamide-in-men-with-metastatic-castration-resistant-prostate-cancer-mcrpc-and-dna-damage-repair-ddr-deficiency


The TALAPRO-2 study is assessing whether the study drug is safe and effective when given in combination with enzalutamide as a treatment option for men with metastatic castration-resistant prostate cancer and DDR deficiency. NOTE: This study is no longer enrolling patients. 

A National Survey to Share the Voice and Treatment Preferences of Ovarian Cancer Patients

https://www.facingourrisk.org/research-clinical-trials/study/163 /a-national-survey-to-share-the-voice-and-treatment-preferences-of-ovarian-cancer-patients


Ovarian cancer

We would like to invite you to make your views heard as to the real-world burden and impact of ovarian cancer and preference for different ways of taking medication.  The research hopes to identify areas for improvement in supporting the lives of patients living with ovarian cancer and the people that care for them after 1st surgery and chemotherapy.  NOTE: This survey is closed to enrollment.

Interview: Understanding the Experiences of Black Women after Cancer Genetic Testing

https://www.facingourrisk.org/research-clinical-trials/study/160 /understanding-the-experiences-of-black-women-after-cancer-genetic-testing


Black women who have tested positive for an inherited mutation

We are looking to interview Black women who have received a positive result in a cancer-associated genetic test. We want to hear your story. This research will look at Black women's experiences with cancer genetic testing. If you decide to take part in the study, you would participate in an approximately hour-long phone interview. Participants will be compensated for their time with a $20 gift card. Contact Malika Sud at [email protected] for more information or to participate. NOTE: This study is now closed. 

HOPE: Olaparib, Palbociclib and Fulvestrant for BRCA-Associated, ER/PR-Positive, Her2-Negative Metastatic Breast Cancer

https://www.facingourrisk.org/research-clinical-trials/study/147 /olaparib-palbociclib-and-fulvestrant-for-brca-associated-erpr-positive-her2-negative-metastatic-breast-cancer


The goal of this study is to find the best dose and measure side effects of palbociclib when given together with olaparib and fulvestrant, in treating people with hormone receptor-positive (HR+), HER2-negative metastatic breast cancer who have a BRCA1 or BRCA2 mutation. Palbociclib and Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Fulvestrant is a type of treatment that may prevent breast cancer cell growth by blocking estrogen and progesterone receptor stimulation.

Fear of Recurrence, Adversity, and Pain

https://www.facingourrisk.org/research-clinical-trials/study/161 /fear-of-recurrence-adversity-and-pain


We are investigating the relation of adversity, pain, and fear of cancer recurrence among adult cancer survivors. Participation involves completing a 30-minute computerized survey online from your home computer. No compensation is being offered for participation in this research study.

Enhancing Genetic Risk Assessment in Underserved Blacks and Latinas at Risk of Hereditary Breast Cancer

https://www.facingourrisk.org/research-clinical-trials/study/142 /breast-and-ovarian-cancer-education-research-for-african-americanblack-and-latina-women


Researchers are conducting a study to test how well education materials increase use knowledge about hereditary cancer risk. Participants will watch 90 minutes of educational videos and complete 2 short surveys. In all, this will take approximately 3 hours to complete over a two-week period. Everything will be completed over the phone or online. Compensation will be provided for participation. NOTE: This study is no longer enrolling participants. 

Treating Metastatic Pancreatic Cancer with an Inherited or Tumor BRCA1/2 or PALB2 Mutation with Niraparib and Dostarlimab

https://www.facingourrisk.org/research-clinical-trials/study/135 /treating-metastatic-pancreatic-cancer-with-an-inherited-or-tumor-brca12-or-palb2-mutation-with-niraparib-and-dostarlimab


This study looks at how well the PARP inhibitor niraparib and the immunotherapy drug dostarlimab work together in treating patients with metastatic pancreatic cancer, who also have an inherited or tumor mutation in one of the following genes: BRCA1, BRCA2, PALB2, BARD1, RAD51c, or RAD51d.

AMPLIFY: a new online weight loss study specifically for cancer survivors!

https://www.facingourrisk.org/research-clinical-trials/study/139 /amplify-a-new-online-weight-loss-study-specifically-for-cancer-survivors


AMPLIFY is a nation-wide, web-based diet and exercise study recruiting overweight survivors of early stage breast, prostate, ovarian, renal, colorectal and endometrial cancer and multiple myeloma. This study is enrolling qualified cancer survivors age 50 and older who are interested in becoming more active, eating better and losing weight.

Treating Advanced Solid Tumors in People with Inherited PTEN Mutations Using the Investigational Drug TAS-117

https://www.facingourrisk.org/research-clinical-trials/study/159 /treating-advanced-solid-tumors-in-people-with-inherited-pten-mutations-using-the-investigational-drug-tas-117


People with advanced cancer and an inherited PTEN mutation

This study will look at how well the targeted therapy TAS-117 works for treating people with an inherited PTEN mutation and advanced or metastatic solid tumors (excluding primary brain tumors). 

Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After First-Line Treatment in Advanced Triple Negative Breast Cancer (KEYLYNK-009)

https://www.facingourrisk.org/research-clinical-trials/study/148 /olaparib-plus-pembrolizumab-versus-chemotherapy-plus-pembrolizumab-after-first-line-treatment-in-advanced-triple-negative-breast-cancer-keylynk-009


This study will look at how people with advanced triple-negative breast cancer (TNBC) respond to different combinations of drugs. During an initial study period participants will receive a combination of chemotherapy and immunotherapy drugs. Participants with stable cancer or an improvement will be able to continue with the study. Continuing participants will be assigned to one of two groups. One group will receive the same drug combination during the followup period. The second group will instead immunotherapy plus a type of targeted therapy known as a PARP inhibitor during the follow-up period.  NOTE: This study is no longer enrolling patients. 

Pembrolizumab Plus Lenvatinib Versus Chemotherapy for Endometrial Cancer

https://www.facingourrisk.org/research-clinical-trials/study/114 /pembrolizumab-plus-lenvatinib-versus-chemotherapy-for-endometrial-cancer


The purpose of this study is to compare the effectiveness of using a combination of the immunotherapy drug pembrolizumab (Keytruda) and the targeted therapy lenvatinib (Lenvima) in women with Stage III, IV, or recurrent endometrial cancer versus using chemotherapy treatment alone. NOTE: This study has completed enrollment

TALAVE: A Pilot Trial of Induction Talazoparib Followed by Combination of Talazoparib and Avelumab in Advanced Breast Cancer

https://www.facingourrisk.org/research-clinical-trials/study/125 /talave-talazoparib-followed-by-combination-of-talazoparib-and-avelumab-in-advanced-breast-cancer


TALAVE is a study for patients who have advanced or metastatic breast cancer that will not be cured by treatment with surgery or radiotherapy, and either have a BRCA1/2 mutation (germline or somatic) or have triple negative breast cancer who are not known to have a BRCA1/2 mutation. The goal of TALAVE is to look at whether giving talazoparib alone followed by talazoparib with avelumab is a safe and effective treatment for advanced breast cancer. THIS STUDY IS NO LONGER ENROLLING.

COVID-19 Breast Cancer Care Survey

https://www.facingourrisk.org/research-clinical-trials/study/145 /covid-19-breast-cancer-care-survey


The purpose of this research study is to learn about how the COVID-19 pandemic has affected cancer care and quality of life in breast cancer survivors. Participants will complete an online survey and some women will be invited to participate in an online interview to learn more about their cancer treatment experiences during the pandemic. NOTE: This study is no longer enrolling. 

Omega 3 Fatty Acids in Colorectal Cancer (CRC) Prevention in Patients With Lynch Syndrome (COLYNE)

https://www.facingourrisk.org/research-clinical-trials/study/146 /omega-3-fatty-acids-in-colorectal-cancer-crc-prevention-in-patients-with-lynch-syndrome-colyne


This study looks at how well omega-3 fatty acid ethyl esters (generic Lovaza) work in preventing colorectal cancer in patients with Lynch syndrome. Omega-3 fatty acids work by decreasing inflammation, or swelling, in the body, and suppressing certain chemicals in the body that are known to cause cancer. The addition of omega-3 fatty acids to patients' diets may help decrease colon inflammation or suppress cancer-causing chemicals in the body. NOTE: This study is no longer enrolling people. 

Research Study to Help Improve Family Communication About Inherited Mutations

https://www.facingourrisk.org/research-clinical-trials/study/118 /research-study-to-help-improve-family-communication-about-inherited-brca1-or-brca2-mutations


The Ohio State University and FORCE want to understand if a family communication guide for people with BRCA mutations is helpful and if it’s also useful to have a video that you can text or email to family members that explains your BRCA mutation. We are currently looking for people between the ages of 18-80 who have mutation in BRCA1 or BRCA2, have an active email address, and an internet capable device like a computer, tablet, or smartphone.  Participants will be asked to complete a total of 3 surveys.  Participants will be randomly assigned to either receive just the communication guide or the guide plus the sharable.  Each survey will take 10-15 minutes (the study could take up to 1.5 hours to complete depending on how much time you spend reviewing the study materials). 

You can get more information or ask to participate in the study by sending an email to: [email protected].

Phase 1/1b Study of Oral Drug PMD-026 in People with Metastatic Breast Cancer and Metastatic Triple Negative Breast Cancer

https://www.facingourrisk.org/research-clinical-trials/study/124 /phase-1-study-of-oral-drug-pmd-026-in-people-with-metastatic-breast-cancer-and-metastatic-triple-negative-breast-cancer


PMD-026 is a study for people who have been diagnosed with metastatic triple negative breast cancer (mTNBC) who have no further treatment options. This research study is investigating if a study drug called PMD-026 is safe and effective for patients with mTNBC. NOTE: This study is no longer enrolling. 

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer

https://www.facingourrisk.org/research-clinical-trials/study/111 /addition-of-pembrolizumab-to-radiation-treatment-for-newly-diagnosed-early-stage-msi-high-endometrial-cancer


The purpose of this study is to determine whether the addition of the immunotherapy agent pembrolizumab to radiation therapy is more effective than radiation therapy alone in reducing the risk of cancer recurrence in patients with newly diagnosed stage I-II endometrial cancer that is MSI-High. This study is no longer enrolling.

A Study of EDP1503 in Patients With Colorectal or Triple Negative Breast Cancer or Cancer That Came Back After Treatment with a Checkpoint Inhibitor

https://www.facingourrisk.org/research-clinical-trials/study/116 /a-study-of-edp1503-in-patients-with-colorectal-cancer-breast-cancer-or-checkpoint-inhibitor-relapsed-tumors


Medicines that affect bacteria in the stomach and intestines may assist immunotherapy agents like pembrolizumab (Keytruda) in treating cancer. This study will look at the effect of a drug, EDP1503 on enhancing the anti-cancer response when used with pembrolizumab, in patients with advanced metastatic colorectal carcinoma, triple-negative breast cancer, or cancers that have recurred after a type of immunotherapy known as an immune checkpoint inhibitor. NOTE: This this study is no longer enrolling patients. 

RESTORE: A virtual study comparing 2 digital apps to improve mental and physical well-being of patients with stage I – 3 cancer

https://www.facingourrisk.org/research-clinical-trials/study/192 /restore-a-virtual-study-comparing-2-digital-apps-to-improve-mental-and-physical-well-being-of-patients-with-stage-i-3-cancer


People with stage 1-3 cancer

Many cancer patients experience cancer-related distress, which includes psychological symptoms of anxiety and depression. The RESTORE study will enroll up to 415 adults who have been diagnosed with stage I-III cancer. The goal is to test how effective two different apps are at improving physical and mental health. Participants use their smartphone or tablet to download and access their assigned treatment app without ever needing to visit a clinic in person.

Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects

https://www.facingourrisk.org/research-clinical-trials/study/58 /parp-inhibitor-for-metastatic-prostate-cancer-with-dna-repair-defects


This is a phase II study looking at different treatment combinations for men with metastatic, castration resistant prostate cancer (mCRPC) to see which is most effective for improving progression free survival (keeping the cancer from progressing). The study will include testing for genes within the tumor to determine eligibility for the study. 

Patients with tumors that have ATM, BRCA1 and/or BRCA2 mutations or defects will be randomly assigned to one of the treatment arms of the study. Patients with tumors that have mutations in other DNA repair genes including FANCA, PALB2, RAD51, ERCC3, MRE11, NBN, MLH3, CDK12, CHEK2, HDAC2, ATR, PMS2, GEN1, MSH2, MSH6, BRIP1, or FAM175A will be assigned to Arm IV with single agent olaparib. NOTE: This study is now closed. 

Mobile Mindfulness Meditation Intervention to Improve Neuropathy in Cancer Survivors

https://www.facingourrisk.org/research-clinical-trials/study/132 /mobile-mindfulness-meditation-intervention-to-improve-neuropathy-in-cancer-survivors


Aloha! The University of Hawai‘i Cancer Center is running a mobile app study to see how it impacts cancer-related neuropathy. We are asking people who have been diagnosed with cancer, have finished primary treatment and are experiencing neuropathy if they would like to use a mobile app for mindfulness meditation to see if it helps their neuropathy.  

Interested participants will be asked to follow the link for either anxiety OR neuropathy and to participate in only one of the studies, one time only. Upon enrollment, you will randomly be assigned to begin using the mobile app either immediately or after eight weeks. You will be asked to complete online questionnaires about your well-being upon your initial enrollment, 8 weeks later, and 16 weeks later.

Niraparib + Ipilimumab or Nivolumab in Pancreatic Cancer that Has Not Progressed After Platinum Chemotherapy (Parpvax)

https://www.facingourrisk.org/research-clinical-trials/study/136 /niraparib-ipilimumab-or-nivolumab-in-pancreatic-cancer-that-has-not-progressed-after-platinum-chemotherapy-parpvax


The purpose of this study is to look at the effectiveness, safety, and anti-cancer activity of the drug Niraparib combined with one of two immunotherapy agents: Ipilimumab or Nivolumab on patients with locally advanced or metastatic pancreatic cancer.  Patients in this study must also have previously received Platinum-based chemotherapy without evidence of disease progression.  NOTE: This study is no longer enrolling patients. 

Parenting Adolescent-Aged Children While Managing a Parental Cancer Diagnosis – Share Your Story

https://www.facingourrisk.org/research-clinical-trials/study/130 /parenting-adolescent-aged-children-while-managing-a-parental-cancer-diagnosis-share-your-story


The study explores how families faced with a parental cancer diagnosis communicate, or why they choose not to communicate, with their children about the cancer diagnosis, treatments, and other related topics. At least one family member (diagnosed parent or non-diagnosed parent) is asked to participate, but more than one member can sign up to be interviewed. NOTE: This study is no longer enrolling people. 

Mobile Mindfulness Meditation Intervention to Improve the Well-Being of Cancer Survivors

https://www.facingourrisk.org/research-clinical-trials/study/131 /mobile-mindfulness-meditation-intervention-for-cancer-survivors


Aloha! The University of Hawai‘i Cancer Center is running a mobile app study to see how it impacts different areas of well-being in cancer survivors – namely, anxiety and cancer-related neuropathy. We are asking people who have been diagnosed with cancer and finished primary treatment if they would like to use a mobile app for mindfulness meditation to see if it impacts anxiety.  

Interested participants will be asked to follow the link for anxiety. Upon enrollment, you will randomly be assigned to begin using the mobile app either immediately or after eight weeks. You will be asked to complete online questionnaires about your well-being upon your initial enrollment, 8 weeks later, and 16 weeks later.

Nous-209 Genetic Vaccine for the Treatment of Microsatellite -High (MSI-H) Colorectal, Gastric and Gastro-esophageal junction Tumors

https://www.facingourrisk.org/research-clinical-trials/study/105 /nous-209-genetic-vaccine-for-the-treatment-of-msi-h-colorectal-gastric-and-gastro-esophageal-junction-tumors


Treatment study for people with advanced colorectal, gastric and gastro-esophageal junction tumors

The goal of this cancer treatment study is to find the best dose and learn how safe and effective this cancer vaccine is for treating advanced colorectal, gastric and gastro-esophageal junction tumors that test positive for the biomarkers MSI-High or dMMR. Participants will receive the vaccine in combination with the immunotherapy drug Keytruda (pembrolizumab). 

A Study of Rucaparib Verses Physician's Choice of Therapy in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency (TRITON3)

https://www.facingourrisk.org/research-clinical-trials/study/17 /triton3-rucaparib-vs-physician-choice-for-castration-resistant-prostate-cancer


The purpose of Triton3 is to determine how patients with metastatic castration-resistant prostate cancer, and an inherited gene mutation or tumor genetic deficiency, respond to treatment with the PARP inhibitor rucaparib compared to treatment with physician's choice of abiraterone acetate, enzalutamide, or docetaxel. NOTE: This study is no longer enrolling patients. 

Prostate Cancer Genetic Risk, Experience, and Support Study (PROGRESS)

https://www.facingourrisk.org/research-clinical-trials/study/108 /prostate-cancer-genetic-risk-experience-and-support-study-progress


Prostate Cancer Genetic Risk, Experience, and Support Study (PROGRESS) is a national, patient-driven registry for any male who has undergone or is currently undergoing genetic testing for prostate cancer. Note: This study is no longer enrolling. 

 

A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment with Immune Checkpoint Inhibitors (QUILT-3.055)

https://www.facingourrisk.org/research-clinical-trials/study/106 /combination-immunotherapies-in-patients-who-previously-received-immune-checkpoint-inhibitors-quilt-3055


Immune checkpoint inhibitors immunotherapy drugs that allow the immune system to find and destroy cancer cells.

This study will use a combination of immunotherapies in people who's cancer got worse after treatment with a PD-1 or PD-L1 immune checkpoint inhibitor. NOTE: This study is no longer recruiting.

Safety and Efficacy of Olaparib Combined with Agents Targeting DNA Damage Repair Compared to Olaparib Alone

https://www.facingourrisk.org/research-clinical-trials/study/104 /olaparib-combined-with-agents-targeting-dna-damage-repair-compared-to-olaparib-alone


The purpose of this study is to assess the efficacy and safety of treatment with the PARP inhibitor, olaparib combined with the drug Ceralasertib compared with olaparib alone for patients with Triple-Negative Breast Cancer.

NOTE: This study is no longer enrolling patients. 

A Study of Nivolumab Combined With Ipilimumab and Nivolumab Alone in Patients With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden

https://www.facingourrisk.org/research-clinical-trials/study/77 /studying-a-combination-of-immunotherapies-and-biomarker-for-advanced-solid-tumors


This study is researching a combination of two immunotherapy drugs for advanced solid tumors that contain a tumor biomarker known as "High Tumor Mutation Burden" (TMB-H). The researchers are studying whether treatment  of these tumors with a combination of the drugs nivolumab plus ipilimumab is safe and effective compared with nivolumab alone. NOTE: This study is no longer enrolling.

A Study of Nivolumab in Selected Uterine Cancer Patients

https://www.facingourrisk.org/research-clinical-trials/study/110 /a-study-of-nivolumab-in-selected-uterine-cancer-patients


The purpose of this study is to test the effectiveness, safety, and tolerability of Nivolumab on patients with metastatic or recurrent uterine cancer. 

Nivolumab is a type of immunotherapy known as an immune checkpoint inhibitor. Immune checkpoint inhibitors are drugs that prevent cancer cells from switching off immune cells. This allows the immune system to find, unmask and destroy cancer cells.  NOTE: This study is no longer enrolling. 

GENetic Education Risk Assessment and TEsting Study (GENERATE)

https://www.facingourrisk.org/research-clinical-trials/study/69 /generate


The goal of the GENERATE study is to increase the uptake of genetic testing among family members of pancreatic cancer patients who may carry a genetic mutation.

This study involves education about genetic testing, undergoing genetic testing for cancer risk (for those who choose to) and completion of a series of 4 sets of questionnaires. Note: This study is no longer enrolling patients.

 

A Study in Advanced Breast Cancer Patients with BRCA 1/2 Mutations Evaluating Olaparib alone or in Combination with Atezolizumab

https://www.facingourrisk.org/research-clinical-trials/study/66 /parp-inhibitor-alone-or-plus-immunotherapy-for-advanced-brca-associated-breast-cancer


This is a study for women or men who have been diagnosed with advanced breast cancer with a BRCA 1/2 mutation. The goal of the study is to look at whether giving the PARP inhibitor olaparib in combination with the immunotherapy atezolizumab improves outcomes for patients compared to olaparib alone.  NOTE: This study is no longer enrolling people.

 

Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair

https://www.facingourrisk.org/research-clinical-trials/study/107 /combination-chemotherapy-with-or-without-atezolizumab-in-treating-patients-with-stage-iii-colon-cancer-and-deficient-dna-mismatch-repair


This study is no longer enrolling people. 

PHACT Study: Population Health and Cancer Testing

https://www.facingourrisk.org/research-clinical-trials/study/75 /phact-study


NOTE: The PHACT study is no longer recruiting patients. 

Pilot Study of Denosumab in BRCA1 or BRCA2 Mutation Carriers Scheduling Risk-Reducing Salpingo-Oophorectomy

https://www.facingourrisk.org/research-clinical-trials/study/74 /denosumab-in-brca1-or-brca2-mutation-carriers-scheduling-risk-reducing-salpingo-oophorectomy


The purpose of this study is to evaluate the effects of denosumab on ovarian cancer risk markers among premenopausal women with a BRCA1 or BRCA2 mutation, who are scheduled to undergo risk-reducing surgery to remove their ovaries and fallopian tubes. UPDATE: THIS STUDY HAS BEEN DISCONTINUED.

A Study in Hereditary Breast and Ovarian Cancer Families to Provide Men With Up To Date Information About the Personal Importance of Genetic Testing (GEM)

https://www.facingourrisk.org/research-clinical-trials/study/65 /genetic-education-for-men-gem-study


The Genetic Education for Men or GEM study, is a clinical trial evaluating educational tools for men from families in which a BRCA1/2 gene mutation has been identified. In order to identify untested men from BRCA1/2 families, we are seeking women who have received positive BRCA1/2 test results and have at least one untested male relative. NOTE: This study is no longer enrolling people. 

A Phase 2 Study of Nivolumab in Combination with Either Rucaparib, Docetaxel, or Enzalutamide in Men with Castration-resistant Metastatic Prostate Cancer (CheckMate-9KD)

https://www.facingourrisk.org/research-clinical-trials/study/64 /checkmate-9kd-for-men-with-metastatic-prostate-cancer


CheckMate-9KD is a clinical research study for men with metastatic prostate cancer (which means cancer that has spread) that no longer responds to treatments that lower testosterone. The purpose of this study is to compare three different combination therapies, each containing a drug called nivolumab and another anti-cancer drug. All three combination therapies are considered investigational, which means that they are not currently approved to treat men with metastatic prostate cancer. The study doctors want to learn more about which therapy is most effective in treating metastatic prostate cancer. NOTE: This study is no longer enrolling. 

A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy (ATHENA)

https://www.facingourrisk.org/research-clinical-trials/study/62 /athena-rucaparib-and-nivolumab-for-maintenance-in-ovarian-cancer


ATHENA is a study for women who are newly diagnosed with ovarian cancer. The goal of ATHENA is to look at whether giving maintenance therapy with different agents improves outcomes for women who have completed front-line treatment. UPDATE: THIS STUDY IS NO LONGER ENROLLING PATIENTS

Decision Navigation for Advanced Prostate Cancer Treatment Options Using mHealth

https://www.facingourrisk.org/research-clinical-trials/study/59 /decision-navigation-for-advanced-prostate-cancer-treatment-options-using-mhealth


Men with advanced prostate cancer face difficult choices for treatment because of the nature of their disease and having limited options. This study will test the use of an innovative Registered Nurse-Community Patient Navigator team delivered interactive mHealth decision aid for patients with advanced prostate cancer to help facilitate informed shared decisions about anti-cancer treatment that affects their quality of life. NOTE: This study is no longer enrolling. 

Safety and Efficacy of Olaparib Alone Or in Combination with Medication Targeting DNA Damaging Repair for Metastatic Triple Negative Breast Cancer

https://www.facingourrisk.org/research-clinical-trials/study/91 /olaparib-plus-dna-damage-repair-targeted-therapy-for-metastatic-tnbc


The purpose of this study is to learn the safety and effectiveness of the PARP inhibitor, olaparib as a single drug therapy compared with olaparib in combination with the new agent AZD6738 in patients with metastatic Triple-Negative Breast Cancer (TNBC).  NOTE: This study is no longer enrolling people. 

Olive Oil for High Risk Breast Cancer Prevention

https://www.facingourrisk.org/research-clinical-trials/study/97 /olive-oil-for-high-risk-breast-cancer-prevention


This study will evaluate the effect of hydroxytyrosol, a component of olive oil, on breast density in women who are at high risk for developing breast cancer. UPDATE: THIS STUDY IS NO LONGER ENROLLING PATIENTS.

 

Auricular Point Acupressure to Self-Manage Aromatase Inhibitor Musculoskeletal Symptoms in Breast Cancer Survivors

https://www.facingourrisk.org/research-clinical-trials/study/94 /acupressure-to-self-manage-aromatase-inhibitor-musculoskeletal-symptoms-in-breast-cancer-survivors


Severe joint pain and muscle stiffness are common side effects of taking Aromatase Inhibitors.  Aromatase inhibitor musculoskeletal symptoms have a negative effect on a woman's physical function and quality of life. Auricular point acupressure uses stimulation applied to points on the ear without using needles. This study will look at and test auricular (ear) point acupressure to manage aromatase-inhibitor-caused joint pain and muscle stiffness in breast cancer survivors. 

Note: This study is no longer enrolling patients.

 

A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Patients With a Solid Tumor (SEASTAR)

https://www.facingourrisk.org/research-clinical-trials/study/92 /a-study-to-evaluate-rucaparib-in-combination-with-other-anticancer-agents-in-patients-with-a-solid-tumor-seastar


This study will look at how safe, effective and tolerable the oral PARP inhibitor Rucaparib is when used in combination with other anticancer agents in patients with advanced solid tumors, including triple-negative breast cancer, ovarian cancer or urothelial cancer. Note: This study has completed enrollment. 

Study of Safety and Effectiveness of Motiva® Breast Implants

https://www.facingourrisk.org/research-clinical-trials/study/80 /study-of-safety-and-effectiveness-of-motiva-breast-implants


Note: This study is no longer enrolling. 

The Women Choosing Surgical Prevention (WISP) Trial

https://www.facingourrisk.org/research-clinical-trials/study/4 /women-choosing-surgical-prevention-wisp-trial


The WISP Study is closed to enrollment. Stay tuned for updates from FORCE on study results or new studies for ovarian cancer prevention. 

 

A Study to Evaluate Rucaparib in Patients with Solid Tumors and with Deleterious Mutations in HRR Genes (LODESTAR)

https://www.facingourrisk.org/research-clinical-trials/study/88 /a-study-to-evaluate-rucaparib-in-patients-with-solid-tumors-and-with-deleterious-mutations-in-hrr-genes


The LODESTAR study is evaluating the response of the PARP inhibitor rucaparib in people with advanced solid tumors (including breast, ovarian, pancreatic, prostate and other cancers) who have an inherited mutation or an acquired mutation in any of the following genes: BRCA1, BRCA2, PALB2, RAD51C, RAD51D, BARD1, BRIP1, FANCA, NBN, RAD51 or RAD51B.   NOTE: This study is no longer enrolling people.

A Non-Randomized Phase II Research Study of M6620 (VX-970) in Selected Solid Tumors to Inhibit the ATR Enzyme.

https://www.facingourrisk.org/research-clinical-trials/study/87 /study-using-m6620-vx-970-an-atr-inhibitor-to-treat-solid-tumors


This clinical trial is studying how well M6620 works in treating patients with advanced solid tumors. M6620 is a drug designed to block the ATR enzyme. ATR repairs damaged DNA. In cancer, ATR may protect the cancer cells by helping them repair damage. Blocking ATR may keep cancers from repairing their damaged DNA; slowing the growth of, or killing cancer cells. The study will be recruiting people with different types of cancer, including people with advanced solid tumors and a BRCA1, BRCA2 or ATM mutation.  UPDATE: THIS STUDY IS NO LONGER ENROLLING PATIENTS.

A Study of IMMray™ PanCan-d Test for Early Detection of Pancreatic Cancer in High-risk Groups

https://www.facingourrisk.org/research-clinical-trials/study/83 /immray-pancan-d-test-for-early-detection-of-pancreatic-cancer-in-high-risk-groups


This study will validate and evaluate the performance of the IMMray PanCan-d test for pancreatic cancer diagnosis in comparison to standard of care imaging currently used in pancreatic cancer disease surveillance by the research sites’ institutions. ENROLLMENT HAS CLOSED FOR THIS STUDY!

INTense Exercise foR surVivAL Among Men With Metastatic Castrate-Resistant Prostate Cancer (INTERVAL)

https://www.facingourrisk.org/research-clinical-trials/study/82 /interval-intense-exercise-for-survival-in-men-with-metastatic-prostate-cancer


This study will determine if high intensity aerobic and resistance training (with supervised exercise) plus psychosocial support increases overall survival compared to psychosocial support alone (with self-directed exercise) in patients with metastatic castrate-resistant prostate cancer. NOTE: This study is no longer enrolling people. 

Patient-Driven Clinical Classification of Genetic VUS (Variants of Uncertain Significance)

https://www.facingourrisk.org/research-clinical-trials/study/28 /find-my-variant


NOTE: This study is no longer enrolling. 

 

Making Genetic Testing Accessible (MAGENTA)

https://www.facingourrisk.org/research-clinical-trials/study/27 /making-genetic-testing-accessible-magenta


The goal of this research study is to test the effects of online genetic education alone or in combination with telephone genetic counseling in order to compare the two methods and the stress a person feels about their risk of cancer.  NOTE: This study has closed for enrollment.

IMProving Executive function Study

https://www.facingourrisk.org/research-clinical-trials/study/22 /impres-improving-memory-after-rrso


Dr. C. Neill Epperson and her research team at the Penn Center for Women's Behavioral Wellness are studying the effects of a stimulant medication called Vyvanse® on memory and attention in women who had surgery to remove their ovaries to lower their risk for ovarian cancer (risk-reducing salpingo-oophorectomy or RRSO). NOTE: The study offers travel reimbursements and hotel accommodations for those eligible to participate. 

NOTE: This study is no longer enrolling people. 

Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer. (OlympiA)

https://www.facingourrisk.org/research-clinical-trials/study/19 /olympia-olaparib-adjuvant-therapy-for-brca-related-breast-cancer


The OlympiA trial is the first major study to test a targeted therapy for people with BRCA mutation-associated breast cancer in the adjuvant setting (after surgery) for people with earlier-stage (stage 2 or stage 3) cancers. The OlympiA trial has now completed enrollment. Interim results from OlympiA were presented at the 2021 ASCO Annual Symposium. 

Dose-Response of Aerobic Training in Post-Menopausal Women at High-Risk for Development of Breast Cancer

https://www.facingourrisk.org/research-clinical-trials/study/10 /aerobic-training-in-post-menopausal-women-at-high-risk-for-breast-cancer


In this study, researchers wanted to determine the optimal amount of exercise needed to change certain factors associated with breast cancer risk for post-menopausal, high-risk women. 

NOTE:  THIS STUDY ENROLLMENT HAS CLOSED

Prospective Registry Of MultiPlex Testing (PROMPT)

https://www.facingourrisk.org/research-clinical-trials/study/50 /prompt


PROMPT is an online research registry for people who have had genetic panel testing (also known as multiplex testing) — a newer form of genetic testing that looks for mutations in several different genes at once. All genes on the panels have been linked to an increased risk of cancer, but some risks are better known than others.

The goal of the PROMPT Registry is to follow people with mutations or variants in genes on these panels, so that patients, physicians, and researchers can more clearly understand these lesser-known risks.

Serum Folate in Patients Treated with Olaparib

https://www.facingourrisk.org/research-clinical-trials/study/99 /serum-folate-in-patients-treated-with-olaparib


This is a study looking at folate deficiency (lack of folic acid in the blood) in patients who take the drug olaparib (Lynparza) to treat their advanced ovarian or breast cancer. The main goal of this study is to measure how often and when folate deficiency is most likely to occur; and to learn more about whether giving folic acid supplements (vitamins) will help delay or avoid deficiency in these patients. Folate deficiency can cause side effects and lead to reduction or stopping of treatment with olaparib.  NOTE: This study is no longer enrolling people.

Talazoparib Beyond BRCA (TBB) Trial

https://www.facingourrisk.org/research-clinical-trials/study/35 /talazoparib-beyond-brca-tbb-trial


The goal of the study is to evaluate the anti-cancer activity of Talazoparib (a type of treatment known as a PARP inhibitor) in patients with advanced breast cancer with specific genetic mutations based on a blood, saliva, or tumor test. See the clinicaltrials.gov listing for additional information. NOTE: This study is no longer enrolling people.

ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients

https://www.facingourrisk.org/research-clinical-trials/study/38 /ariel4-rucaparib-and-recurrent-ovarian-cancer


ARIEL4 is a treatment study for women with relapsed, high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who have a BRCA1 or BRCA2 mutation. ARIEL4 is designed to evaluate rucaparib against standard of care chemotherapy in women who have had at least two prior chemotherapy regimens.  UPDATE: THIS STUDY IS NO LONGER ENROLLING PATIENTS

Additional Results on Clinicaltrials.gov
1000 results

Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability
NCT ID: NCT03428802 (https://clinicaltrials.gov/study/NCT03428802)

CRC Screening in Unscreened Individuals 45-54
NCT ID: NCT06757192 (https://clinicaltrials.gov/study/NCT06757192)

Exercise Therapy to Improve Cardiovascular Health in Post-Menopausal Women After Treatment for Early Stage Breast Cancer
NCT ID: NCT04458532 (https://clinicaltrials.gov/study/NCT04458532)

Contrast Enhanced Spectral Mammography for the Evaluation of Pathologic Nipple Discharge
NCT ID: NCT05056844 (https://clinicaltrials.gov/study/NCT05056844)

Avera Cancer Sequencing and Analytics Protocol (ASAP)
NCT ID: NCT05142033 (https://clinicaltrials.gov/study/NCT05142033)

[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
NCT ID: NCT07432633 (https://clinicaltrials.gov/study/NCT07432633)

The Immune Effects of Fermented Wheat Germ Nutritional Supplementation in Patients With Advanced Solid Tumor Cancers Being Treated With Standard of Care Checkpoint Inhibitors
NCT ID: NCT05967533 (https://clinicaltrials.gov/study/NCT05967533)

Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery
NCT ID: NCT03384238 (https://clinicaltrials.gov/study/NCT03384238)

The DRAGON 2 Trial
NCT ID: NCT05428735 (https://clinicaltrials.gov/study/NCT05428735)

Prospective Analysis of EnVisio Spatial Intelligence for Soft Tissue Localization and Guided Surgical Excision
NCT ID: NCT06572410 (https://clinicaltrials.gov/study/NCT06572410)

Inspiratory Muscle Training in Obese Breast Cancer Survivors
NCT ID: NCT05193149 (https://clinicaltrials.gov/study/NCT05193149)

Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer
NCT ID: NCT01954992 (https://clinicaltrials.gov/study/NCT01954992)

Couple-Based Mindfulness Intervention for Metastatic Colorectal Cancer
NCT ID: NCT05840263 (https://clinicaltrials.gov/study/NCT05840263)

Rectal Spacers Use in Prostate Cancer Radiation Therapy
NCT ID: NCT06594887 (https://clinicaltrials.gov/study/NCT06594887)

Impact of the Enhanced Recovery After Surgery System for Colorectal Surgery
NCT ID: NCT02997293 (https://clinicaltrials.gov/study/NCT02997293)

STUDY02001740;22SCH740: Estradiol For ER+ Advanced Breast Cancer (ESTHER)
NCT ID: NCT05716516 (https://clinicaltrials.gov/study/NCT05716516)

An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib
NCT ID: NCT05887609 (https://clinicaltrials.gov/study/NCT05887609)

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
NCT ID: NCT06580314 (https://clinicaltrials.gov/study/NCT06580314)

Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer
NCT ID: NCT06321484 (https://clinicaltrials.gov/study/NCT06321484)

Phase 2 Randomized Trial of Flexible Dosing Schedule of 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT)
NCT ID: NCT06216249 (https://clinicaltrials.gov/study/NCT06216249)

GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care
NCT ID: NCT05391126 (https://clinicaltrials.gov/study/NCT05391126)

A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
NCT ID: NCT04590326 (https://clinicaltrials.gov/study/NCT04590326)

Prostate Tissue BioBank
NCT ID: NCT06659614 (https://clinicaltrials.gov/study/NCT06659614)

A Study of Pasritamig Versus Placebo in Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
NCT ID: NCT07164443 (https://clinicaltrials.gov/study/NCT07164443)

Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer
NCT ID: NCT04768426 (https://clinicaltrials.gov/study/NCT04768426)

FES BPET-DBT in Newly Diagnosed Breast Cancer
NCT ID: NCT05659797 (https://clinicaltrials.gov/study/NCT05659797)

Mobile Health for Adherence in Breast Cancer Patients
NCT ID: NCT06112613 (https://clinicaltrials.gov/study/NCT06112613)

MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors
NCT ID: NCT05076760 (https://clinicaltrials.gov/study/NCT05076760)

Exercise as a Preventive Agent to Combat Immobility in Patients With Ovarian or Endometrial Cancers Receiving Chemotherapy
NCT ID: NCT04997096 (https://clinicaltrials.gov/study/NCT04997096)

Sipuleucel-T Combined With Bipolar Androgen Therapy in Men With mCRPC
NCT ID: NCT06100705 (https://clinicaltrials.gov/study/NCT06100705)

Exosome-derived Extrahepatic Metastasis Detection By Liquid Biopsy In Colorectal Cancer Liver Metastases
NCT ID: NCT07224724 (https://clinicaltrials.gov/study/NCT07224724)

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of Azirkitug (ABBV-514) Alone or in Combination With Budigalimab or Bevacizumab
NCT ID: NCT05005403 (https://clinicaltrials.gov/study/NCT05005403)

Th-1 Dendritic Cell Immunotherapy Plus Standard Chemotherapy for Pancreatic Adenocarcinoma
NCT ID: NCT04157127 (https://clinicaltrials.gov/study/NCT04157127)

Single Cell Immune and Non-immune Correlates of Response to Neoadjuvant Abemaciclib
NCT ID: NCT04614194 (https://clinicaltrials.gov/study/NCT04614194)

Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy
NCT ID: NCT02945579 (https://clinicaltrials.gov/study/NCT02945579)

Comprehensive Outcomes for After Cancer Health
NCT ID: NCT05349227 (https://clinicaltrials.gov/study/NCT05349227)

RAD 1802: Pilot Trial of Five Fraction Stereotactic Body Radiotherapy for Early Stage Breast Cancer Patients Eligible for Post-Operative Accelerated Partial Breast Irradiation (APBI)
NCT ID: NCT03643861 (https://clinicaltrials.gov/study/NCT03643861)

Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
NCT ID: NCT06445062 (https://clinicaltrials.gov/study/NCT06445062)

Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)
NCT ID: NCT02861573 (https://clinicaltrials.gov/study/NCT02861573)

Study of Zelenectide Pevedotin in Participants With Advanced Breast Cancer
NCT ID: NCT06840483 (https://clinicaltrials.gov/study/NCT06840483)

Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
NCT ID: NCT05929768 (https://clinicaltrials.gov/study/NCT05929768)

Prolonged Overnight Fasting and/or Exercise on Fatigue and Other Patient Reported Outcomes in Women With Hormone Receptor Positive Advanced Breast Cancer
NCT ID: NCT06123988 (https://clinicaltrials.gov/study/NCT06123988)

Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer
NCT ID: NCT06179303 (https://clinicaltrials.gov/study/NCT06179303)

Evolution of Metabolic and Immune Dysfunction in In-transit Melanoma
NCT ID: NCT04658303 (https://clinicaltrials.gov/study/NCT04658303)

Cleveland African American Prostate Cancer Project
NCT ID: NCT05469269 (https://clinicaltrials.gov/study/NCT05469269)

A Study of Short-Course Radiation Therapy With Chemotherapy in People With Endometrial Cancer
NCT ID: NCT05691010 (https://clinicaltrials.gov/study/NCT05691010)

Time-Restricted Eating Versus Nutritional Counseling for the Reduction of Radiation or Chemoradiation Tx Side Effects in Patients With Prostate, Cervical, or Rectal Cancers
NCT ID: NCT05722288 (https://clinicaltrials.gov/study/NCT05722288)

First-in-human Study of 225Ac-PSMA-Trillium (BAY 3563254) in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)
NCT ID: NCT06217822 (https://clinicaltrials.gov/study/NCT06217822)

A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
NCT ID: NCT06022029 (https://clinicaltrials.gov/study/NCT06022029)

Every Day Counts: A Lifestyle Program for Women With Metastatic Breast Cancer
NCT ID: NCT03824145 (https://clinicaltrials.gov/study/NCT03824145)

A Non-randomized, Open-Label Study to Evaluate the Safety and Effectiveness of the Dayspring Technology for Patients With Breast Cancer Related Lymphedema (BCRL) After Lymphatic Surgery
NCT ID: NCT04888975 (https://clinicaltrials.gov/study/NCT04888975)

DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs
NCT ID: NCT06176261 (https://clinicaltrials.gov/study/NCT06176261)

Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer
NCT ID: NCT07022483 (https://clinicaltrials.gov/study/NCT07022483)

Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
NCT ID: NCT07491445 (https://clinicaltrials.gov/study/NCT07491445)

Utility of 18F-rhPSMA-7.3 in the Diagnosis of Prostate Cancer After Focal Gland Treatment
NCT ID: NCT07011342 (https://clinicaltrials.gov/study/NCT07011342)

Investigation Into Detection of Prostate Cancer Using Voided Urine (Prostate VPAC)
NCT ID: NCT04788277 (https://clinicaltrials.gov/study/NCT04788277)

Breast Mesh Used in Two-staged Breast Reconstruction
NCT ID: NCT04967976 (https://clinicaltrials.gov/study/NCT04967976)

Testing a Mammography Decision Intervention in a Rural Setting
NCT ID: NCT06522568 (https://clinicaltrials.gov/study/NCT06522568)

A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
NCT ID: NCT05859074 (https://clinicaltrials.gov/study/NCT05859074)

Study of EGFRBi Armed Fresh PBMC in Metastatic or Unresectable Pancreatic Cancer
NCT ID: NCT06479239 (https://clinicaltrials.gov/study/NCT06479239)

The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
NCT ID: NCT07285044 (https://clinicaltrials.gov/study/NCT07285044)

Precision-Based Genomics in Prostate Cancer
NCT ID: NCT04706663 (https://clinicaltrials.gov/study/NCT04706663)

Phase II Single Arm Trial of Low Dose Capecitabine in Patients With Advanced Breast Cancer
NCT ID: NCT06105684 (https://clinicaltrials.gov/study/NCT06105684)

The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid Tumors
NCT ID: NCT05037825 (https://clinicaltrials.gov/study/NCT05037825)

HER-2 B Cell Peptide Vaccine
NCT ID: NCT06414733 (https://clinicaltrials.gov/study/NCT06414733)

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
NCT ID: NCT05879926 (https://clinicaltrials.gov/study/NCT05879926)

Everyday Exposures: How Chemicals and Weight Impact Breast Cancer Risk
NCT ID: NCT07137468 (https://clinicaltrials.gov/study/NCT07137468)

DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
NCT ID: NCT06953089 (https://clinicaltrials.gov/study/NCT06953089)

Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)
NCT ID: NCT04862663 (https://clinicaltrials.gov/study/NCT04862663)

Storage and Research Use of Human Bio-specimens From Melanoma Patients and Clinical Testing for Assignment of Treatment
NCT ID: NCT01205815 (https://clinicaltrials.gov/study/NCT01205815)

Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
NCT ID: NCT01441089 (https://clinicaltrials.gov/study/NCT01441089)

Risk Stratified De-escalated Hormone Therapy With Radiation Therapy for the Treatment of Prostate Cancer
NCT ID: NCT06369610 (https://clinicaltrials.gov/study/NCT06369610)

Prostate Cancer Treatment Using Androgen Deprivation Therapy and Focal Prostate Ablation
NCT ID: NCT05790213 (https://clinicaltrials.gov/study/NCT05790213)

Proof-of-Concept Trial to Assess the Efficacy and Safety of Fezolinetant in Improving Vasomotor Symptoms in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy
NCT ID: NCT06957691 (https://clinicaltrials.gov/study/NCT06957691)

Evaluation of Hypoxia in Primary Melanoma
NCT ID: NCT06831071 (https://clinicaltrials.gov/study/NCT06831071)

A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours
NCT ID: NCT04969835 (https://clinicaltrials.gov/study/NCT04969835)

Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer
NCT ID: NCT03606967 (https://clinicaltrials.gov/study/NCT03606967)

The CArdiovascular Risk Evaluation in Men With Prostate Cancer Study (CARE-PC) Pilot Feasibility Study
NCT ID: NCT06064149 (https://clinicaltrials.gov/study/NCT06064149)

Prostate Cancer Screening for People at Genetic Risk for Aggressive Disease, PATROL Study
NCT ID: NCT04472338 (https://clinicaltrials.gov/study/NCT04472338)

Web-based Pain Coping Skills Training for Breast Cancer Survivors With AI-Associated Arthralgia
NCT ID: NCT05703178 (https://clinicaltrials.gov/study/NCT05703178)

Comparison of Synthetic Mammography Versus Full-Field Digital Mammography in Image Interpretation and Performance Metrics
NCT ID: NCT05056818 (https://clinicaltrials.gov/study/NCT05056818)

Stereotactic Radiation & Abemaciclib in the Management of HR+/HER2- Breast Cancer Brain Metastases
NCT ID: NCT04923542 (https://clinicaltrials.gov/study/NCT04923542)

ASHBY: Accelerated Super-Hypofractionated Breast Brachytherapy
NCT ID: NCT06185205 (https://clinicaltrials.gov/study/NCT06185205)

The Immune System's Response to Young Women's Breast Cancer
NCT ID: NCT01503190 (https://clinicaltrials.gov/study/NCT01503190)

A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
NCT ID: NCT05123482 (https://clinicaltrials.gov/study/NCT05123482)

A Web-Based Dyadic Intervention for Colorectal Cancer
NCT ID: NCT05663203 (https://clinicaltrials.gov/study/NCT05663203)

Core Biopsies for Establishing a Breast Tumor Tissue Repository
NCT ID: NCT02250352 (https://clinicaltrials.gov/study/NCT02250352)

A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
NCT ID: NCT03526835 (https://clinicaltrials.gov/study/NCT03526835)

Feasibility of Patient-Centered Home Care (PCHC) to Reduce Disparities in High-Risk Black Men (BM) With Prostate Cancer (CaP)
NCT ID: NCT06470750 (https://clinicaltrials.gov/study/NCT06470750)

A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors
NCT ID: NCT07085091 (https://clinicaltrials.gov/study/NCT07085091)

Schedule De-Escalation of 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer
NCT ID: NCT06200103 (https://clinicaltrials.gov/study/NCT06200103)

Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
NCT ID: NCT04468061 (https://clinicaltrials.gov/study/NCT04468061)

Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients
NCT ID: NCT01530373 (https://clinicaltrials.gov/study/NCT01530373)

A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TJ101 in Patients With Advanced/Metastatic Solid Tumors
NCT ID: NCT07181473 (https://clinicaltrials.gov/study/NCT07181473)

Opioid-Sparing Effects of Nurse-Delivered Hypnosis During Breast Cancer Surgery
NCT ID: NCT05766891 (https://clinicaltrials.gov/study/NCT05766891)

Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer
NCT ID: NCT05467891 (https://clinicaltrials.gov/study/NCT05467891)

5-strain Probiotic Formulation in HR-positive Breast Cancer Receiving Aromatase Inhibitor to Prevent Bone Loss
NCT ID: NCT07044310 (https://clinicaltrials.gov/study/NCT07044310)

Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer
NCT ID: NCT06369259 (https://clinicaltrials.gov/study/NCT06369259)

TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
NCT ID: NCT04485013 (https://clinicaltrials.gov/study/NCT04485013)

Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors
NCT ID: NCT07006727 (https://clinicaltrials.gov/study/NCT07006727)

Trial of 5-Fluorouracil (5FU)-Based Therapy in Combination With Fruquintinib in Patients With Locally Advanced Unresectable or Metastatic Colorectal Cancer
NCT ID: NCT07042685 (https://clinicaltrials.gov/study/NCT07042685)

Non-significant Risk (NSR) Study of [68Ga]-PSMA-11 (Illuccix) as a BgRT BioGuide on RefleXion X1
NCT ID: NCT06353321 (https://clinicaltrials.gov/study/NCT06353321)

Immune Response to Anti-HER2 Therapies in Patients With HER2-Positive Stage I-IV Breast Cancer
NCT ID: NCT04517838 (https://clinicaltrials.gov/study/NCT04517838)

A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing
NCT ID: NCT06066138 (https://clinicaltrials.gov/study/NCT06066138)

Study of Pembrolizumab Treatment After CYAD-101 With FOLFOX Preconditioning in Metastatic Colorectal Cancer
NCT ID: NCT04991948 (https://clinicaltrials.gov/study/NCT04991948)

Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors
NCT ID: NCT04074135 (https://clinicaltrials.gov/study/NCT04074135)

Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC
NCT ID: NCT03257033 (https://clinicaltrials.gov/study/NCT03257033)

Data Collection for Patients With Low Grade Ovarian or Peritoneal Tumors
NCT ID: NCT00488878 (https://clinicaltrials.gov/study/NCT00488878)

Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
NCT ID: NCT05168618 (https://clinicaltrials.gov/study/NCT05168618)

Phase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ovarian Cancer
NCT ID: NCT05636111 (https://clinicaltrials.gov/study/NCT05636111)

A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
NCT ID: NCT04370587 (https://clinicaltrials.gov/study/NCT04370587)

Real World Prostate Cancer Registry
NCT ID: NCT06355336 (https://clinicaltrials.gov/study/NCT06355336)

Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy
NCT ID: NCT04071236 (https://clinicaltrials.gov/study/NCT04071236)

Low PSMA SUV Boost (LPS-Boost): Intensified 177Lu-PSMA-617 Treatment for Patients With Metastatic Castrate-Resistant Prostate Cancer With Low PSMA Expressing Disease
NCT ID: NCT06526299 (https://clinicaltrials.gov/study/NCT06526299)

Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome
NCT ID: NCT04792463 (https://clinicaltrials.gov/study/NCT04792463)

Activity Coaching During Pelvic Radiation Therapy
NCT ID: NCT06746428 (https://clinicaltrials.gov/study/NCT06746428)

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
NCT ID: NCT05581004 (https://clinicaltrials.gov/study/NCT05581004)

Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer
NCT ID: NCT05873192 (https://clinicaltrials.gov/study/NCT05873192)

Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
NCT ID: NCT06757634 (https://clinicaltrials.gov/study/NCT06757634)

Pilot of 18F-DCFPyL-PSMA PET in mCRPC Patients Receiving 117Lu-Vipivotide Tetraxetan
NCT ID: NCT06099093 (https://clinicaltrials.gov/study/NCT06099093)

Extending Outcomes for Pancreas Cancer Patients With Nominal Oligometastatic Disease (EXPAND): A Randomized Phase III Trial
NCT ID: NCT06593431 (https://clinicaltrials.gov/study/NCT06593431)

Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
NCT ID: NCT05112601 (https://clinicaltrials.gov/study/NCT05112601)

Imaging Studies to Check the Local Response of Prostate Cancer to Radiation Therapy
NCT ID: NCT01834001 (https://clinicaltrials.gov/study/NCT01834001)

The SUGAR Study; SBRT and Relugolix) for Prostate Cancer
NCT ID: NCT06111781 (https://clinicaltrials.gov/study/NCT06111781)

Contrast Enhanced Ultrasound Medical Imaging for Identifying Breast Masses
NCT ID: NCT06171607 (https://clinicaltrials.gov/study/NCT06171607)

MK2 Inhibitor in Combination With mFOLFIRINOX for Untreated Metastatic Pancreatic Ductal Adenocarcinoma
NCT ID: NCT06648434 (https://clinicaltrials.gov/study/NCT06648434)

A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
NCT ID: NCT07029399 (https://clinicaltrials.gov/study/NCT07029399)

Impact of Intermittent Fasting on Biomarkers of Inflammation and Health-Related Quality of Life: A Feasibility Trial for Women With HR+/HER2- Early Breast Cancer
NCT ID: NCT06106477 (https://clinicaltrials.gov/study/NCT06106477)

4-aminopyridine Treatment for Nerve Injury
NCT ID: NCT03701581 (https://clinicaltrials.gov/study/NCT03701581)

Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
NCT ID: NCT05315700 (https://clinicaltrials.gov/study/NCT05315700)

Impact of Dietary Inflammatory Potential on Breast Cancer Risk
NCT ID: NCT05178498 (https://clinicaltrials.gov/study/NCT05178498)

Endoscopic Radiofrequency Ablation of Celiac Ganglion for Pain Management and Improvement of Quality of Life in Patients With Unresectable Pancreatic Cancer
NCT ID: NCT05535894 (https://clinicaltrials.gov/study/NCT05535894)

Cardiometabolic Screening Program
NCT ID: NCT05386719 (https://clinicaltrials.gov/study/NCT05386719)

Evaluation of Circulating Immune Response After Histosonics in Colorectal Cancer (ECHO-CRC)
NCT ID: NCT07361107 (https://clinicaltrials.gov/study/NCT07361107)

Increasing Germline Genetic Testing for Patients With Cancer
NCT ID: NCT07307664 (https://clinicaltrials.gov/study/NCT07307664)

PLX038 for Treatment of Metastatic Platinum-resistant Ovarian, Primary Peritoneal, and Fallopian Tube Cancer
NCT ID: NCT05465941 (https://clinicaltrials.gov/study/NCT05465941)

MRI-Based Machine Learning Approach Versus Radiologist MRI Reading for the Detection of Prostate Cancer, The PRIMER Trial
NCT ID: NCT07162194 (https://clinicaltrials.gov/study/NCT07162194)

A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors
NCT ID: NCT06399757 (https://clinicaltrials.gov/study/NCT06399757)

Outcomes and Cosmesis With Whole Breast Irradiation and Boost
NCT ID: NCT06295744 (https://clinicaltrials.gov/study/NCT06295744)

Evaluation of Neoadjuvant Xaluritamig in Localized Prostate Cancer
NCT ID: NCT06613100 (https://clinicaltrials.gov/study/NCT06613100)

Transcutaneous Electrical Nerve Stimulation in Chemotherapy Induced Peripheral Neuropathy in Patients With Stage I-III Early Stage Breast Cancer
NCT ID: NCT05368428 (https://clinicaltrials.gov/study/NCT05368428)

American Hepato-Pancreato-Biliary Association (AHPBA) Pancreatic Irreversible Electroporation (IRE) Registry
NCT ID: NCT02674100 (https://clinicaltrials.gov/study/NCT02674100)

Prostate Assessment with Restriction Spectrum Imaging (RSI) MRI
NCT ID: NCT04992728 (https://clinicaltrials.gov/study/NCT04992728)

A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
NCT ID: NCT05941507 (https://clinicaltrials.gov/study/NCT05941507)

A Study Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer
NCT ID: NCT06614192 (https://clinicaltrials.gov/study/NCT06614192)

Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Cancer
NCT ID: NCT03213041 (https://clinicaltrials.gov/study/NCT03213041)

MRI Screening in Men at High Risk of Developing Prostate Cancer
NCT ID: NCT05608694 (https://clinicaltrials.gov/study/NCT05608694)

A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
NCT ID: NCT05774951 (https://clinicaltrials.gov/study/NCT05774951)

TMEM-MRI: A Pilot Feasibility Study of MRI for Imaging of TMEM in Patients With Operable Breast Cancer
NCT ID: NCT03694756 (https://clinicaltrials.gov/study/NCT03694756)

Virtual Support Platform (HERCaRE Application) for the Improvement of Survivorship Among Black Breast Cancer Survivors
NCT ID: NCT07126522 (https://clinicaltrials.gov/study/NCT07126522)

Data Collection for the Assessment of Acute and Late Normal Tissue in Patients Treated With Proton Therapy
NCT ID: NCT00991094 (https://clinicaltrials.gov/study/NCT00991094)

A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
NCT ID: NCT05932862 (https://clinicaltrials.gov/study/NCT05932862)

A Study of BRIA-OTS Cellular Immunotherapy in Metastatic Recurrent Breast Cancer
NCT ID: NCT06471673 (https://clinicaltrials.gov/study/NCT06471673)

Adding a Genetic Risk Evaluation to Standard Breast Cancer Risk Assessment for African American and Hispanic Women
NCT ID: NCT05755269 (https://clinicaltrials.gov/study/NCT05755269)

A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer
NCT ID: NCT06067841 (https://clinicaltrials.gov/study/NCT06067841)

A Study of Mesothelin-Targeted CAR T-Cell Therapy in People With Esophagogastric Cancer
NCT ID: NCT06623396 (https://clinicaltrials.gov/study/NCT06623396)

Effects of Chemotherapy on Cognitive Function in Breast Cancer Patients & Non-Cancer Control Subjects With Optional Sub-Study Research Brain MRI
NCT ID: NCT03137095 (https://clinicaltrials.gov/study/NCT03137095)

Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer
NCT ID: NCT04633239 (https://clinicaltrials.gov/study/NCT04633239)

Genomic Services Research Program
NCT ID: NCT02595957 (https://clinicaltrials.gov/study/NCT02595957)

Evaluation of a Targeted Magnetic Resonance Imaging Contrast Agent in Prostate Cancer Patients
NCT ID: NCT06262139 (https://clinicaltrials.gov/study/NCT06262139)

FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
NCT ID: NCT07216105 (https://clinicaltrials.gov/study/NCT07216105)

A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
NCT ID: NCT07318805 (https://clinicaltrials.gov/study/NCT07318805)

Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response
NCT ID: NCT07142551 (https://clinicaltrials.gov/study/NCT07142551)

Hugo™ Robotic-Assisted Surgery (RAS) System in Gynecological Subjects (Embrace Gynecology)
NCT ID: NCT07120945 (https://clinicaltrials.gov/study/NCT07120945)

Prediction of Neoadjuvant Chemotherapy Response in Pancreatic Cancer
NCT ID: NCT07226154 (https://clinicaltrials.gov/study/NCT07226154)

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations
NCT ID: NCT04550494 (https://clinicaltrials.gov/study/NCT04550494)

A Multilevel Approach to Connecting Underrepresented Populations to Clinical Trials
NCT ID: NCT05655494 (https://clinicaltrials.gov/study/NCT05655494)

Identify microRNAs in Cachexia in Pancreatic Carcinoma
NCT ID: NCT05275075 (https://clinicaltrials.gov/study/NCT05275075)

Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer
NCT ID: NCT05378464 (https://clinicaltrials.gov/study/NCT05378464)

Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
NCT ID: NCT06726148 (https://clinicaltrials.gov/study/NCT06726148)

Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
NCT ID: NCT06014255 (https://clinicaltrials.gov/study/NCT06014255)

Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
NCT ID: NCT06072612 (https://clinicaltrials.gov/study/NCT06072612)

Statins for Reduction of Cardiac Toxicity in Patients Receiving HER2 Targeted
NCT ID: NCT05559164 (https://clinicaltrials.gov/study/NCT05559164)

Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors
NCT ID: NCT06784193 (https://clinicaltrials.gov/study/NCT06784193)

Virtual Reality Headset and/or Aromatherapy for Patients Undergoing a Transperineal Prostate Biopsy
NCT ID: NCT06296147 (https://clinicaltrials.gov/study/NCT06296147)

Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant Disease
NCT ID: NCT06875128 (https://clinicaltrials.gov/study/NCT06875128)

A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
NCT ID: NCT06790693 (https://clinicaltrials.gov/study/NCT06790693)

Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics
NCT ID: NCT04315233 (https://clinicaltrials.gov/study/NCT04315233)

Fasting Mimicking Diet in Chemotherapy of Gynecologic Malignancies
NCT ID: NCT06376604 (https://clinicaltrials.gov/study/NCT06376604)

Hippocampal Avoidance in Craniospinal Irradiation for the Treatment of Leptomeningeal Metastases From Breast Cancer or Non-small Cell Lung Cancer
NCT ID: NCT06518057 (https://clinicaltrials.gov/study/NCT06518057)

Tirzepatide Weight Loss for MRD+ Early Breast Cancer
NCT ID: NCT06517212 (https://clinicaltrials.gov/study/NCT06517212)

Integrated Cancer Repository for Cancer Research
NCT ID: NCT02012699 (https://clinicaltrials.gov/study/NCT02012699)

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
NCT ID: NCT01174121 (https://clinicaltrials.gov/study/NCT01174121)

PROMs After Pancreatectomy
NCT ID: NCT07173257 (https://clinicaltrials.gov/study/NCT07173257)

TRUDI: TDXD+Durva in HER2+/Low IBC
NCT ID: NCT05795101 (https://clinicaltrials.gov/study/NCT05795101)

The Intestinal Microbiome in Triple Negative Breast Cancer Treated with Immunotherapy
NCT ID: NCT06318507 (https://clinicaltrials.gov/study/NCT06318507)

A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer
NCT ID: NCT06966453 (https://clinicaltrials.gov/study/NCT06966453)

Weight Loss Management in Endometrial Cancer Survivors
NCT ID: NCT06877572 (https://clinicaltrials.gov/study/NCT06877572)

To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer
NCT ID: NCT07368998 (https://clinicaltrials.gov/study/NCT07368998)

BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
NCT ID: NCT05768932 (https://clinicaltrials.gov/study/NCT05768932)

A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
NCT ID: NCT05902988 (https://clinicaltrials.gov/study/NCT05902988)

Molecular Profile-related Individualized Targeted Therapy in Resected Pancreatic Cancer With High-Risk of Cancer Recurrence
NCT ID: NCT06228599 (https://clinicaltrials.gov/study/NCT06228599)

Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast Cancer
NCT ID: NCT06434064 (https://clinicaltrials.gov/study/NCT06434064)

A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) Study
NCT ID: NCT06531499 (https://clinicaltrials.gov/study/NCT06531499)

Sample Collection for Ongoing Research and Product Evaluation Study
NCT ID: NCT07318051 (https://clinicaltrials.gov/study/NCT07318051)

A Study of Multiparametric MRI and pHLIP® ICG in Breast Cancer Imaging During Surgery
NCT ID: NCT05130801 (https://clinicaltrials.gov/study/NCT05130801)

FTT PET/CT in Pancreatic Neuroendocrine Tumors
NCT ID: NCT07114939 (https://clinicaltrials.gov/study/NCT07114939)

An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
NCT ID: NCT05952557 (https://clinicaltrials.gov/study/NCT05952557)

A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
NCT ID: NCT06150664 (https://clinicaltrials.gov/study/NCT06150664)

Two Versus One Week Breast Radiotherapy (RT)
NCT ID: NCT06960707 (https://clinicaltrials.gov/study/NCT06960707)

A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue
NCT ID: NCT05837767 (https://clinicaltrials.gov/study/NCT05837767)

Immunological Effects of Vitamin D Replacement Among Black/African American Prostate Cancer Patients
NCT ID: NCT05045066 (https://clinicaltrials.gov/study/NCT05045066)

A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation
NCT ID: NCT07023731 (https://clinicaltrials.gov/study/NCT07023731)

Cervical and Endometrial Cancer Screening in Patients Seeking Gender-Affirming Hysterectomy
NCT ID: NCT07075731 (https://clinicaltrials.gov/study/NCT07075731)

SMP-3124LP in Adults With Advanced Solid Tumors
NCT ID: NCT06526819 (https://clinicaltrials.gov/study/NCT06526819)

Reiki Breast Surgery QOL Project for Women Undergoing Breast Surgery
NCT ID: NCT06524895 (https://clinicaltrials.gov/study/NCT06524895)

BP1001-A in Patients With Advanced or Recurrent Solid Tumors
NCT ID: NCT04196257 (https://clinicaltrials.gov/study/NCT04196257)

Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
NCT ID: NCT06787612 (https://clinicaltrials.gov/study/NCT06787612)

A Study of LY4257496 in Participants With Cancer (OMNIRAY)
NCT ID: NCT07114601 (https://clinicaltrials.gov/study/NCT07114601)

Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial
NCT ID: NCT05554328 (https://clinicaltrials.gov/study/NCT05554328)

Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants
NCT ID: NCT06566092 (https://clinicaltrials.gov/study/NCT06566092)

Addressing Health Literacy With a Tailored Survivorship Care Plan
NCT ID: NCT06674863 (https://clinicaltrials.gov/study/NCT06674863)

Prostate Cancer Postoperative Stereotactic Body Radiotherapy With Adaptive Technology for Minimizing Toxicity
NCT ID: NCT07077239 (https://clinicaltrials.gov/study/NCT07077239)

Fezolinetant for Treating Hot Flashes in Men With Prostate Cancer
NCT ID: NCT06972875 (https://clinicaltrials.gov/study/NCT06972875)

A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer
NCT ID: NCT06457919 (https://clinicaltrials.gov/study/NCT06457919)

EBRT and HDR Brachytherapy for Unfavorable-intermediate, High, and Very High-risk Prostate Cancer
NCT ID: NCT04465500 (https://clinicaltrials.gov/study/NCT04465500)

Cemiplimab With or Without Fianlimab to Treat Older Patients With Localized or Locally Advanced MSI-H Colorectal Cancer
NCT ID: NCT06205836 (https://clinicaltrials.gov/study/NCT06205836)

The DETECT Study: Discovery and Evaluation of Testing for Endometrial and Ovarian Cancer in Tampons
NCT ID: NCT03538665 (https://clinicaltrials.gov/study/NCT03538665)

Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression
NCT ID: NCT04363164 (https://clinicaltrials.gov/study/NCT04363164)

The LYMPH Trial - Microsurgical Versus Conservative Treatment of Chronic Breast Cancer Associated Lymphedema
NCT ID: NCT05890677 (https://clinicaltrials.gov/study/NCT05890677)

A Comparison of Radical Prostatectomy and Precision Prostatectomy in Low- and Intermediate-risk Prostate Cancers.
NCT ID: NCT07348367 (https://clinicaltrials.gov/study/NCT07348367)

Changes in Reproductive and Sexual Health in People With Early Onset Colorectal Cancer
NCT ID: NCT04812912 (https://clinicaltrials.gov/study/NCT04812912)

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
NCT ID: NCT06625775 (https://clinicaltrials.gov/study/NCT06625775)

ABemacicliB or Abemaciclib and HydroxYchloroquine to Target Minimal Residual Disease in Breast Cancer
NCT ID: NCT04523857 (https://clinicaltrials.gov/study/NCT04523857)

Development of a Shared Decision Tool to Facilitate Uptake of the Levonorgestrel-releasing Intrauterine System for the Primary Prevention of Endometrial Cancer
NCT ID: NCT07382583 (https://clinicaltrials.gov/study/NCT07382583)

Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells With or Without Naxitamab (Danyelza) for the Treatment of Patients With Metastatic, GD2 Expressing, HER2 Negative Breast Cancer
NCT ID: NCT06026657 (https://clinicaltrials.gov/study/NCT06026657)

Quantitative Microvasculature Imaging for Breast Cancer Detection and Monitoring
NCT ID: NCT04799535 (https://clinicaltrials.gov/study/NCT04799535)

A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
NCT ID: NCT07213674 (https://clinicaltrials.gov/study/NCT07213674)

A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib
NCT ID: NCT05512208 (https://clinicaltrials.gov/study/NCT05512208)

Colonoscopy vs Stool Testing for Older Adults With Colon Polyps
NCT ID: NCT05612347 (https://clinicaltrials.gov/study/NCT05612347)

Efficacy of OneMark Device in Identifying Breast Cancer for Surgery and Surveillance
NCT ID: NCT07087691 (https://clinicaltrials.gov/study/NCT07087691)

Talking to Employers and Medical Staff About Breast Cancer Treatment and Your Job
NCT ID: NCT03572374 (https://clinicaltrials.gov/study/NCT03572374)

Study to Assess the Feasibility of Stopping Prostate Cancer Treatment Early in Elderly Patients
NCT ID: NCT06824818 (https://clinicaltrials.gov/study/NCT06824818)

Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
NCT ID: NCT06797635 (https://clinicaltrials.gov/study/NCT06797635)

A Study to Estimate Early Clinical Efficacy Signals of GLP-1 Agonist Administration in Conjunction With Levonorgestrel Intrauterine Device in Obese Patients With Endometrioid Intraepithelial Neoplasia
NCT ID: NCT07107334 (https://clinicaltrials.gov/study/NCT07107334)

Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)
NCT ID: NCT06358430 (https://clinicaltrials.gov/study/NCT06358430)

Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients
NCT ID: NCT04291105 (https://clinicaltrials.gov/study/NCT04291105)

A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
NCT ID: NCT06586957 (https://clinicaltrials.gov/study/NCT06586957)

Circulating Tumor DNA to Guide Changes in Standard of Care Chemotherapy
NCT ID: NCT05770531 (https://clinicaltrials.gov/study/NCT05770531)

3D Ultrasound for the Imaging of Lymph Nodes in Patients With Breast Cancer
NCT ID: NCT05704283 (https://clinicaltrials.gov/study/NCT05704283)

A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel
NCT ID: NCT06940739 (https://clinicaltrials.gov/study/NCT06940739)

Menstrual Cup for Early Endometrial Cancer Detection in Lynch Syndrome
NCT ID: NCT07220239 (https://clinicaltrials.gov/study/NCT07220239)

A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
NCT ID: NCT05652686 (https://clinicaltrials.gov/study/NCT05652686)

PAS 1ml Magtrace® for Sentinel Lymph Node Biopsy in Breast Cancer Patients
NCT ID: NCT06610539 (https://clinicaltrials.gov/study/NCT06610539)

Predicting Response to Neoadjuvant Endocrine Therapy (Neo-PREDICT)
NCT ID: NCT06806930 (https://clinicaltrials.gov/study/NCT06806930)

Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
NCT ID: NCT05856981 (https://clinicaltrials.gov/study/NCT05856981)

PHL Treatment in Pancreatic Cancer
NCT ID: NCT05365893 (https://clinicaltrials.gov/study/NCT05365893)

S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
NCT ID: NCT03723928 (https://clinicaltrials.gov/study/NCT03723928)

Converting HR+ Breast Cancer Into an Individualized Vaccine
NCT ID: NCT03804944 (https://clinicaltrials.gov/study/NCT03804944)

FOG-001 in Locally Advanced or Metastatic Solid Tumors
NCT ID: NCT05919264 (https://clinicaltrials.gov/study/NCT05919264)

IKS014 in Advanced Solid Tumors That Express HER2
NCT ID: NCT05872295 (https://clinicaltrials.gov/study/NCT05872295)

A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
NCT ID: NCT02621021 (https://clinicaltrials.gov/study/NCT02621021)

Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
NCT ID: NCT03935893 (https://clinicaltrials.gov/study/NCT03935893)

A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors
NCT ID: NCT04482309 (https://clinicaltrials.gov/study/NCT04482309)

Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
NCT ID: NCT06760637 (https://clinicaltrials.gov/study/NCT06760637)

Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer
NCT ID: NCT05877430 (https://clinicaltrials.gov/study/NCT05877430)

Minimal Residual Disease Testing for the Early Detection of Cancer Recurrence in Resectable Stage II-IV Colorectal Cancer Patients
NCT ID: NCT07125729 (https://clinicaltrials.gov/study/NCT07125729)

Evaluating Digital Micro-Interventions to Reduce Distress and Increase Wellbeing in Breast Cancer Survivors
NCT ID: NCT07160439 (https://clinicaltrials.gov/study/NCT07160439)

A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy
NCT ID: NCT06055439 (https://clinicaltrials.gov/study/NCT06055439)

Pre-Surgical Tirzepatide-Assisted Weight Loss in Overweight and Obese Men With Intermediate Risk Prostate Cancer: A Pilot Feasibility Study
NCT ID: NCT06759701 (https://clinicaltrials.gov/study/NCT06759701)

DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
NCT ID: NCT06989112 (https://clinicaltrials.gov/study/NCT06989112)

Gabapentin And Breast Surgery Decision Architecture Randomization Trial (GABS-DART) Protocol
NCT ID: NCT07308717 (https://clinicaltrials.gov/study/NCT07308717)

A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations
NCT ID: NCT06906562 (https://clinicaltrials.gov/study/NCT06906562)

Letrozole With and Without Simvastatin for the Treatment of Stage I-III Hormone Receptor Positive, HER2 Negative Breast Cancer
NCT ID: NCT05464810 (https://clinicaltrials.gov/study/NCT05464810)

Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical Prostatectomy
NCT ID: NCT02064673 (https://clinicaltrials.gov/study/NCT02064673)

Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors
NCT ID: NCT03740256 (https://clinicaltrials.gov/study/NCT03740256)

Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
NCT ID: NCT04222413 (https://clinicaltrials.gov/study/NCT04222413)

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer
NCT ID: NCT04802759 (https://clinicaltrials.gov/study/NCT04802759)

Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302)
NCT ID: NCT05804370 (https://clinicaltrials.gov/study/NCT05804370)

Phytocannabinoids for Reducing Chronic Chemotherapy-Induced Peripheral Neuropathy in Breast and Colon Cancer Survivors
NCT ID: NCT06731894 (https://clinicaltrials.gov/study/NCT06731894)

Memantine and Exercise to Improve Cognitive Function and Modulate Biological Pathways of Cognitive Decline During Chemotherapy in Breast Cancer
NCT ID: NCT06727773 (https://clinicaltrials.gov/study/NCT06727773)

Prostate Cancer Genetic Risk Evaluation and Screening Study
NCT ID: NCT05129605 (https://clinicaltrials.gov/study/NCT05129605)

Alpha Radiation Emitters Device for the Treatment of Pancreatic Cancer With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer
NCT ID: NCT06698458 (https://clinicaltrials.gov/study/NCT06698458)

Resistance Exercise and Creatine in Colorectal Cancer
NCT ID: NCT06420726 (https://clinicaltrials.gov/study/NCT06420726)

[18F]-rhPSMA PET-CT Imaging Performance in Patients With Prostate Cancer
NCT ID: NCT06580015 (https://clinicaltrials.gov/study/NCT06580015)

Real-Time MRI-Guided 3-Fraction Accelerated Partial Breast Irradiation in Early Breast Cancer
NCT ID: NCT03936478 (https://clinicaltrials.gov/study/NCT03936478)

Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer
NCT ID: NCT06190899 (https://clinicaltrials.gov/study/NCT06190899)

Tebentafusp-tebn With LDT in Metastatic UM
NCT ID: NCT06626516 (https://clinicaltrials.gov/study/NCT06626516)

Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial
NCT ID: NCT04134260 (https://clinicaltrials.gov/study/NCT04134260)

Neoadjuvant Weekly Paclitaxel and Biomarkers of Therapy Response
NCT ID: NCT03096418 (https://clinicaltrials.gov/study/NCT03096418)

AOH1996 for the Treatment of Refractory Solid Tumors
NCT ID: NCT05227326 (https://clinicaltrials.gov/study/NCT05227326)

OMO-103 for the Treatment of Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma
NCT ID: NCT07089940 (https://clinicaltrials.gov/study/NCT07089940)

A Study of Multiparametric Ultrasound Imaging (mpUS) for People With Endometrial Cancer
NCT ID: NCT07318415 (https://clinicaltrials.gov/study/NCT07318415)

A Prospective Study of Video-assisted Exercise Program for the Breast Cancer Survivors
NCT ID: NCT07071896 (https://clinicaltrials.gov/study/NCT07071896)

First-in-human Study of 7MW4911 in GI Cancer
NCT ID: NCT07216560 (https://clinicaltrials.gov/study/NCT07216560)

Neoadjuvant Pembrolizumab Plus Androgen Axis Blockade Prior to Prostatectomy for High Risk Localized Prostate Cancer
NCT ID: NCT03753243 (https://clinicaltrials.gov/study/NCT03753243)

Surviving Daily Life
NCT ID: NCT07054723 (https://clinicaltrials.gov/study/NCT07054723)

A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors
NCT ID: NCT07300150 (https://clinicaltrials.gov/study/NCT07300150)

Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial
NCT ID: NCT06639074 (https://clinicaltrials.gov/study/NCT06639074)

Tucatinib+Trastuzumab+Eribulin in HER2+ MBC
NCT ID: NCT05458674 (https://clinicaltrials.gov/study/NCT05458674)

Impact of Omitting Chemo Based on Patient's Selection for ER-Positive, HER2-Negative Breast Cancer With Ribociclib and Endocrine Therapy
NCT ID: NCT06953882 (https://clinicaltrials.gov/study/NCT06953882)

A Study of 2141-V11 in Combination With Standard Treatments in People With Prostate Cancer
NCT ID: NCT06347705 (https://clinicaltrials.gov/study/NCT06347705)

Gadopiclenol in Contrast Enhanced MRI of the Prostate
NCT ID: NCT06226129 (https://clinicaltrials.gov/study/NCT06226129)

The FYI on MRI: A Multilevel Decision Support Intervention for Screening Breast MRI
NCT ID: NCT06892275 (https://clinicaltrials.gov/study/NCT06892275)

DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma
NCT ID: NCT07288112 (https://clinicaltrials.gov/study/NCT07288112)

Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advanced or Metastatic Pancreatic Cancer
NCT ID: NCT06381154 (https://clinicaltrials.gov/study/NCT06381154)

Pancreatic Cancer & Surgical Resection
NCT ID: NCT05170802 (https://clinicaltrials.gov/study/NCT05170802)

Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer
NCT ID: NCT05950945 (https://clinicaltrials.gov/study/NCT05950945)

Axillary Radiotherapy or Axillary Lymph Node Dissection in Patients With Clinically Node- Positive Breast Cancer Undergoing Upfront Tailored Axillary Surgery
NCT ID: NCT07140172 (https://clinicaltrials.gov/study/NCT07140172)

Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer
NCT ID: NCT04918186 (https://clinicaltrials.gov/study/NCT04918186)

Study of Pelvic Hypofractionated Radiotherapy in Endometrial Cancer
NCT ID: NCT04683653 (https://clinicaltrials.gov/study/NCT04683653)

Neuromodulation of Cardiovascular Risks Associated With Cardiotoxic Chemotherapy
NCT ID: NCT05921253 (https://clinicaltrials.gov/study/NCT05921253)

Definitive Radiation Therapy for Inoperable Breast Cancer
NCT ID: NCT07122713 (https://clinicaltrials.gov/study/NCT07122713)

Evaluation of Resection Techniques for Pancreatic Tumors
NCT ID: NCT05128890 (https://clinicaltrials.gov/study/NCT05128890)

A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer
NCT ID: NCT04486378 (https://clinicaltrials.gov/study/NCT04486378)

Genomics in Michigan to AdJust Outcomes in Prostate canceR (G-MAJOR) for Men With Newly Diagnosed Favorable Risk Prostate Cancer
NCT ID: NCT04396808 (https://clinicaltrials.gov/study/NCT04396808)

Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Hypertension Receiving Bevacizumab for Breast Cancer
NCT ID: NCT02610413 (https://clinicaltrials.gov/study/NCT02610413)

Pilot Study of an Implantable Microdevice for In Situ Evaluation of Drug Response in Patients With Colorectal Liver Metastasis
NCT ID: NCT07193862 (https://clinicaltrials.gov/study/NCT07193862)

PRE-I-SPY Phase I/Ib Oncology Platform Program
NCT ID: NCT05868226 (https://clinicaltrials.gov/study/NCT05868226)

Optimizing Surgical Decisions in Young Adults With Breast Cancer
NCT ID: NCT06275126 (https://clinicaltrials.gov/study/NCT06275126)

A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors
NCT ID: NCT06544655 (https://clinicaltrials.gov/study/NCT06544655)

Y-90, Capecitabine, and Atezolizumab for Oligometastatic CRC
NCT ID: NCT06555133 (https://clinicaltrials.gov/study/NCT06555133)

Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
NCT ID: NCT03772028 (https://clinicaltrials.gov/study/NCT03772028)

A Phase 1/1b Study of IAM1363 in HER2 Cancers
NCT ID: NCT06253871 (https://clinicaltrials.gov/study/NCT06253871)

Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T
NCT ID: NCT06134232 (https://clinicaltrials.gov/study/NCT06134232)

Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)
NCT ID: NCT06691984 (https://clinicaltrials.gov/study/NCT06691984)

Accelerated Partial Breast Irradiation (APBI) Using Stereotactic Body Radiation Therapy (SBRT)
NCT ID: NCT04985032 (https://clinicaltrials.gov/study/NCT04985032)

Evaluation of Radiobiological Effects in Skin Toxicities for Breast Cancer Patients With Pencil Beam Scanning Proton Therapy
NCT ID: NCT06006806 (https://clinicaltrials.gov/study/NCT06006806)

A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
NCT ID: NCT06925737 (https://clinicaltrials.gov/study/NCT06925737)

The COMPASSION Study
NCT ID: NCT06507930 (https://clinicaltrials.gov/study/NCT06507930)

Collecting and Storing Tissue Samples From Women With or Without Breast Cancer
NCT ID: NCT00899301 (https://clinicaltrials.gov/study/NCT00899301)

Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer
NCT ID: NCT05659381 (https://clinicaltrials.gov/study/NCT05659381)

Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer
NCT ID: NCT06062498 (https://clinicaltrials.gov/study/NCT06062498)

Profiling of Radiological Factors in Treatment and Outcomes in Prostate Cancer
NCT ID: NCT03354416 (https://clinicaltrials.gov/study/NCT03354416)

First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer
NCT ID: NCT06239467 (https://clinicaltrials.gov/study/NCT06239467)

Intravital Microscopy in Human Solid Tumors
NCT ID: NCT03823144 (https://clinicaltrials.gov/study/NCT03823144)

Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System
NCT ID: NCT03067051 (https://clinicaltrials.gov/study/NCT03067051)

A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer
NCT ID: NCT07319871 (https://clinicaltrials.gov/study/NCT07319871)

iCCaRE Consortium Pilot Project 1: Feasibility of a Point of Prostate Cancer Diagnosis Intervention for Newly Diagnosed Black Men
NCT ID: NCT06535802 (https://clinicaltrials.gov/study/NCT06535802)

A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer
NCT ID: NCT06948448 (https://clinicaltrials.gov/study/NCT06948448)

RCT of NLP-Based Feedback for Improving SDM in Men With Localized Prostate Cancer
NCT ID: NCT06856694 (https://clinicaltrials.gov/study/NCT06856694)

Sequential TAS-OX Alternating With TAS-IRI Plus Bevacizumab for Late-Line Metastatic Colorectal Cancer
NCT ID: NCT05806931 (https://clinicaltrials.gov/study/NCT05806931)

Accuracy of 18F-rhPSMA-7.3 PET/ MRI for Prediction of Lymph Node Metastasis in Localized High-Risk Prostate Cancer
NCT ID: NCT06389786 (https://clinicaltrials.gov/study/NCT06389786)

Phase II Trial of PSA Response-based Androgen Deprivation Therapy and Nodal Coverage for Prostate Cancer Early Salvage Radiotherapy (RANGER)
NCT ID: NCT07313241 (https://clinicaltrials.gov/study/NCT07313241)

Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer
NCT ID: NCT04947254 (https://clinicaltrials.gov/study/NCT04947254)

High-Risk Metachronous Oligometastatic Prostate Cancer Trial
NCT ID: NCT06212583 (https://clinicaltrials.gov/study/NCT06212583)

Initial Safety of SFM Plus OTOLoc for Creating Side-to-side or End-to-side Colorectal Anastomoses
NCT ID: NCT07276529 (https://clinicaltrials.gov/study/NCT07276529)

HIFU for Focal Ablation of Prostate Tissue: An Observational Study
NCT ID: NCT03620786 (https://clinicaltrials.gov/study/NCT03620786)

SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells
NCT ID: NCT04150042 (https://clinicaltrials.gov/study/NCT04150042)

A Study of VS-6766 and Cetuximab in Patients With Advanced Colorectal Cancer
NCT ID: NCT05200442 (https://clinicaltrials.gov/study/NCT05200442)

Extending Prostate Genetic Awareness, Navigation, and Delivery: The EXPAND Network
NCT ID: NCT05627219 (https://clinicaltrials.gov/study/NCT05627219)

Impact of an Electronic Health Record Maintenance Alert on PSA Screening Rates in a 10-Hospital Integrated Health System
NCT ID: NCT07109427 (https://clinicaltrials.gov/study/NCT07109427)

A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor.
NCT ID: NCT06247995 (https://clinicaltrials.gov/study/NCT06247995)

Use of a Colorectal Cancer Screening Decision Support Tool in Primary Care
NCT ID: NCT06625983 (https://clinicaltrials.gov/study/NCT06625983)

Post-mastectomy Recovery: Comparing Preoperative PECS-II Blocks With Intraoperative Pectoral Blocks
NCT ID: NCT06574022 (https://clinicaltrials.gov/study/NCT06574022)

Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer
NCT ID: NCT07166094 (https://clinicaltrials.gov/study/NCT07166094)

A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
NCT ID: NCT05669430 (https://clinicaltrials.gov/study/NCT05669430)

A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors
NCT ID: NCT06789172 (https://clinicaltrials.gov/study/NCT06789172)

Active Surveillance for Cancer of the Prostate (ASCaP)
NCT ID: NCT00949819 (https://clinicaltrials.gov/study/NCT00949819)

Clinical Trial of Approaches to Prostate Cancer Surgery
NCT ID: NCT05155501 (https://clinicaltrials.gov/study/NCT05155501)

The PhOCus Trial: Implementation of Pharmacogenomic Testing in Oncology Care
NCT ID: NCT04541381 (https://clinicaltrials.gov/study/NCT04541381)

Weight Management After Cancer for Survivors in Rural Communities
NCT ID: NCT07426952 (https://clinicaltrials.gov/study/NCT07426952)

Active Surveillance in Older Women With ER+ Breast Cancer
NCT ID: NCT07262138 (https://clinicaltrials.gov/study/NCT07262138)

Video Education With Result Dependent dIsclosure
NCT ID: NCT05225428 (https://clinicaltrials.gov/study/NCT05225428)

A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
NCT ID: NCT06890338 (https://clinicaltrials.gov/study/NCT06890338)

Lymphedema Surveillance Study
NCT ID: NCT02743858 (https://clinicaltrials.gov/study/NCT02743858)

WATER IV Prostate Cancer
NCT ID: NCT06651632 (https://clinicaltrials.gov/study/NCT06651632)

Breast Mapping and Detection of Suspicious Breast Lesions Using Feminai
NCT ID: NCT07220863 (https://clinicaltrials.gov/study/NCT07220863)

Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
NCT ID: NCT04348747 (https://clinicaltrials.gov/study/NCT04348747)

DPYD Pharmacogenomics and Fluoropyrimidine (FP) Dose-Adjustment
NCT ID: NCT07158164 (https://clinicaltrials.gov/study/NCT07158164)

Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer
NCT ID: NCT07228832 (https://clinicaltrials.gov/study/NCT07228832)

Plasma exoRNA-Based Liquid Biopsy to Diagnose Clinically Significant Prostate Cancer
NCT ID: NCT07492927 (https://clinicaltrials.gov/study/NCT07492927)

Evaluation of PET Probe [68Ga]CBP8 in the Detection of Radiation Induced Tissue Injury
NCT ID: NCT04485286 (https://clinicaltrials.gov/study/NCT04485286)

Tumor Cell and DNA Detection in the Blood, Urine, and Bone Marrow
NCT ID: NCT03551951 (https://clinicaltrials.gov/study/NCT03551951)

Vaginal Cuff Brachytherapy Fractionation Study
NCT ID: NCT03785288 (https://clinicaltrials.gov/study/NCT03785288)

Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer
NCT ID: NCT06235151 (https://clinicaltrials.gov/study/NCT06235151)

A Dose Finding Study of Debio 4228 in Participants With Advanced Prostate Cancer
NCT ID: NCT06395753 (https://clinicaltrials.gov/study/NCT06395753)

Gemcitabine and Leflunomide in Patients With Advanced Unresectable Pancreatic Cancer
NCT ID: NCT06454383 (https://clinicaltrials.gov/study/NCT06454383)

Developing a Test of Uterine Lavage for the Detection of Ovarian Cancer
NCT ID: NCT04794322 (https://clinicaltrials.gov/study/NCT04794322)

Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort
NCT ID: NCT05693766 (https://clinicaltrials.gov/study/NCT05693766)

Resistance and Aerobic Exercise for Prevention in Women With Dense Breasts (REP-D)
NCT ID: NCT06322888 (https://clinicaltrials.gov/study/NCT06322888)

Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
NCT ID: NCT04956640 (https://clinicaltrials.gov/study/NCT04956640)

Cryoablation+Ipilimumab+Nivolumab in Melanoma
NCT ID: NCT05779423 (https://clinicaltrials.gov/study/NCT05779423)

ASPEN-09: A Study of Evorpacept in Combination With Anti-cancer Therapies in Advanced / Metastatic Malignancies
NCT ID: NCT07007559 (https://clinicaltrials.gov/study/NCT07007559)

Walnuts and Colon Health
NCT ID: NCT05195970 (https://clinicaltrials.gov/study/NCT05195970)

Ultrasound and Photoacoustic Imaging for Enhanced Differential Diagnosis of Rectal Cancer
NCT ID: NCT04339374 (https://clinicaltrials.gov/study/NCT04339374)

A Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate Cancer
NCT ID: NCT06990880 (https://clinicaltrials.gov/study/NCT06990880)

PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC
NCT ID: NCT06245889 (https://clinicaltrials.gov/study/NCT06245889)

HER2-positive Breast Cancer Registry
NCT ID: NCT06603597 (https://clinicaltrials.gov/study/NCT06603597)

Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma
NCT ID: NCT05559879 (https://clinicaltrials.gov/study/NCT05559879)

PROGRESS: Precision Oncology Using Genomic Reflexive Evaluations for Study Selection and Survival
NCT ID: NCT06896162 (https://clinicaltrials.gov/study/NCT06896162)

Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
NCT ID: NCT03678025 (https://clinicaltrials.gov/study/NCT03678025)

AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
NCT ID: NCT07094113 (https://clinicaltrials.gov/study/NCT07094113)

At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
NCT ID: NCT05969860 (https://clinicaltrials.gov/study/NCT05969860)

Perioperative Mindfulness Proposal
NCT ID: NCT04049214 (https://clinicaltrials.gov/study/NCT04049214)

Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory
NCT ID: NCT05576896 (https://clinicaltrials.gov/study/NCT05576896)

Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer
NCT ID: NCT06801236 (https://clinicaltrials.gov/study/NCT06801236)

A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
NCT ID: NCT05877599 (https://clinicaltrials.gov/study/NCT05877599)

Personalized Second Chance Breast Conservation (PSCBC): A Prospective Phase II Clinical Study
NCT ID: NCT04371913 (https://clinicaltrials.gov/study/NCT04371913)

Phase II Study of Anti-PD-1/VEGF Bispecific Antibody Ivonescimab in Patients With Previously Treated Metastatic Colorectal Cancer
NCT ID: NCT06959550 (https://clinicaltrials.gov/study/NCT06959550)

Study of Screening Brain MRIs in Stage IV Breast Cancer
NCT ID: NCT05115474 (https://clinicaltrials.gov/study/NCT05115474)

Evaluating the Implementation of a Comprehensive Multilevel Virtual Oncology Program Among Veterans Diagnosed With Lung, Colorectal, Prostate, and Breast Cancers in the US Department of Veterans Affairs
NCT ID: NCT06559059 (https://clinicaltrials.gov/study/NCT06559059)

[18F]FTT Positron Emission Tomography for the Measurement of PARP Tumor Expression in Patients With Metastatic Breast Cancer
NCT ID: NCT06502691 (https://clinicaltrials.gov/study/NCT06502691)

Daily Adaptive Radiation Therapy Using an Individualized Approach for Prostate Cancer
NCT ID: NCT05804318 (https://clinicaltrials.gov/study/NCT05804318)

Intraperitoneal Oxaliplatin and Fluorouracil for the Treatment of Patients With Peritoneal Metastases From Colorectal Cancer
NCT ID: NCT06269978 (https://clinicaltrials.gov/study/NCT06269978)

Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
NCT ID: NCT05727904 (https://clinicaltrials.gov/study/NCT05727904)

A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
NCT ID: NCT07458347 (https://clinicaltrials.gov/study/NCT07458347)

Evaluation of the Safety, Efficacy, and Pharmacokinetics of NBM-BMX in Patients With Metastatic Uveal Melanoma
NCT ID: NCT07136181 (https://clinicaltrials.gov/study/NCT07136181)

Sacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy
NCT ID: NCT06065371 (https://clinicaltrials.gov/study/NCT06065371)

A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
NCT ID: NCT07020221 (https://clinicaltrials.gov/study/NCT07020221)

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
NCT ID: NCT06103864 (https://clinicaltrials.gov/study/NCT06103864)

Cryoablation as a Minimally Invasive Alternative to Surgery for Managing Ductal Carcinoma In Situ
NCT ID: NCT05218044 (https://clinicaltrials.gov/study/NCT05218044)

A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
NCT ID: NCT06778863 (https://clinicaltrials.gov/study/NCT06778863)

Utility of a Mobile Application for Young Women With Breast Cancer
NCT ID: NCT07009093 (https://clinicaltrials.gov/study/NCT07009093)

A Study of HLD-0915 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
NCT ID: NCT06800313 (https://clinicaltrials.gov/study/NCT06800313)

Community Partnership for Telehealth Solutions to Convey Information and Enhance Care
NCT ID: NCT06542835 (https://clinicaltrials.gov/study/NCT06542835)

Implementation of a ColoRectal Cancer Screening Tool in US Primary Care Practices - Usual Quality Improvement (10 Clinics) vs Normalization Process Theory-Participatory Learning in Action (10 Clinics)
NCT ID: NCT06682650 (https://clinicaltrials.gov/study/NCT06682650)

A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
NCT ID: NCT07115043 (https://clinicaltrials.gov/study/NCT07115043)

Early Detection of Advanced Adenomas and Colorectal Cancer
NCT ID: NCT06342440 (https://clinicaltrials.gov/study/NCT06342440)

Study of Aerobic Training for People Receiving Chemotherapy for Breast Cancer
NCT ID: NCT05716893 (https://clinicaltrials.gov/study/NCT05716893)

The Preventive Role of Fractionated Laser Resurfacing Against Actinic Neoplasia in an At-Risk Geriatric Population
NCT ID: NCT06428721 (https://clinicaltrials.gov/study/NCT06428721)

Novel Cavity Marking Technique in Breast Cancer Patients Undergoing Breast Conservation Surgery With Oncoplastic Reconstruction for the Delivery of Adjuvant Radiotherapy and Accuracy of Recommended Re-excisions
NCT ID: NCT06903468 (https://clinicaltrials.gov/study/NCT06903468)

A Clinical Study of V940 and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)
NCT ID: NCT06961006 (https://clinicaltrials.gov/study/NCT06961006)

Splicing-based Predictive Learning for Individual Chemotherapy Evaluation in Colorectal Cancer
NCT ID: NCT07226115 (https://clinicaltrials.gov/study/NCT07226115)

Pioglitazone Therapy Targeting Fatigue in Breast Cancer
NCT ID: NCT05013255 (https://clinicaltrials.gov/study/NCT05013255)

A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer
NCT ID: NCT04486352 (https://clinicaltrials.gov/study/NCT04486352)

177^Lu-PSMA-617 in Combination With Sipuleucel-T for the Treatment of Metastatic Castration-Resistant Prostate Cancer
NCT ID: NCT07219147 (https://clinicaltrials.gov/study/NCT07219147)

TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd
NCT ID: NCT06533826 (https://clinicaltrials.gov/study/NCT06533826)

A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
NCT ID: NCT04104776 (https://clinicaltrials.gov/study/NCT04104776)

Losartan to Reduce Radiation Induced Fibrosis in Breast Cancer Patients
NCT ID: NCT05637216 (https://clinicaltrials.gov/study/NCT05637216)

Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer
NCT ID: NCT05524584 (https://clinicaltrials.gov/study/NCT05524584)

A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours
NCT ID: NCT06305247 (https://clinicaltrials.gov/study/NCT06305247)

Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer
NCT ID: NCT06616155 (https://clinicaltrials.gov/study/NCT06616155)

A Digital Health Intervention to Improve Symptoms and Physical Activity During Breast Radiation
NCT ID: NCT06772181 (https://clinicaltrials.gov/study/NCT06772181)

Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Carcinomas
NCT ID: NCT06202066 (https://clinicaltrials.gov/study/NCT06202066)

Adjuvant Chemoradiation and Biomarkers of Response in High-risk Breast Cancer
NCT ID: NCT05288777 (https://clinicaltrials.gov/study/NCT05288777)

Excision of Lymph Node Trial (EXCILYNT) (Mel69)
NCT ID: NCT05839912 (https://clinicaltrials.gov/study/NCT05839912)

Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial
NCT ID: NCT05863195 (https://clinicaltrials.gov/study/NCT05863195)

ColoCare Study - Colorectal Cancer Cohort
NCT ID: NCT02328677 (https://clinicaltrials.gov/study/NCT02328677)

The Better, Harder, Faster, Stronger Study
NCT ID: NCT07220512 (https://clinicaltrials.gov/study/NCT07220512)

Men at High Genetic Risk for Prostate Cancer
NCT ID: NCT03805919 (https://clinicaltrials.gov/study/NCT03805919)

BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer
NCT ID: NCT06756932 (https://clinicaltrials.gov/study/NCT06756932)

Evaluation of SINGLE PORT (SP) Robotic Technology in Colorectal Surgery
NCT ID: NCT05321134 (https://clinicaltrials.gov/study/NCT05321134)

Radiation Therapy for the Treatment of Metastatic Gastrointestinal Cancers
NCT ID: NCT04221893 (https://clinicaltrials.gov/study/NCT04221893)

A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)
NCT ID: NCT07244341 (https://clinicaltrials.gov/study/NCT07244341)

Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)
NCT ID: NCT06686394 (https://clinicaltrials.gov/study/NCT06686394)

Using MRI to Identify Areas to Receive Lower Doses of Radiation Treatment in Men With Prostate Cancerdose Mapping to Preserve Quality of Life
NCT ID: NCT06171269 (https://clinicaltrials.gov/study/NCT06171269)

Prostate Specific Membrane Antigen (PSMA) or (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study
NCT ID: NCT04175431 (https://clinicaltrials.gov/study/NCT04175431)

A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
NCT ID: NCT02960022 (https://clinicaltrials.gov/study/NCT02960022)

An Investigational Scan (64Cu-DOTA-Trastuzumab PET/MRI) in Imaging Patients With HER2+ Breast Cancer With Brain Metastasis
NCT ID: NCT05376878 (https://clinicaltrials.gov/study/NCT05376878)

Neoadjuvant Lu-177-PSMA-617 in Patients With High Risk Localized Prostate Cancer Undergoing Radical Prostatectomy
NCT ID: NCT06798558 (https://clinicaltrials.gov/study/NCT06798558)

Tumor Microenvironment Analysis of Prostate Cancer Metastasis
NCT ID: NCT05304858 (https://clinicaltrials.gov/study/NCT05304858)

Cardiac Outcomes With Near-Complete Estrogen Deprivation
NCT ID: NCT05309655 (https://clinicaltrials.gov/study/NCT05309655)

Gemcitabine, Nab-paclitaxel Plus the TheraBionic P1 (an Amplitude-Modulated Radiofrequency Electromagnetic Fields) Device to Treat Metastatic Pancreatic Cancer
NCT ID: NCT06576115 (https://clinicaltrials.gov/study/NCT06576115)

Improving Health Literacy in African-American Prostate Cancer Patients
NCT ID: NCT03322891 (https://clinicaltrials.gov/study/NCT03322891)

Surgical Excision vs Neoadjuvant Radiotherapy+Delayed Surgical Excision of Ductal Carcinoma
NCT ID: NCT03909282 (https://clinicaltrials.gov/study/NCT03909282)

Early Diagnosis of Pancreatic Cancer Duodenal Fluid-Based Biomarker Exploratory Study
NCT ID: NCT07030348 (https://clinicaltrials.gov/study/NCT07030348)

Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab
NCT ID: NCT06249048 (https://clinicaltrials.gov/study/NCT06249048)

A Post-treatment Supportive Service Program for the Transition Into Survivorship for Black Women Breast Cancer Survivors in Western New York
NCT ID: NCT06833255 (https://clinicaltrials.gov/study/NCT06833255)

VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
NCT ID: NCT03556228 (https://clinicaltrials.gov/study/NCT03556228)

A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
NCT ID: NCT07225946 (https://clinicaltrials.gov/study/NCT07225946)

GB1211 and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma
NCT ID: NCT05913388 (https://clinicaltrials.gov/study/NCT05913388)

Interrogation of Exosome-mediated Intercellular Signaling in Patients With Pancreatic Cancer
NCT ID: NCT02393703 (https://clinicaltrials.gov/study/NCT02393703)

Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer
NCT ID: NCT04090567 (https://clinicaltrials.gov/study/NCT04090567)

A Study of NX-1607 in Adults With Advanced Malignancies
NCT ID: NCT05107674 (https://clinicaltrials.gov/study/NCT05107674)

Resistance Training and Post Workout Protein to Improve Body Composition During Neoadjuvant Chemotherapy for Breast Cancer
NCT ID: NCT06858449 (https://clinicaltrials.gov/study/NCT06858449)

Global Cardio Oncology Registry
NCT ID: NCT05598879 (https://clinicaltrials.gov/study/NCT05598879)

Study of Alpha Radioligand Therapy AB001 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
NCT ID: NCT07214961 (https://clinicaltrials.gov/study/NCT07214961)

Effects of Relugolix vs Leuprolide on Cardiac Function in Patients With Prostate Cancer
NCT ID: NCT06330805 (https://clinicaltrials.gov/study/NCT06330805)

Telmisartan in Prostate Cancer
NCT ID: NCT06168487 (https://clinicaltrials.gov/study/NCT06168487)

Support Through Remote Observation and Nutrition Guidance Program (STRONG-PCS)
NCT ID: NCT06001268 (https://clinicaltrials.gov/study/NCT06001268)

A Study of Surgery and Radiotherapy in People With Breast Cancer
NCT ID: NCT07053085 (https://clinicaltrials.gov/study/NCT07053085)

PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC)
NCT ID: NCT06673017 (https://clinicaltrials.gov/study/NCT06673017)

Digital Remote Monitoring of Immune Checkpoint Inhibitor Therapy Induced Toxicity Using the Vigilant App
NCT ID: NCT06675643 (https://clinicaltrials.gov/study/NCT06675643)

Ipilumumab and Nivolumab With or Without Hypofractionated Radiotherapy in Patients With Metastatic Melanoma
NCT ID: NCT03646617 (https://clinicaltrials.gov/study/NCT03646617)

Positron Emission Tomography (PET) Guided Stereotactic Body Radiation Therapy for the Treatment of Oligoprogressive Non-small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma
NCT ID: NCT05830058 (https://clinicaltrials.gov/study/NCT05830058)

Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
NCT ID: NCT05985655 (https://clinicaltrials.gov/study/NCT05985655)

DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer
NCT ID: NCT06964009 (https://clinicaltrials.gov/study/NCT06964009)

Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment
NCT ID: NCT06235697 (https://clinicaltrials.gov/study/NCT06235697)

Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
NCT ID: NCT04119024 (https://clinicaltrials.gov/study/NCT04119024)

A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
NCT ID: NCT06179160 (https://clinicaltrials.gov/study/NCT06179160)

Enhancing Mammography Programs for Outreach, Wellness, Education, and Resources (EMPOWER) in Underserved Populations Study
NCT ID: NCT07029490 (https://clinicaltrials.gov/study/NCT07029490)

Nab-Sirolimus and Endocrine Therapy in Recurrent Low Grade Serous Ovarian Cancer (NARETO)
NCT ID: NCT06494150 (https://clinicaltrials.gov/study/NCT06494150)

5-Fluorouracil/Leucovorin (5FU/LV) in Combination With Regorafenib in Patients With Metastatic Colorectal Cancer
NCT ID: NCT06887218 (https://clinicaltrials.gov/study/NCT06887218)

Mediterranean Diet and Weight Loss: Targeting the Bile Acid/Gut Microbiome Axis to Reduce Colorectal Cancer
NCT ID: NCT04753359 (https://clinicaltrials.gov/study/NCT04753359)

A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.
NCT ID: NCT06447662 (https://clinicaltrials.gov/study/NCT06447662)

CYTALUX for Intraoperative Imaging of Patients With Endometrial Cancer
NCT ID: NCT07278986 (https://clinicaltrials.gov/study/NCT07278986)

Prospective Screening for Breast Cancer-related Lymphedema
NCT ID: NCT01521741 (https://clinicaltrials.gov/study/NCT01521741)

Nab-Paclitaxel + Cisplatin + Gemcitabine + TTF in pt. w/ Metastatic PAC
NCT ID: NCT04605913 (https://clinicaltrials.gov/study/NCT04605913)

A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
NCT ID: NCT04903873 (https://clinicaltrials.gov/study/NCT04903873)

A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)
NCT ID: NCT06997497 (https://clinicaltrials.gov/study/NCT06997497)

WellSpan-THRIVE Cancer QOL Study
NCT ID: NCT07433660 (https://clinicaltrials.gov/study/NCT07433660)

Lifting More Than Weights: Resistance Exercise Program Across Socioeconomic Groups for Cancer-Related Fatigue Management
NCT ID: NCT06960720 (https://clinicaltrials.gov/study/NCT06960720)

Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer
NCT ID: NCT05462496 (https://clinicaltrials.gov/study/NCT05462496)

A Study Evaluating AMG 193 in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)
NCT ID: NCT06360354 (https://clinicaltrials.gov/study/NCT06360354)

Preoperative Radiotherapy and Immunotherapy for Sinonasal and Anorectal Mucosal Melanoma
NCT ID: NCT05546827 (https://clinicaltrials.gov/study/NCT05546827)

Telehealth Exercise Program Evaluating Fatigue and Physical Function in Rural Cancer Survivors
NCT ID: NCT07001241 (https://clinicaltrials.gov/study/NCT07001241)

A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma
NCT ID: NCT07288203 (https://clinicaltrials.gov/study/NCT07288203)

Enhanced Pain Coping in Cancer (EPIC): A Study of Managing Treatment-Related Joint Pain in Breast Cancer Survivors
NCT ID: NCT06728579 (https://clinicaltrials.gov/study/NCT06728579)

Trial of ProAgio in Advanced/Metastatic Colorectal Cancer
NCT ID: NCT06867822 (https://clinicaltrials.gov/study/NCT06867822)

The Role of MicroRNA in the Diagnosis, Prognosis and Response to Treatment in Pancreatic Cancer
NCT ID: NCT04406831 (https://clinicaltrials.gov/study/NCT04406831)

Behavioral Exercise Training to Reduce Cardiovascular Disease Risk
NCT ID: NCT06237179 (https://clinicaltrials.gov/study/NCT06237179)

ASk Questions in GYnecologic Oncology (ASQ-GYO)
NCT ID: NCT06339827 (https://clinicaltrials.gov/study/NCT06339827)

Single Arm Study of Neoadjuvant Dostarlimab in Stage II and III Deficient Mismatch Repair Colon Cancers
NCT ID: NCT05239546 (https://clinicaltrials.gov/study/NCT05239546)

A Novel Approach Utilizing Organ Specific Age Proteomics
NCT ID: NCT06789653 (https://clinicaltrials.gov/study/NCT06789653)

LYMPHA Procedure for the Prevention of Lymphedema After Axillary Lymphadenectomy
NCT ID: NCT05366699 (https://clinicaltrials.gov/study/NCT05366699)

Interpretations and Predictions of Patient Reported Outcomes by Breast Cancer Patients
NCT ID: NCT05064098 (https://clinicaltrials.gov/study/NCT05064098)

All-extremity Exercise During Breast Cancer Chemotherapy
NCT ID: NCT04914663 (https://clinicaltrials.gov/study/NCT04914663)

Study of 68Ga-R10602
NCT ID: NCT06745804 (https://clinicaltrials.gov/study/NCT06745804)

Study of ctDNA Guided Change in Tx for Refractory Minimal Residual Disease in Colon Adenocarcinomas
NCT ID: NCT04920032 (https://clinicaltrials.gov/study/NCT04920032)

A Study of Revaree Plus in People With Breast Cancer
NCT ID: NCT07042581 (https://clinicaltrials.gov/study/NCT07042581)

The Vanguard Study: Testing a New Way to Screen for Cancer
NCT ID: NCT06995898 (https://clinicaltrials.gov/study/NCT06995898)

Repeat Breast Conserving Surgery Followed by Daily Partial Breast Irradiation in Ipsilateral Breast
NCT ID: NCT06129747 (https://clinicaltrials.gov/study/NCT06129747)

The Breast Cancer Survivors and Partners Online Research Together (SUPORT) Project
NCT ID: NCT05676255 (https://clinicaltrials.gov/study/NCT05676255)

Randomized Feasibility Trial for Mesh in Pre-Pectoral Reconstruction
NCT ID: NCT05190978 (https://clinicaltrials.gov/study/NCT05190978)

THRIVE Well Cancer FDTN/Exercise_Creatine Supplementation
NCT ID: NCT06395506 (https://clinicaltrials.gov/study/NCT06395506)

EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)
NCT ID: NCT06401421 (https://clinicaltrials.gov/study/NCT06401421)

NeoTAILOR: ABiomarker-directed Approach to Guide Neoadjuvant Therapy for Patients With Stage II/III ER-positive, HER2-negative Breast Cancer
NCT ID: NCT05837455 (https://clinicaltrials.gov/study/NCT05837455)

A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma
NCT ID: NCT06007690 (https://clinicaltrials.gov/study/NCT06007690)

A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss
NCT ID: NCT05593497 (https://clinicaltrials.gov/study/NCT05593497)

A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer
NCT ID: NCT06110793 (https://clinicaltrials.gov/study/NCT06110793)

Combination Immunotherapy for the Treatment of Chemotherapy-refractory Metastatic MSS CRC
NCT ID: NCT07281716 (https://clinicaltrials.gov/study/NCT07281716)

Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors
NCT ID: NCT05896189 (https://clinicaltrials.gov/study/NCT05896189)

An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
NCT ID: NCT05939414 (https://clinicaltrials.gov/study/NCT05939414)

Immunologic Targeting of ESR1 Receptor for Hormone Receptor Expressing Metastatic Breast Cancer
NCT ID: NCT06691035 (https://clinicaltrials.gov/study/NCT06691035)

A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (mCRC)
NCT ID: NCT07011576 (https://clinicaltrials.gov/study/NCT07011576)

Exploring the Potential of Robotic Telesurgery in Remote Settings
NCT ID: NCT07130708 (https://clinicaltrials.gov/study/NCT07130708)

Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
NCT ID: NCT04573231 (https://clinicaltrials.gov/study/NCT04573231)

PET Scan Study to Detect Prostate Cancer in Patients with Early PSA Recurrence
NCT ID: NCT06617481 (https://clinicaltrials.gov/study/NCT06617481)

Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)
NCT ID: NCT06149481 (https://clinicaltrials.gov/study/NCT06149481)

Clonal Hematopoiesis and Therapy-Emergent Myeloid Neoplasms in Patients With Cancers, CHANCES Study
NCT ID: NCT06295965 (https://clinicaltrials.gov/study/NCT06295965)

Evaluation of the Bexa Breast Examination
NCT ID: NCT06643767 (https://clinicaltrials.gov/study/NCT06643767)

Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
NCT ID: NCT05269381 (https://clinicaltrials.gov/study/NCT05269381)

EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors
NCT ID: NCT07262619 (https://clinicaltrials.gov/study/NCT07262619)

A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer
NCT ID: NCT05379595 (https://clinicaltrials.gov/study/NCT05379595)

Fusion or Cognitive Ultrasound-guided Biopsy to Detect Prostate Cancer
NCT ID: NCT06517901 (https://clinicaltrials.gov/study/NCT06517901)

Targeted Palliative Care Intervention for Patients With Metastatic Breast Cancer
NCT ID: NCT06795529 (https://clinicaltrials.gov/study/NCT06795529)

A RAndomizeD Intervention for Cardiovascular and Lifestyle Risk Factors in Prostate Cancer Patients
NCT ID: NCT03127631 (https://clinicaltrials.gov/study/NCT03127631)

Longitudinal Advanced Prostate Cancer Cohort (LAPCC)
NCT ID: NCT06067295 (https://clinicaltrials.gov/study/NCT06067295)

IDOV-Immune for Advanced Solid Tumors
NCT ID: NCT06910657 (https://clinicaltrials.gov/study/NCT06910657)

Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
NCT ID: NCT07030257 (https://clinicaltrials.gov/study/NCT07030257)

Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer
NCT ID: NCT06253494 (https://clinicaltrials.gov/study/NCT06253494)

Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer
NCT ID: NCT07181161 (https://clinicaltrials.gov/study/NCT07181161)

WATD and Cancer-Related Fatigue: A Study For Patients Undergoing Anti-Cancer Treatment
NCT ID: NCT06291324 (https://clinicaltrials.gov/study/NCT06291324)

Pilot Study of Pancreatic Cancer Screening
NCT ID: NCT05058846 (https://clinicaltrials.gov/study/NCT05058846)

Study of How People Make Decisions About Prostate Cancer Risk
NCT ID: NCT07197723 (https://clinicaltrials.gov/study/NCT07197723)

Diversity and Inclusion in Research Underpinning Prevention and Therapy Trials
NCT ID: NCT05146297 (https://clinicaltrials.gov/study/NCT05146297)

SOC Chemotherapy +/- Tocilizumab for Triple Negative and ER-low Breast Cancers
NCT ID: NCT05846789 (https://clinicaltrials.gov/study/NCT05846789)

DermaSensor Postmarket Surveillance Study
NCT ID: NCT06666790 (https://clinicaltrials.gov/study/NCT06666790)

Phase 1 Dose Escalation and Expansion Study of PRAME T Cell Receptor (TCR) Engineered NK Cells in Participants With Recurrent and/or Refractory Melanoma (PRAMETIME-Mel)
NCT ID: NCT06660420 (https://clinicaltrials.gov/study/NCT06660420)

KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
NCT ID: NCT05483491 (https://clinicaltrials.gov/study/NCT05483491)

A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
NCT ID: NCT05208762 (https://clinicaltrials.gov/study/NCT05208762)

A Study of DS9051b in Participants With Advanced or Metastatic Adrenocortical Carcinoma and Metastatic Castration-resistant Prostate Cancer
NCT ID: NCT07189403 (https://clinicaltrials.gov/study/NCT07189403)

A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
NCT ID: NCT05361174 (https://clinicaltrials.gov/study/NCT05361174)

Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA Trial
NCT ID: NCT06288113 (https://clinicaltrials.gov/study/NCT06288113)

Non-Invasive Identification of Endometrial Cancer/Endometrial Atypical Hyperplasia With an AI-Based Classifier Applied to Transvaginal Ultrasound in Patients With Post-Menopausal Bleeding
NCT ID: NCT06365905 (https://clinicaltrials.gov/study/NCT06365905)

This Study is Evaluating a New Radiation Treatment Technique for Patients Who Have Had Prostate Cancer, Undergone Surgery for Cancer, and Then Have Evidence That Their Prostate Cancer Has Returned.
NCT ID: NCT05946824 (https://clinicaltrials.gov/study/NCT05946824)

Phase 2A Pilot C3 Trial of Recurrent/Refractory Metastatic Advanced Pancreatic Cancer
NCT ID: NCT06030622 (https://clinicaltrials.gov/study/NCT06030622)

In Vivo Real-time Detection of Circulating Melanoma Cells
NCT ID: NCT01776905 (https://clinicaltrials.gov/study/NCT01776905)

Real-Time Assessment Of Breast Cancer Lumpectomy Specimen Margins With Nonlinear Microscopy
NCT ID: NCT02926729 (https://clinicaltrials.gov/study/NCT02926729)

Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma
NCT ID: NCT06295159 (https://clinicaltrials.gov/study/NCT06295159)

Opioid Dispensing Device for Post-Operative Pain in Cancer Patients
NCT ID: NCT05585788 (https://clinicaltrials.gov/study/NCT05585788)

Cabazitaxel +/- Carboplatin vs 177Lu-PSMA-617 in Metastatic Castrate-resistant Prostate Cancer
NCT ID: NCT06738303 (https://clinicaltrials.gov/study/NCT06738303)

Precision Medicine in Action: Phase II Trial of Response Adaptive Ablative Pre-operative SPBI (RAPS) and Non-operative Sentinel Lymph Node Biopsy in Patients With Early-stage ER+ Breast Cancer: RAPS Trial
NCT ID: NCT06444269 (https://clinicaltrials.gov/study/NCT06444269)

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
NCT ID: NCT05579366 (https://clinicaltrials.gov/study/NCT05579366)

TR-002 for the Treatment of Advanced, Unresectable or Metastatic Solid Tumors and Unresectable or Metastatic, Refractory Pancreatic Adenocarcinoma
NCT ID: NCT07189195 (https://clinicaltrials.gov/study/NCT07189195)

Autologous huMNC2-CAR44 or huMNC2-CAR22 T Cells for Breast Cancer Targeting Cleaved Form of MUC1 (MUC1*)
NCT ID: NCT04020575 (https://clinicaltrials.gov/study/NCT04020575)

Sacituzumab Govitecan in Combination With Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial Cancer
NCT ID: NCT06040970 (https://clinicaltrials.gov/study/NCT06040970)

Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer
NCT ID: NCT01492972 (https://clinicaltrials.gov/study/NCT01492972)

Evaluation of the Acceptability, Appropriateness, and Feasibility/Usability of a Metastatic Breast-cancer Specific Prognostic Calculator Among Clinicians
NCT ID: NCT05440929 (https://clinicaltrials.gov/study/NCT05440929)

Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or Gastroesophageal Cancer
NCT ID: NCT04511039 (https://clinicaltrials.gov/study/NCT04511039)

Effectiveness of Fractionated Laser Resurfacing to Protect Geriatric Skin From Actinic Neoplasia
NCT ID: NCT03906253 (https://clinicaltrials.gov/study/NCT03906253)

A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer
NCT ID: NCT06792695 (https://clinicaltrials.gov/study/NCT06792695)

Pancreatic Cancer Early Detection Consortium
NCT ID: NCT04970056 (https://clinicaltrials.gov/study/NCT04970056)

Study of INCB123667 in Subjects With Advanced Solid Tumors
NCT ID: NCT05238922 (https://clinicaltrials.gov/study/NCT05238922)

Neurocutaneous Melanocytosis Registry
NCT ID: NCT04548817 (https://clinicaltrials.gov/study/NCT04548817)

Identification of Metabolic Phenotypes Associated With Melanoma Metastasis
NCT ID: NCT06400550 (https://clinicaltrials.gov/study/NCT06400550)

Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
NCT ID: NCT06451497 (https://clinicaltrials.gov/study/NCT06451497)

Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF
NCT ID: NCT03604315 (https://clinicaltrials.gov/study/NCT03604315)

STereotActic Body Radiotherapy and 177Lutetium PSMA in Locally Advanced Prostate Cancer
NCT ID: NCT06574880 (https://clinicaltrials.gov/study/NCT06574880)

Creatine Supplementation and Resistance Training to Preserve Muscle Mass and Attenuate Cancer Progression
NCT ID: NCT06112990 (https://clinicaltrials.gov/study/NCT06112990)

A Study of PHN-012 in Patients With Advanced Solid Tumors
NCT ID: NCT07127874 (https://clinicaltrials.gov/study/NCT07127874)

Building Community Living Labs in Black Communities to Advance Prostate Health Equity and Reduce Prostate Cancer Disparities in Black Men
NCT ID: NCT06541210 (https://clinicaltrials.gov/study/NCT06541210)

TNBC Gut Microbiota During Neoadjuvant Treatment
NCT ID: NCT06610097 (https://clinicaltrials.gov/study/NCT06610097)

A Study of OT-101 With mFOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer
NCT ID: NCT06079346 (https://clinicaltrials.gov/study/NCT06079346)

A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
NCT ID: NCT06805825 (https://clinicaltrials.gov/study/NCT06805825)

A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
NCT ID: NCT07213791 (https://clinicaltrials.gov/study/NCT07213791)

Perioperative Fostamatinib With Gemcitabine and Nab-paclitaxel in Resectable Pancreatic Cancer
NCT ID: NCT06639724 (https://clinicaltrials.gov/study/NCT06639724)

Screening and Staging of Benign vs Malignant Pelvic Abnormalities
NCT ID: NCT07407959 (https://clinicaltrials.gov/study/NCT07407959)

Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors
NCT ID: NCT04354064 (https://clinicaltrials.gov/study/NCT04354064)

Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer
NCT ID: NCT07140900 (https://clinicaltrials.gov/study/NCT07140900)

Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies
NCT ID: NCT04137900 (https://clinicaltrials.gov/study/NCT04137900)

Biomarkers of Resiliency In Childhood Cancer Surgery
NCT ID: NCT06674811 (https://clinicaltrials.gov/study/NCT06674811)

Clinical Trial of CD40L-augmented TIL for Patients With Advanced Melanoma
NCT ID: NCT06961357 (https://clinicaltrials.gov/study/NCT06961357)

Improving Colonoscopy Surveillance for Patients With High Risk Colon Polyps
NCT ID: NCT06376565 (https://clinicaltrials.gov/study/NCT06376565)

A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
NCT ID: NCT03972657 (https://clinicaltrials.gov/study/NCT03972657)

A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC)
NCT ID: NCT05035836 (https://clinicaltrials.gov/study/NCT05035836)

BRE-04: Window of Opportunity Trial of Preoperative Low Dose Azacitidine in High-Risk Early Stage Breast Cancer
NCT ID: NCT04891068 (https://clinicaltrials.gov/study/NCT04891068)

Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness
NCT ID: NCT05691491 (https://clinicaltrials.gov/study/NCT05691491)

Magseed Enabled Long-Term Localization of Axillary Lymph Nodes
NCT ID: NCT03796559 (https://clinicaltrials.gov/study/NCT03796559)

Physical Activity Targeting Metabolic Syndrome for Prevention of Breast Cancer in SAI Women
NCT ID: NCT06827704 (https://clinicaltrials.gov/study/NCT06827704)

A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors
NCT ID: NCT06188520 (https://clinicaltrials.gov/study/NCT06188520)

Studying Off Label Insurance Coverage for Patients With Cutaneous Cancers a "Filter" Observational Study
NCT ID: NCT07215988 (https://clinicaltrials.gov/study/NCT07215988)

Maternal Cancer Diagnosis and Treatment During Pregnancy:a Database for Maternal, Fetal, and Neonatal Outcomes
NCT ID: NCT02749474 (https://clinicaltrials.gov/study/NCT02749474)

Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery
NCT ID: NCT05111574 (https://clinicaltrials.gov/study/NCT05111574)

A Study of NovoTTF-200T(P) in Combination With Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic Adenocarcinoma
NCT ID: NCT05624918 (https://clinicaltrials.gov/study/NCT05624918)

Axitinib + Ipilimumab in Advanced Melanoma
NCT ID: NCT04996823 (https://clinicaltrials.gov/study/NCT04996823)

A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease
NCT ID: NCT07023289 (https://clinicaltrials.gov/study/NCT07023289)

Pragmatic Trial of Metformin for Glucose Intolerance or Increased BMI in Prostate Cancer Patients
NCT ID: NCT05515978 (https://clinicaltrials.gov/study/NCT05515978)

Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors
NCT ID: NCT07424547 (https://clinicaltrials.gov/study/NCT07424547)

UNTOLD Ovarian Cancer Unmet Needs Survey
NCT ID: NCT07070726 (https://clinicaltrials.gov/study/NCT07070726)

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
NCT ID: NCT06618287 (https://clinicaltrials.gov/study/NCT06618287)

Active Surveillance SNEP Assay Registry Trial for Prostate Cancer
NCT ID: NCT04052048 (https://clinicaltrials.gov/study/NCT04052048)

A Study to Evaluate the Safety and Tolerability of SX-682 in Combination With Nivolumab as a Maintenance Therapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
NCT ID: NCT04477343 (https://clinicaltrials.gov/study/NCT04477343)

STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers
NCT ID: NCT06975293 (https://clinicaltrials.gov/study/NCT06975293)

A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
NCT ID: NCT04251052 (https://clinicaltrials.gov/study/NCT04251052)

Feasibility of Symptom Management for Patients With Metastatic Breast Cancer to Increase Exercise
NCT ID: NCT07313306 (https://clinicaltrials.gov/study/NCT07313306)

OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
NCT ID: NCT06016738 (https://clinicaltrials.gov/study/NCT06016738)

Green Tea and Quercetin in Combination With Docetaxel Chemotherapy in Castration-resistant Prostate Cancer Patients
NCT ID: NCT06615752 (https://clinicaltrials.gov/study/NCT06615752)

Effect of Education on Treatment Decision Making for Patients With Prostate Cancer on Chronic Hormone Treatments
NCT ID: NCT04705038 (https://clinicaltrials.gov/study/NCT04705038)

Clinical Validation of the Role of microRNA Binding Site Mutations in Cancer Risk, Prevention and Treatment
NCT ID: NCT02253251 (https://clinicaltrials.gov/study/NCT02253251)

Pilot Randomized Controlled Trial of a Collaborative Agenda-setting Intervention (CASI) for Patients With Ovarian Cancer
NCT ID: NCT06543537 (https://clinicaltrials.gov/study/NCT06543537)

A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
NCT ID: NCT06051695 (https://clinicaltrials.gov/study/NCT06051695)

Estradiol Plus Olaparib for Breast Cancer (PHOEBE)
NCT ID: NCT05900895 (https://clinicaltrials.gov/study/NCT05900895)

Isunakinra Alone and in Combination With Pembrolizumab in Patients With Colorectal Cancer (MSS)
NCT ID: NCT06634875 (https://clinicaltrials.gov/study/NCT06634875)

MIRAI-MRI: Comparing Screening MRI for Patients at High Risk for Breast Cancer Identified by Mirai and Tyrer-Cuzick
NCT ID: NCT05968157 (https://clinicaltrials.gov/study/NCT05968157)

Monitoring Breast Cancer Immunotherapy Treatment With Advanced Positron Emission Tomography Magnetic Resonance Imaging (PET/MRI)
NCT ID: NCT04861077 (https://clinicaltrials.gov/study/NCT04861077)

Safely Optimizing Body Weight With TCMCB07 in Patients With Newly Diagnosed Metastatic Colorectal Cancer Undergoing Chemotherapy
NCT ID: NCT06937177 (https://clinicaltrials.gov/study/NCT06937177)

High Dose-Rate Brachytherapy and Stereotactic Body Radiotherapy for the Treatment of Prostate Adenocarcinoma
NCT ID: NCT04945642 (https://clinicaltrials.gov/study/NCT04945642)

Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer
NCT ID: NCT05051722 (https://clinicaltrials.gov/study/NCT05051722)

iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
NCT ID: NCT03608631 (https://clinicaltrials.gov/study/NCT03608631)

A Feasibility Study Utilizing Immune Recall to Increase Response to Checkpoint Therapy
NCT ID: NCT05077137 (https://clinicaltrials.gov/study/NCT05077137)

Study of PSMA PET/MR Guided Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost (SBRT-SIB) for High-Intermediate and High Risk Prostate Cancer
NCT ID: NCT04402151 (https://clinicaltrials.gov/study/NCT04402151)

UNC Pleural Fluid Registry
NCT ID: NCT05620329 (https://clinicaltrials.gov/study/NCT05620329)

High-Resolution Lower Dose Dedicated Breast Computed Tomography (CT)
NCT ID: NCT03954431 (https://clinicaltrials.gov/study/NCT03954431)

Phase II Study of Systemic Screening in Pathologic Node Positive Breast Cancer
NCT ID: NCT06833502 (https://clinicaltrials.gov/study/NCT06833502)

PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma
NCT ID: NCT05286814 (https://clinicaltrials.gov/study/NCT05286814)

A Study of VET3-TGI in Patients With Solid Tumors
NCT ID: NCT06444815 (https://clinicaltrials.gov/study/NCT06444815)

JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
NCT ID: NCT05490472 (https://clinicaltrials.gov/study/NCT05490472)

A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab Plus Capecitabine in Stage I-III Triple Negative Breast Cancer With High-Risk Residual Disease (EMPOWER)
NCT ID: NCT04333706 (https://clinicaltrials.gov/study/NCT04333706)

A Trial to Study the Safety and Efficacy of SM-020 Gel 1.0% in Subjects With Seborrheic Keratoses and Non-Melanoma Skin Cancers
NCT ID: NCT06409195 (https://clinicaltrials.gov/study/NCT06409195)

Improving Exercise Capacity With a Tailored Physical Activity Intervention
NCT ID: NCT05595577 (https://clinicaltrials.gov/study/NCT05595577)

First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
NCT ID: NCT05768139 (https://clinicaltrials.gov/study/NCT05768139)

Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma
NCT ID: NCT05428007 (https://clinicaltrials.gov/study/NCT05428007)

Metronomic Cyclophosphamide With Pembrolizumab in Checkpoint Inhibitor Refractory Melanoma
NCT ID: NCT06771544 (https://clinicaltrials.gov/study/NCT06771544)

24GUT540 : Meeting of Breast Cancer Patients and Pathologists
NCT ID: NCT07040514 (https://clinicaltrials.gov/study/NCT07040514)

Fluoxetine for the Modification of Colorectal Tumor Immune Cells Before Surgery in Patients With Colorectal Cancer
NCT ID: NCT06225011 (https://clinicaltrials.gov/study/NCT06225011)

Phase 1 Study of CLR 125 in Triple Negative Breast Cancer
NCT ID: NCT07311993 (https://clinicaltrials.gov/study/NCT07311993)

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
NCT ID: NCT06492616 (https://clinicaltrials.gov/study/NCT06492616)

Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor
NCT ID: NCT05523947 (https://clinicaltrials.gov/study/NCT05523947)

Breast Cancer Patient Engagement With Patient Reported Outcome Measure Survey
NCT ID: NCT03995082 (https://clinicaltrials.gov/study/NCT03995082)

A Study to Prevent and Improve Sexual Health Concerns for People With Breast Cancer
NCT ID: NCT05910294 (https://clinicaltrials.gov/study/NCT05910294)

Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer
NCT ID: NCT05422794 (https://clinicaltrials.gov/study/NCT05422794)

Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers
NCT ID: NCT04886531 (https://clinicaltrials.gov/study/NCT04886531)

A Ph Ib Study of REGN5678 Plus Cemiplimab in Patients With mCRPC
NCT ID: NCT06826768 (https://clinicaltrials.gov/study/NCT06826768)

Trial of Curcumin to Prevent Progression of Low-risk Prostate Cancer Under Active Surveillance
NCT ID: NCT03769766 (https://clinicaltrials.gov/study/NCT03769766)

Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer
NCT ID: NCT05231122 (https://clinicaltrials.gov/study/NCT05231122)

A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
NCT ID: NCT05253651 (https://clinicaltrials.gov/study/NCT05253651)

Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors
NCT ID: NCT05176483 (https://clinicaltrials.gov/study/NCT05176483)

Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer
NCT ID: NCT05751941 (https://clinicaltrials.gov/study/NCT05751941)

A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
NCT ID: NCT07023627 (https://clinicaltrials.gov/study/NCT07023627)

EDRN Prostate MRI Biomarker Study
NCT ID: NCT03784924 (https://clinicaltrials.gov/study/NCT03784924)

Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin
NCT ID: NCT06677190 (https://clinicaltrials.gov/study/NCT06677190)

Investigating Targetable Metabolic Pathways Sustaining Pancreatic Cancer
NCT ID: NCT05296421 (https://clinicaltrials.gov/study/NCT05296421)

A Study of Elacestrant Alone or in Combination With Abemaciclib in People With Endometrial Cancer
NCT ID: NCT07209449 (https://clinicaltrials.gov/study/NCT07209449)

CT-95 in Advanced Cancers Associated With Mesothelin Expression
NCT ID: NCT06756035 (https://clinicaltrials.gov/study/NCT06756035)

SDM POSSIBLE: A Breast Cancer Treatment Decision Aid for Women 70+ With Low-Risk Stage I Breast Cancers
NCT ID: NCT06896474 (https://clinicaltrials.gov/study/NCT06896474)

Magnetic Resonance Imaging (MRI) With Hyperpolarized Pyruvate (13C) as Diagnostic Tool in Advanced Prostate Cancer
NCT ID: NCT04346225 (https://clinicaltrials.gov/study/NCT04346225)

Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation
NCT ID: NCT05806515 (https://clinicaltrials.gov/study/NCT05806515)

Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer
NCT ID: NCT03488693 (https://clinicaltrials.gov/study/NCT03488693)

SBRT Versus Hypofractionated Radiotherapy for Biochemically Recurrent or Oligometastatic Prostate Adenocarcinoma
NCT ID: NCT06205316 (https://clinicaltrials.gov/study/NCT06205316)

Project SOAR (Speaking Our African American Realities) Awakenings for Black American Women Diagnosed With Breast Cancer
NCT ID: NCT07208084 (https://clinicaltrials.gov/study/NCT07208084)

Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction
NCT ID: NCT06195306 (https://clinicaltrials.gov/study/NCT06195306)

Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
NCT ID: NCT03449238 (https://clinicaltrials.gov/study/NCT03449238)

A Patient Navigation Intervention for the Improvement of Risk Management Among Women at High Risk of Breast Cancer
NCT ID: NCT06950008 (https://clinicaltrials.gov/study/NCT06950008)

A Study of Breast Cancer Risk Factors and Outcomes of People in Florida
NCT ID: NCT06780176 (https://clinicaltrials.gov/study/NCT06780176)

Lesion Composition and Quantitative Imaging Analysis on Breast Cancer Diagnosis
NCT ID: NCT05369546 (https://clinicaltrials.gov/study/NCT05369546)

The Florida ASCENT Study
NCT ID: NCT07042243 (https://clinicaltrials.gov/study/NCT07042243)

Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
NCT ID: NCT06276491 (https://clinicaltrials.gov/study/NCT06276491)

Pembro With Radiation With or Without Olaparib
NCT ID: NCT05568550 (https://clinicaltrials.gov/study/NCT05568550)

Trial of THEO-260 (Administered Via Intraperitoneal Route) in Ovarian Cancer Patients
NCT ID: NCT07211659 (https://clinicaltrials.gov/study/NCT07211659)

APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
NCT ID: NCT04858334 (https://clinicaltrials.gov/study/NCT04858334)

Determining Individualized Cancer Therapy in Pancreatic Cancer
NCT ID: NCT05914987 (https://clinicaltrials.gov/study/NCT05914987)

Study to Evaluate Biomarkers and Safety of Dapagliflozin Concomitant with Neoadjuvant Therapy
NCT ID: NCT05989347 (https://clinicaltrials.gov/study/NCT05989347)

[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
NCT ID: NCT00588185 (https://clinicaltrials.gov/study/NCT00588185)

Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
NCT ID: NCT02870244 (https://clinicaltrials.gov/study/NCT02870244)

mPATH-Cloud for Colorectal Cancer Screening
NCT ID: NCT06441487 (https://clinicaltrials.gov/study/NCT06441487)

A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer
NCT ID: NCT04569747 (https://clinicaltrials.gov/study/NCT04569747)

PSCA-Targeting CAR-T Cells Plus or Minus Radiation for the Treatment of Patients With PSCA+ Metastatic Castration-Resistant Prostate Cancer
NCT ID: NCT05805371 (https://clinicaltrials.gov/study/NCT05805371)

Prevention of Frailty With Fisetin and Exercise in Breast Cancer Survivors
NCT ID: NCT06113016 (https://clinicaltrials.gov/study/NCT06113016)

A Study of Avutometinib, Defactinib, and Letrozole in People With Low-Grade Serous Ovarian Cancer
NCT ID: NCT06394804 (https://clinicaltrials.gov/study/NCT06394804)

Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases
NCT ID: NCT03965234 (https://clinicaltrials.gov/study/NCT03965234)

Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
NCT ID: NCT07397338 (https://clinicaltrials.gov/study/NCT07397338)

Maintenance Combinatorial Myeloid Immunotherapy for Unresectable Pancreatic Cancer
NCT ID: NCT07199764 (https://clinicaltrials.gov/study/NCT07199764)

Nodal Radiation Therapy for Sentinel Lymph Node Positive Melanoma
NCT ID: NCT04594187 (https://clinicaltrials.gov/study/NCT04594187)

Individualized Dose Escalation of 5-FU for Gastrointestinal Cancer
NCT ID: NCT05780684 (https://clinicaltrials.gov/study/NCT05780684)

Collection of Information to Better Understand Young Onset Colorectal Cancer
NCT ID: NCT04489238 (https://clinicaltrials.gov/study/NCT04489238)

Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer
NCT ID: NCT06930755 (https://clinicaltrials.gov/study/NCT06930755)

Patient Care Outreach, Navigation, Technology and Support 2.0
NCT ID: NCT06648278 (https://clinicaltrials.gov/study/NCT06648278)

Alternate Day Fasting After Surgery for Patients Undergoing Chemotherapy
NCT ID: NCT05990426 (https://clinicaltrials.gov/study/NCT05990426)

Myeloid-Derived Suppressor Cell Function in Breast Cancer Patients
NCT ID: NCT04022616 (https://clinicaltrials.gov/study/NCT04022616)

Intra-tumoral Mitazalimab (CD40 Antibody) With Irreversible Electroporation (IRE) in Locally Advanced Pancreas Cancer
NCT ID: NCT06205849 (https://clinicaltrials.gov/study/NCT06205849)

Temporal Immunologic Changes With Hypofractionated Radiation-Induced DNA Damage in Breast Cancer
NCT ID: NCT05406232 (https://clinicaltrials.gov/study/NCT05406232)

Laboratory Study of Cancer & Immune Cells in Ascites Fluid of Ovarian Cancer Patients to Test Alternative Therapies
NCT ID: NCT03943316 (https://clinicaltrials.gov/study/NCT03943316)

Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors
NCT ID: NCT05053971 (https://clinicaltrials.gov/study/NCT05053971)

A Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer
NCT ID: NCT06315491 (https://clinicaltrials.gov/study/NCT06315491)

Proton Radiation Therapy for the Treatment of Patients With High Risk Prostate Cancer
NCT ID: NCT04725903 (https://clinicaltrials.gov/study/NCT04725903)

Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer
NCT ID: NCT05766371 (https://clinicaltrials.gov/study/NCT05766371)

Optimal Perioperative Pain Control in Minimally Invasive Abdominal Cancer Surgery
NCT ID: NCT06731998 (https://clinicaltrials.gov/study/NCT06731998)

Study of Acute Normovolemic Hemodilution (ANH) in People With Ovarian Cancer Who Are Having Cytoreductive Surgery
NCT ID: NCT06290193 (https://clinicaltrials.gov/study/NCT06290193)

Enzalutamide Implants (Enolen) in Patients With Prostate Cancer
NCT ID: NCT06257693 (https://clinicaltrials.gov/study/NCT06257693)

Study of STM-416p Administered to Patients Undergoing Radical Prostatectomy
NCT ID: NCT06450106 (https://clinicaltrials.gov/study/NCT06450106)

A Study of Stereotactic Body Radiotherapy and 177Lu-PSMA-617 for the Treatment of Prostate Cancer
NCT ID: NCT05079698 (https://clinicaltrials.gov/study/NCT05079698)

Hypofractionated Radiotherapy With a Focal Microboost for High-Risk and Locally Advanced Prostate Cancer
NCT ID: NCT07325721 (https://clinicaltrials.gov/study/NCT07325721)

Exercise in Metastatic Breast Cancer: EMBody
NCT ID: NCT05468034 (https://clinicaltrials.gov/study/NCT05468034)

Integrating Molecular Pathology, Radiology, and Genetics to Improve Breast Cancer Risk
NCT ID: NCT07207564 (https://clinicaltrials.gov/study/NCT07207564)

Trial Evaluating the Safety and Efficacy Of MR-Linac-Guided Radiotherapy as Salvage Treatment After External Beam Radiotherapy Recurrence (TUMORNATOR II)
NCT ID: NCT07142967 (https://clinicaltrials.gov/study/NCT07142967)

A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
NCT ID: NCT06842498 (https://clinicaltrials.gov/study/NCT06842498)

Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer
NCT ID: NCT04115306 (https://clinicaltrials.gov/study/NCT04115306)

Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer
NCT ID: NCT05254171 (https://clinicaltrials.gov/study/NCT05254171)

[68Ga]Ga DOTA-5G as a Diagnostic Imaging Agent for Metastatic/Advanced Invasive Lobular Breast Cancer (LBC)
NCT ID: NCT07020806 (https://clinicaltrials.gov/study/NCT07020806)

A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
NCT ID: NCT04895709 (https://clinicaltrials.gov/study/NCT04895709)

SPECT/CT Imaging for Dosimetry in 177Lu-PSMA-617 (Pluvicto) Therapy
NCT ID: NCT07096999 (https://clinicaltrials.gov/study/NCT07096999)

X-ray Psoralen Activated Cancer Therapy in Head and Neck, Breast, Sarcoma and Melanoma
NCT ID: NCT04389281 (https://clinicaltrials.gov/study/NCT04389281)

Study of STP938 in Advanced Solid Tumours
NCT ID: NCT06297525 (https://clinicaltrials.gov/study/NCT06297525)

Phase Ib Study of AlpeliSib With PEmbroLizumab in Patients With mEtastatic Breast caNcer or melanomA (SELENA)
NCT ID: NCT06545682 (https://clinicaltrials.gov/study/NCT06545682)

AMNIOX CORD Study - Radical Prostatectomy With and Without Cryopreserved Umbilical Cord Allograft
NCT ID: NCT04263025 (https://clinicaltrials.gov/study/NCT04263025)

A First-in-Human Study of SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors
NCT ID: NCT05989724 (https://clinicaltrials.gov/study/NCT05989724)

Observational Study of Iris Tumors
NCT ID: NCT03809585 (https://clinicaltrials.gov/study/NCT03809585)

A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
NCT ID: NCT07227168 (https://clinicaltrials.gov/study/NCT07227168)

Personalized Health Self-Management Training for Colorectal Cancer Survivors
NCT ID: NCT05984589 (https://clinicaltrials.gov/study/NCT05984589)

CIPN Decision Aid for the Improvement of Chemotherapy Decision Making in Patients With Breast Cancer
NCT ID: NCT06915168 (https://clinicaltrials.gov/study/NCT06915168)

Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors
NCT ID: NCT05687123 (https://clinicaltrials.gov/study/NCT05687123)

Neoadjuvant INBRX-106 in Combination With Pembrolizumab for Stage II/III TNBC Patients
NCT ID: NCT06353997 (https://clinicaltrials.gov/study/NCT06353997)

Brain Health in Breast Cancer Survivors
NCT ID: NCT04297020 (https://clinicaltrials.gov/study/NCT04297020)

Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis
NCT ID: NCT06374459 (https://clinicaltrials.gov/study/NCT06374459)

Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer
NCT ID: NCT05319873 (https://clinicaltrials.gov/study/NCT05319873)

Evaluation of a Mixed Meal Test for Diagnosis and Characterization and Type 3c Diabetes Mellitus Secondary to Pancreatic Cancer and Chronic Pancreatitis (DETECT)
NCT ID: NCT03460769 (https://clinicaltrials.gov/study/NCT03460769)

Androgen Deprivation Therapy (Relugolix) for the Improvement of Diagnostic Imaging (PSMA PET/CT Scan) in Patients With High Risk or Very High Risk Prostate Cancer, The EnrichPSMA Trial
NCT ID: NCT07025369 (https://clinicaltrials.gov/study/NCT07025369)

Hormone Therapy (Apalutamide) and Image-guided Stereotactic Body Radiation Therapy for the Treatment of Patients With Prostate Cancer, HEATWAVE Trial
NCT ID: NCT06067269 (https://clinicaltrials.gov/study/NCT06067269)

Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
NCT ID: NCT07349537 (https://clinicaltrials.gov/study/NCT07349537)

F-Tryptophan PET/CT in Human Cancers
NCT ID: NCT05556473 (https://clinicaltrials.gov/study/NCT05556473)

Comprehensive Assessment of Cancer Theranostic Response
NCT ID: NCT06815354 (https://clinicaltrials.gov/study/NCT06815354)

Intraperitoneal FT536 in Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
NCT ID: NCT06342986 (https://clinicaltrials.gov/study/NCT06342986)

Promoting CT Engagement for Pancreatic Cancer With App
NCT ID: NCT06252545 (https://clinicaltrials.gov/study/NCT06252545)

Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory Melanoma
NCT ID: NCT05130177 (https://clinicaltrials.gov/study/NCT05130177)

Cognitive Rehabilitation Following Breast Cancer Treatment
NCT ID: NCT06545045 (https://clinicaltrials.gov/study/NCT06545045)

Tumor Genomic Pre-test Counseling Tool for Black or African-American Men With Prostate Cancer
NCT ID: NCT06171139 (https://clinicaltrials.gov/study/NCT06171139)

Breast Cancer, Reasoning, and Activity Intervention
NCT ID: NCT04816006 (https://clinicaltrials.gov/study/NCT04816006)

A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal Cancer
NCT ID: NCT06992258 (https://clinicaltrials.gov/study/NCT06992258)

Infusion of Autologous T Cells Engineered to Target FSH Receptor in Recurrent Ovarian Cancer
NCT ID: NCT05316129 (https://clinicaltrials.gov/study/NCT05316129)

Endometrial Cell Collection With the PadKit
NCT ID: NCT06464107 (https://clinicaltrials.gov/study/NCT06464107)

Preop Laxatives in Robotic Urologic Surgery
NCT ID: NCT05805436 (https://clinicaltrials.gov/study/NCT05805436)

Biomarkers and Clinical Features of Metastatic Breast Cancer in Patients Treated With CDK4/6 Inhibitors
NCT ID: NCT04526587 (https://clinicaltrials.gov/study/NCT04526587)

Rapid Autopsy and Procurement of Cancer Tissue
NCT ID: NCT01851395 (https://clinicaltrials.gov/study/NCT01851395)

Low Dose Aspirin for the Prevention of Postpartum Related Breast Cancer
NCT ID: NCT05557877 (https://clinicaltrials.gov/study/NCT05557877)

Neoadjuvant Ipilimumab/Nivolumab for Patients With Recurrent, High Risk, Resectable Melanoma
NCT ID: NCT06365619 (https://clinicaltrials.gov/study/NCT06365619)

A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs
NCT ID: NCT06908928 (https://clinicaltrials.gov/study/NCT06908928)

Chemo4METPANC Combination Chemokine Inhibitor, Immunotherapy, and Chemotherapy in Pancreatic Adenocarcinoma
NCT ID: NCT04543071 (https://clinicaltrials.gov/study/NCT04543071)

Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
NCT ID: NCT05640999 (https://clinicaltrials.gov/study/NCT05640999)

IIT2023-09-Chung-UpfrontTAD: Upfront TAD/SNB in Patients With Breast Cancer With Nodal Metastases
NCT ID: NCT06092892 (https://clinicaltrials.gov/study/NCT06092892)

Ultrasound Microvessel Imaging for the Evaluation of Ovarian and Adnexal Lesions
NCT ID: NCT07280312 (https://clinicaltrials.gov/study/NCT07280312)

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
NCT ID: NCT05059444 (https://clinicaltrials.gov/study/NCT05059444)

Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer
NCT ID: NCT05896839 (https://clinicaltrials.gov/study/NCT05896839)

Comparison of Proton or Intensity Modulated Radiation Therapy After Surgery for Endometrial or Cervical Cancer
NCT ID: NCT04567771 (https://clinicaltrials.gov/study/NCT04567771)

ATEMPT 2.0: Adjuvant T-DM1 vs TH
NCT ID: NCT04893109 (https://clinicaltrials.gov/study/NCT04893109)

Neoadjuvant Therapy and Contrast-enhanced Mammography for Early Stage Breast Cancer
NCT ID: NCT06220214 (https://clinicaltrials.gov/study/NCT06220214)

Genetic & Pathological Studies of BRCA1/BRCA2: Associated Tumors & Blood Samples
NCT ID: NCT01034033 (https://clinicaltrials.gov/study/NCT01034033)

Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer
NCT ID: NCT05673200 (https://clinicaltrials.gov/study/NCT05673200)

A Study of MGC028 in Participants With Advanced Solid Tumors
NCT ID: NCT06723236 (https://clinicaltrials.gov/study/NCT06723236)

PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.
NCT ID: NCT06274047 (https://clinicaltrials.gov/study/NCT06274047)

Study to Detect Changes in Urinary and Gut Microbiome During Androgen Deprivation Therapy and Radiation Therapy in Patients With Prostate Cancer
NCT ID: NCT04775355 (https://clinicaltrials.gov/study/NCT04775355)

FES Imaging to Optimize Tamoxifen for Metastatic Breast Cancer
NCT ID: NCT04174352 (https://clinicaltrials.gov/study/NCT04174352)

Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
NCT ID: NCT07085767 (https://clinicaltrials.gov/study/NCT07085767)

Together After Cancer
NCT ID: NCT05645471 (https://clinicaltrials.gov/study/NCT05645471)

A Prospective Study of Plasma Genotyping as a Noninvasive Biomarker for Genotype-directed Cancer Care
NCT ID: NCT02279004 (https://clinicaltrials.gov/study/NCT02279004)

Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline Therapy
NCT ID: NCT06083844 (https://clinicaltrials.gov/study/NCT06083844)

A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations
NCT ID: NCT06412198 (https://clinicaltrials.gov/study/NCT06412198)

Preoperative Lenvatinib Plus Pembrolizumab in Early-Stage Triple-Negative Breast Cancer (TNBC)
NCT ID: NCT04427293 (https://clinicaltrials.gov/study/NCT04427293)

IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)
NCT ID: NCT06112314 (https://clinicaltrials.gov/study/NCT06112314)

Vitamin D for Prostate Endocrine Therapy
NCT ID: NCT05838716 (https://clinicaltrials.gov/study/NCT05838716)

Artificial Intelligence in Endoscopic Ultrasound
NCT ID: NCT06564571 (https://clinicaltrials.gov/study/NCT06564571)

A Study of Lorigerlimab in Participants With Advanced Solid Tumors
NCT ID: NCT06730347 (https://clinicaltrials.gov/study/NCT06730347)

Molecular Testing for the MD Anderson Cancer Center Personalized Cancer Therapy Program
NCT ID: NCT01772771 (https://clinicaltrials.gov/study/NCT01772771)

Internet-Based Lifestyle Intervention to Eradicate Obese Frailty in Prostate Cancer Survivors, iLIVE
NCT ID: NCT06011499 (https://clinicaltrials.gov/study/NCT06011499)

MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer
NCT ID: NCT06483048 (https://clinicaltrials.gov/study/NCT06483048)

Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
NCT ID: NCT07198074 (https://clinicaltrials.gov/study/NCT07198074)

Locally Ablative TherapY in Oligo-ProgressiVe GEnitourinary TumoRs (LAYOVER)
NCT ID: NCT06101290 (https://clinicaltrials.gov/study/NCT06101290)

A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
NCT ID: NCT04929223 (https://clinicaltrials.gov/study/NCT04929223)

Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals
NCT ID: NCT06122896 (https://clinicaltrials.gov/study/NCT06122896)

Pancreatic Adenocarcinoma Gene Environment Risk Study
NCT ID: NCT00912717 (https://clinicaltrials.gov/study/NCT00912717)

A Study to Evaluate the Safety and Tolerability of TOS-358 in Adults With HR+ Breast Cancer and Other Select Solid Tumors
NCT ID: NCT05683418 (https://clinicaltrials.gov/study/NCT05683418)

Washington University Participant Engagement and Cancer Genomic Sequencing Center (WU-PE-CGS)
NCT ID: NCT06340646 (https://clinicaltrials.gov/study/NCT06340646)

Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE)
NCT ID: NCT05592938 (https://clinicaltrials.gov/study/NCT05592938)

Bio-Repository of High Risk Cohorts for the Early Detection of Pancreas Cancer
NCT ID: NCT03260842 (https://clinicaltrials.gov/study/NCT03260842)

A Study of a Comprehensive Prevention Program to Reduce Lymphedema After Axillary Lymph Node Dissection in People With Breast Cancer
NCT ID: NCT06144164 (https://clinicaltrials.gov/study/NCT06144164)

Evaluation of RBS2418 in Patients With Advanced, Metastatic, and Progressive Colorectal Cancer
NCT ID: NCT06824064 (https://clinicaltrials.gov/study/NCT06824064)

Pancreatic Cancer Registry: For Any Person With a Personal or Family History
NCT ID: NCT02886247 (https://clinicaltrials.gov/study/NCT02886247)

A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
NCT ID: NCT07223047 (https://clinicaltrials.gov/study/NCT07223047)

Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases
NCT ID: NCT05704647 (https://clinicaltrials.gov/study/NCT05704647)

The C-MERIT Screening Cohort: Contrast-enhanced Mammography for Breast Cancer Screening and Risk Assessment in Women With Dense Breasts
NCT ID: NCT05667532 (https://clinicaltrials.gov/study/NCT05667532)

Radiation Therapy With RapidPlan Knowledge-based Planning vs Human-Driven Planning for Treatment of Prostate Cancer
NCT ID: NCT06625034 (https://clinicaltrials.gov/study/NCT06625034)

Platform Study of Immunotherapy Combinations in Colorectal Cancer Liver Metastases
NCT ID: NCT06300463 (https://clinicaltrials.gov/study/NCT06300463)

Improving Survival for Metastatic Lobular Breast Cancer (PLUMB Registry)
NCT ID: NCT05964504 (https://clinicaltrials.gov/study/NCT05964504)

MADRE (Mammograms Available Due to Research and Education)
NCT ID: NCT05841355 (https://clinicaltrials.gov/study/NCT05841355)

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
NCT ID: NCT07174336 (https://clinicaltrials.gov/study/NCT07174336)

Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabolic Health in Prostate Cancer Patients During Androgen Deprivation Therapy, IMPACT-ADT Trial
NCT ID: NCT07202247 (https://clinicaltrials.gov/study/NCT07202247)

RecoverPC: Relugolix vs GnRH Agonist in Quality of Life
NCT ID: NCT05765500 (https://clinicaltrials.gov/study/NCT05765500)

A Phase I/II Study of PDS01ADC With Docetaxel and Abiraterone in Adults With Metastatic Castration Sensitive and PDS01ADC With Docetaxel in Castration Resistant Prostate Cancer
NCT ID: NCT04633252 (https://clinicaltrials.gov/study/NCT04633252)

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
NCT ID: NCT06966700 (https://clinicaltrials.gov/study/NCT06966700)

Single-Port Transvesical Partial Prostatectomy Versus High Intensity Focused Ultrasound
NCT ID: NCT05610852 (https://clinicaltrials.gov/study/NCT05610852)

Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer
NCT ID: NCT05983276 (https://clinicaltrials.gov/study/NCT05983276)

Hyperpolarized 13C MRI to Predict Response in Pancreatic Cancer
NCT ID: NCT06600906 (https://clinicaltrials.gov/study/NCT06600906)

African Cancer Genome: GMD
NCT ID: NCT05754658 (https://clinicaltrials.gov/study/NCT05754658)

A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
NCT ID: NCT07318558 (https://clinicaltrials.gov/study/NCT07318558)

Pathways, Risk Factors, and mOleculeS to Prevent Early-onset Colorectal Tumors
NCT ID: NCT07095517 (https://clinicaltrials.gov/study/NCT07095517)

The Impact of PReOPerative Exercise and NutritionaL Optimization on Perioperative Outcomes for Patients Undergoing Treatment for Rectal Cancer: The PROPEL Trial
NCT ID: NCT06565052 (https://clinicaltrials.gov/study/NCT06565052)

Determine the Utility of Liquid Biopsies and Tumor Molecular Profiling in Predicting Recurrence in Endometrial Cancers
NCT ID: NCT05049538 (https://clinicaltrials.gov/study/NCT05049538)

COAST Therapy in Advanced Solid Tumors and Prostate Cancer
NCT ID: NCT05036226 (https://clinicaltrials.gov/study/NCT05036226)

Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
NCT ID: NCT07444814 (https://clinicaltrials.gov/study/NCT07444814)

A Study Comparing BMS-986504 in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)
NCT ID: NCT07076121 (https://clinicaltrials.gov/study/NCT07076121)

Mutant KRAS -Targeted Long Peptide Vaccine for Patients at High Risk of Developing Pancreatic Cancer
NCT ID: NCT05013216 (https://clinicaltrials.gov/study/NCT05013216)

CV CARE: CardioVascular Care in PC Patients
NCT ID: NCT06202820 (https://clinicaltrials.gov/study/NCT06202820)

A Study of LY4175408 in Participants With Advanced Cancer
NCT ID: NCT07046923 (https://clinicaltrials.gov/study/NCT07046923)

Ultra-Hypofractionated vs. Hypofractionated Radiation for Node-Positive Breast Cancer
NCT ID: NCT06559540 (https://clinicaltrials.gov/study/NCT06559540)

TAS-102 With or Without Celecoxib in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy
NCT ID: NCT05343013 (https://clinicaltrials.gov/study/NCT05343013)

A Study of Changes in Ki67 Expression in People With Breast Cancer Receiving Endocrine Therapy Before Surgery
NCT ID: NCT06127979 (https://clinicaltrials.gov/study/NCT06127979)

Photon Craniospinal Irradiation for the Treatment of Leptomeningeal Disease Secondary to Breast Cancer or Non-small Cell Lung Cancer
NCT ID: NCT06910761 (https://clinicaltrials.gov/study/NCT06910761)

Telemedicine Use in Preoperative Counseling for Endometrial Cancer Survivors
NCT ID: NCT05712668 (https://clinicaltrials.gov/study/NCT05712668)

7-Days Water-Only Fasting Trial in Prostate Cancer
NCT ID: NCT06826924 (https://clinicaltrials.gov/study/NCT06826924)

Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)
NCT ID: NCT05660083 (https://clinicaltrials.gov/study/NCT05660083)

Biospecimen Collection to Identify Gene Mutations for High Risk Pancreatic Cancer in Pediatric Patients, INSPPIRE 2 Study
NCT ID: NCT06651580 (https://clinicaltrials.gov/study/NCT06651580)

Implementation and Effectiveness of the BJC-Pink and Pearl Project on Lung Cancer Screening
NCT ID: NCT06898333 (https://clinicaltrials.gov/study/NCT06898333)

A Study of Changes to Prostate Procedures
NCT ID: NCT06986083 (https://clinicaltrials.gov/study/NCT06986083)

Comparison of Breast Cancer Screening With CESM to DBT in Women With Dense Breasts
NCT ID: NCT05625659 (https://clinicaltrials.gov/study/NCT05625659)

Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen
NCT ID: NCT07087054 (https://clinicaltrials.gov/study/NCT07087054)

MRI Risk Maps for Prostate Cancer Diagnosis Using Targeted Biopsy
NCT ID: NCT05710380 (https://clinicaltrials.gov/study/NCT05710380)

SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma
NCT ID: NCT05568680 (https://clinicaltrials.gov/study/NCT05568680)

Saci Nivo Rela for TNBC
NCT ID: NCT06963905 (https://clinicaltrials.gov/study/NCT06963905)

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
NCT ID: NCT05334069 (https://clinicaltrials.gov/study/NCT05334069)

UCF MammoChat: Image Repository
NCT ID: NCT07214883 (https://clinicaltrials.gov/study/NCT07214883)

BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
NCT ID: NCT05136196 (https://clinicaltrials.gov/study/NCT05136196)

Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy
NCT ID: NCT03821246 (https://clinicaltrials.gov/study/NCT03821246)

BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
NCT ID: NCT06120283 (https://clinicaltrials.gov/study/NCT06120283)

[18F] F-GLN by PET/CT in Breast Cancer
NCT ID: NCT03863457 (https://clinicaltrials.gov/study/NCT03863457)

Manual Lymphatic Drainage Breast Massage in Breast Cancer Patients After Breast Conserving Surgery
NCT ID: NCT06297265 (https://clinicaltrials.gov/study/NCT06297265)

A Study of Antibiotic Delivery to Prevent Infection After Breast Tissue Expander Placement
NCT ID: NCT07220967 (https://clinicaltrials.gov/study/NCT07220967)

Polygenic Risk Stratification Combined With mpMRI to Identify Clinically Relevant Prostate Cancer
NCT ID: NCT06398639 (https://clinicaltrials.gov/study/NCT06398639)

A Study of Isoquercetin in People With Ovarian Cancer
NCT ID: NCT07303894 (https://clinicaltrials.gov/study/NCT07303894)

Pancreatic Cancer Detection Consortium
NCT ID: NCT06388967 (https://clinicaltrials.gov/study/NCT06388967)

Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01)
NCT ID: NCT05464030 (https://clinicaltrials.gov/study/NCT05464030)

Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials
NCT ID: NCT05108298 (https://clinicaltrials.gov/study/NCT05108298)

Assoc. of Genomic Polymorphisms With Cancer Cachexia in Subjects With Panc Adenocarcinoma
NCT ID: NCT05376592 (https://clinicaltrials.gov/study/NCT05376592)

A Randomized Two-Arm Proof of Concept Study Testing A Novel Approach to Exercise Promotion Based on Affect-regulation
NCT ID: NCT06258993 (https://clinicaltrials.gov/study/NCT06258993)

Preparing FIM-BCS - A Lifestyle Modification for African-American Breast Cancer Survivors
NCT ID: NCT06504914 (https://clinicaltrials.gov/study/NCT06504914)

LEgal Guidance and AdvocaCY for CAREgivers (LEGACY CARE): A Pilot Clinical Trial for Caregivers of Persons With Colorectal Cancer
NCT ID: NCT07153016 (https://clinicaltrials.gov/study/NCT07153016)

A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
NCT ID: NCT06326411 (https://clinicaltrials.gov/study/NCT06326411)

A Patient Navigation Program for Addressing Disparities in Breast Cancer Care
NCT ID: NCT06350500 (https://clinicaltrials.gov/study/NCT06350500)

BettER: Biomarker Driven Early Therapeutic Selection in Patients With HR+ HER2- Metastatic or Unresectable Breast Cancer
NCT ID: NCT05977036 (https://clinicaltrials.gov/study/NCT05977036)

Delayed Sentinel Lymph Node Biopsy in Ductal Cancer in Situ
NCT ID: NCT04722692 (https://clinicaltrials.gov/study/NCT04722692)

A Beta-only IL-2 ImmunoTherapY Study
NCT ID: NCT05086692 (https://clinicaltrials.gov/study/NCT05086692)

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
NCT ID: NCT05489211 (https://clinicaltrials.gov/study/NCT05489211)

A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
NCT ID: NCT05538130 (https://clinicaltrials.gov/study/NCT05538130)

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
NCT ID: NCT04851119 (https://clinicaltrials.gov/study/NCT04851119)

MUSE-S Headband System for Improving Anxiety and Insomnia Among Breast Cancer Survivors
NCT ID: NCT06274034 (https://clinicaltrials.gov/study/NCT06274034)

Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial
NCT ID: NCT04575935 (https://clinicaltrials.gov/study/NCT04575935)

A Pilot Trial of "Just ASK™" to Increase Discussions About Breast Cancer Clinical Trials
NCT ID: NCT07040891 (https://clinicaltrials.gov/study/NCT07040891)

A Trial of Pembrolizumab and Metformin Versus Pembrolizumab Alone in Advanced Melanoma
NCT ID: NCT03311308 (https://clinicaltrials.gov/study/NCT03311308)

Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers
NCT ID: NCT05919108 (https://clinicaltrials.gov/study/NCT05919108)

Safety and Immunogenicity of Innocell Autologous Cellular Immunotherapy for Recurrent Epithelial Ovarian Cancer
NCT ID: NCT06366490 (https://clinicaltrials.gov/study/NCT06366490)

The Multicentre Selective Lymphadenectomy Trial - 3
NCT ID: NCT07049276 (https://clinicaltrials.gov/study/NCT07049276)

A Study of 68Gallium PSMA-PET/CT Scans in People With Bladder Cancer or Skin Cancer
NCT ID: NCT05562791 (https://clinicaltrials.gov/study/NCT05562791)

Living Donor Liver Transplant for Unresectable Colorectal Liver Metastases
NCT ID: NCT05248581 (https://clinicaltrials.gov/study/NCT05248581)

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
NCT ID: NCT03424005 (https://clinicaltrials.gov/study/NCT03424005)

FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)
NCT ID: NCT06402331 (https://clinicaltrials.gov/study/NCT06402331)

Preoperative Irradiation for Stage I Breast Cancer
NCT ID: NCT05464667 (https://clinicaltrials.gov/study/NCT05464667)

Uterine Preservation Via Lifestyle Transformation
NCT ID: NCT05903131 (https://clinicaltrials.gov/study/NCT05903131)

Intratumoral and Systemic Hiltonol® (Poly-ICLC) in Prostate Cancer Patients on Active Surveillance
NCT ID: NCT06343077 (https://clinicaltrials.gov/study/NCT06343077)

Evaluation of Tumor Control Based on Serial Multiparametric MRI and Post-Treatment Biopsies For Patients Treated With Dose Intensification to the Dominant Intra-Prostatic Lesion (DIL) Using Ultra-Hypofractionated, MR-Guided Radiotherapy
NCT ID: NCT06542757 (https://clinicaltrials.gov/study/NCT06542757)

Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
NCT ID: NCT06136624 (https://clinicaltrials.gov/study/NCT06136624)

Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
NCT ID: NCT07214779 (https://clinicaltrials.gov/study/NCT07214779)

A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
NCT ID: NCT05970497 (https://clinicaltrials.gov/study/NCT05970497)

Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer
NCT ID: NCT06318897 (https://clinicaltrials.gov/study/NCT06318897)

IORT Following Breast Conserving Surgery for Early Stage Breast Cancer Registry
NCT ID: NCT03536897 (https://clinicaltrials.gov/study/NCT03536897)

Scalp Cooling in MBC
NCT ID: NCT04986579 (https://clinicaltrials.gov/study/NCT04986579)

Tislelizumab in People With Colorectal Cancer
NCT ID: NCT06529523 (https://clinicaltrials.gov/study/NCT06529523)

Prehabilitation for EOC, Fallopian Tube, Primary Peritoneal Carcinoma and Pancreatic Cancer w/ NACT
NCT ID: NCT06412510 (https://clinicaltrials.gov/study/NCT06412510)

FITting Non-invasive Tests in Lynch Syndrome Surveillance
NCT ID: NCT06898996 (https://clinicaltrials.gov/study/NCT06898996)

Impact of COVID-19 Pandemic on Out-of-Pocket Costs, Lost Wages, and Unemployment in Patients With Breast Cancer Undergoing Breast Surgery
NCT ID: NCT04169542 (https://clinicaltrials.gov/study/NCT04169542)

Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Peripheral Neuropathy Receiving Paclitaxel for Breast Cancer
NCT ID: NCT02610439 (https://clinicaltrials.gov/study/NCT02610439)

Well-Being and Health-Related Quality of Life in Melanoma Patients During COVID-19 Pandemic
NCT ID: NCT04474301 (https://clinicaltrials.gov/study/NCT04474301)

Flat Dose vs. Weight-based IP Chemotherapy for CRS/HIPEC
NCT ID: NCT04779554 (https://clinicaltrials.gov/study/NCT04779554)

Collecting Tissue Samples for Future Research From Women Undergoing Surgery for Breast Cancer
NCT ID: NCT00898131 (https://clinicaltrials.gov/study/NCT00898131)

Effect of Meal Timing During Cancer Treatment in Patients in Alaska: A Randomized Clinical Trial
NCT ID: NCT06802172 (https://clinicaltrials.gov/study/NCT06802172)

Follow-Up Study of Subjects Previously Enrolled in Poxviral Vector Gene Transfer Studies
NCT ID: NCT00451022 (https://clinicaltrials.gov/study/NCT00451022)

A Study of Intra-operative Imaging in Women With Ovarian Cancer
NCT ID: NCT04878094 (https://clinicaltrials.gov/study/NCT04878094)

Amplitude-Modulated Radiofrequency Electromagnetic Fields (AM RF EMF) in Combination With Fruquintinib in Refractory Metastatic Colorectal Cancer
NCT ID: NCT07130903 (https://clinicaltrials.gov/study/NCT07130903)

Evaluation of Endoscopic Ultrasound-Guided Radiofrequency Ablation for the Management of Pancreatic Tumors, ERASE Study
NCT ID: NCT05961982 (https://clinicaltrials.gov/study/NCT05961982)

Negative Pressure Wound Therapy in Healing Abdominal Incision in Obese Patients Undergoing Breast Reconstruction Surgery
NCT ID: NCT04003038 (https://clinicaltrials.gov/study/NCT04003038)

Vascular Optimized Radiotherapy Tuned to Critical Structures for Erectile Function Using High-Precision X-Ray Treatment
NCT ID: NCT07293585 (https://clinicaltrials.gov/study/NCT07293585)

Molecular Residual Disease Assessment in a Representative Diverse Population of Patients With Early-stage Breast Cancer
NCT ID: NCT07025785 (https://clinicaltrials.gov/study/NCT07025785)

Comprehensive Monitoring of Men With Prostate Cancer Cared for by "Active Surveillance
NCT ID: NCT05840484 (https://clinicaltrials.gov/study/NCT05840484)

Randomized Phase II Trial of Targeted Radiation With no Castration for Mcrpc
NCT ID: NCT06084338 (https://clinicaltrials.gov/study/NCT06084338)

Immune Response Activation for the Treatment of Unresectable Metastatic Colorectal Cancer or CEA Positive Metastatic Breast Cancer
NCT ID: NCT06130826 (https://clinicaltrials.gov/study/NCT06130826)

Survivorship Care for Women Living With Ovarian Cancer: (POSTCARE-O)
NCT ID: NCT05752448 (https://clinicaltrials.gov/study/NCT05752448)

A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
NCT ID: NCT07100106 (https://clinicaltrials.gov/study/NCT07100106)

A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer
NCT ID: NCT07213804 (https://clinicaltrials.gov/study/NCT07213804)

Comparison of CE-DBT and MRI in Patients With Known Breast Lesions
NCT ID: NCT05754749 (https://clinicaltrials.gov/study/NCT05754749)

Liquid Biomarker Study in Melanoma and Non-Melanoma Skin Cancers
NCT ID: NCT06608511 (https://clinicaltrials.gov/study/NCT06608511)

Patient Navigation Program to Improve Clinical Trial Enrollment in Cancer Patients
NCT ID: NCT06138067 (https://clinicaltrials.gov/study/NCT06138067)

Treatment Monitoring of Patients Receiving CDK 4/6 Inhibitors for Hormone Receptor (HR) Positive, HER2 Negative Metastatic Breast Cancer (MBC) With or Without the Addition of DiviTum® Serum Thymidine Kinase 1 (TK1) Activity Testing
NCT ID: NCT04968964 (https://clinicaltrials.gov/study/NCT04968964)

A Phase 2 Study of Leronlimab in Combination With TAS-102 + Bevacizumab in Previously Treated Participants With mCRC
NCT ID: NCT06699836 (https://clinicaltrials.gov/study/NCT06699836)

Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies
NCT ID: NCT07064018 (https://clinicaltrials.gov/study/NCT07064018)

EMBRACE: Exercising Together
NCT ID: NCT06049355 (https://clinicaltrials.gov/study/NCT06049355)

A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).
NCT ID: NCT06551324 (https://clinicaltrials.gov/study/NCT06551324)

Rutgers University Study of the Genetics of Breast Cancer.
NCT ID: NCT06773897 (https://clinicaltrials.gov/study/NCT06773897)

VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]
NCT ID: NCT06264180 (https://clinicaltrials.gov/study/NCT06264180)

Physical Activity Intervention Among Older Women With Gynecologic Cancers (Fit4Treatment)
NCT ID: NCT05743517 (https://clinicaltrials.gov/study/NCT05743517)

Is Intraperitoneal Drainage Necessary Following Distal Pancreatectomy?
NCT ID: NCT05720338 (https://clinicaltrials.gov/study/NCT05720338)

Pilot Study of (MR) Imaging with Pyruvate (13C) to Detect High Grade Prostate Cancer
NCT ID: NCT02526368 (https://clinicaltrials.gov/study/NCT02526368)

Utilization of Educational Interventions in Completion of Genetic Testing in Black Patients With High-Risk Prostate Cancer
NCT ID: NCT05958082 (https://clinicaltrials.gov/study/NCT05958082)

A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
NCT ID: NCT07109726 (https://clinicaltrials.gov/study/NCT07109726)

A Study of Pembrolizumab and Cryoablation in People With Breast Cancer
NCT ID: NCT06246968 (https://clinicaltrials.gov/study/NCT06246968)

Time Restricted Eating During Chemotherapy for Breast Cancer
NCT ID: NCT05259410 (https://clinicaltrials.gov/study/NCT05259410)

Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer.
NCT ID: NCT04753879 (https://clinicaltrials.gov/study/NCT04753879)

Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
NCT ID: NCT04787042 (https://clinicaltrials.gov/study/NCT04787042)

Intermittent Fasting Using a Fasting-Mimicking Diet to Improve Prostate Cancer Control and Metabolic Outcomes
NCT ID: NCT05832086 (https://clinicaltrials.gov/study/NCT05832086)

Stereotactic Ablative Radiotherapy (SABR) for the Treatment of Patients With Metastatic Cancer, ID-COMET Trial
NCT ID: NCT06563388 (https://clinicaltrials.gov/study/NCT06563388)

MRI And GPS Informing Choices for Prostate Cancer Treatment (MAGIC)
NCT ID: NCT05424783 (https://clinicaltrials.gov/study/NCT05424783)

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
NCT ID: NCT06047379 (https://clinicaltrials.gov/study/NCT06047379)

Engage Psychosocial Intervention for Cancer Symptoms
NCT ID: NCT06555588 (https://clinicaltrials.gov/study/NCT06555588)

Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma
NCT ID: NCT06121180 (https://clinicaltrials.gov/study/NCT06121180)

Study to Assess the Ability of the Portable Scalp Cooling System (PSCS) to Prevent Hair Loss
NCT ID: NCT05484973 (https://clinicaltrials.gov/study/NCT05484973)

Protective Effects of the Nutritional Supplement Sulforaphane on Doxorubicin-Associated Cardiac Dysfunction
NCT ID: NCT03934905 (https://clinicaltrials.gov/study/NCT03934905)

An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
NCT ID: NCT06991556 (https://clinicaltrials.gov/study/NCT06991556)

Targeted Pathway Inhibition in Patients With Pancreatic Cancer
NCT ID: NCT04005690 (https://clinicaltrials.gov/study/NCT04005690)

A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
NCT ID: NCT07020117 (https://clinicaltrials.gov/study/NCT07020117)

A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer
NCT ID: NCT05365581 (https://clinicaltrials.gov/study/NCT05365581)

64Cu-GRIP B in Patients With Advanced Malignancies
NCT ID: NCT05888532 (https://clinicaltrials.gov/study/NCT05888532)

Mechanisms of Resistance to PSMA Radioligand Therapy
NCT ID: NCT05435495 (https://clinicaltrials.gov/study/NCT05435495)

A Validation Study to Determine Concordance of Liquid Biopsy and Breast Cancer Diagnosis
NCT ID: NCT06336928 (https://clinicaltrials.gov/study/NCT06336928)

A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
NCT ID: NCT06157892 (https://clinicaltrials.gov/study/NCT06157892)

CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer
NCT ID: NCT05685602 (https://clinicaltrials.gov/study/NCT05685602)

A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
NCT ID: NCT06395519 (https://clinicaltrials.gov/study/NCT06395519)

Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
NCT ID: NCT04981119 (https://clinicaltrials.gov/study/NCT04981119)

A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
NCT ID: NCT04503265 (https://clinicaltrials.gov/study/NCT04503265)

A First-in-Human Study of FID-022 in Solid Tumor Patients
NCT ID: NCT07249775 (https://clinicaltrials.gov/study/NCT07249775)

Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast Cancer
NCT ID: NCT06518837 (https://clinicaltrials.gov/study/NCT06518837)

Study of Safety/Feasibility of a Hybrid Model of Tertiary and Community Delivery of Hepatic Artery Infusion Chemotherapy
NCT ID: NCT07201519 (https://clinicaltrials.gov/study/NCT07201519)

Diagnostic Utility of rhPSMA-7.3 (18F) PET/CT in Men With Prostate Cancer on Active Surveillance
NCT ID: NCT07285057 (https://clinicaltrials.gov/study/NCT07285057)

Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma
NCT ID: NCT06070012 (https://clinicaltrials.gov/study/NCT06070012)

Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination with Pembrolizumab, in Unresectable Melanoma Patients
NCT ID: NCT06284590 (https://clinicaltrials.gov/study/NCT06284590)

PREDICT-RD: ctDNA Surveillance in TNBC With Residual Disease
NCT ID: NCT07069595 (https://clinicaltrials.gov/study/NCT07069595)

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
NCT ID: NCT04585750 (https://clinicaltrials.gov/study/NCT04585750)

Study of PF-07248144 in Advanced or Metastatic Solid Tumors
NCT ID: NCT04606446 (https://clinicaltrials.gov/study/NCT04606446)

Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study
NCT ID: NCT05287451 (https://clinicaltrials.gov/study/NCT05287451)

COffee and Metabolites Modulating the Gut MicrobiomE in Colorectal caNCER
NCT ID: NCT05692024 (https://clinicaltrials.gov/study/NCT05692024)

Neoadjuvant High Dose Rate Brachytherapy Prior to Radical Prostatectomy in Patients With Prostate Cancer
NCT ID: NCT07182279 (https://clinicaltrials.gov/study/NCT07182279)

Self Reported Pain in Women While Undergoing Treatment for Non-metastatic Breast Cancer
NCT ID: NCT04174742 (https://clinicaltrials.gov/study/NCT04174742)

Identifying and Caring for Individuals With Inherited Cancer Syndrome
NCT ID: NCT04494945 (https://clinicaltrials.gov/study/NCT04494945)

PROton Therapy for Post Surgical Treatment of GYNecologic Cancer
NCT ID: NCT05758688 (https://clinicaltrials.gov/study/NCT05758688)

Minimal Residual Disease Assessment in Patients With Colorectal Cancer, the MiRDA-C Study
NCT ID: NCT04739072 (https://clinicaltrials.gov/study/NCT04739072)

A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
NCT ID: NCT05824975 (https://clinicaltrials.gov/study/NCT05824975)

Improving Communication and Adherence in Black Breast Cancer Survivors (Sisters Informing Sisters)
NCT ID: NCT05334732 (https://clinicaltrials.gov/study/NCT05334732)

Liposomal Bupivacaine Vs Bupivacaine with Dexmedetomidine in Erector Spinae Plane Blocks for Mastectomies
NCT ID: NCT06252662 (https://clinicaltrials.gov/study/NCT06252662)

The Sarah Nanotechnology System for Treatment of Advanced Metastatic Solid Tumors Using Hyperthermia.
NCT ID: NCT07224464 (https://clinicaltrials.gov/study/NCT07224464)

The Utility and Feasibility of Mt-sDNA as a Surveillance Procedure in Colorectal Cancer Survivors
NCT ID: NCT04624555 (https://clinicaltrials.gov/study/NCT04624555)

Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, The ERASur Study
NCT ID: NCT05673148 (https://clinicaltrials.gov/study/NCT05673148)

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
NCT ID: NCT06982521 (https://clinicaltrials.gov/study/NCT06982521)

Breast Re-irradiation After Second Ipsilateral Lumpectomy
NCT ID: NCT06867484 (https://clinicaltrials.gov/study/NCT06867484)

The Effect of IBD Flares on Serum PSA
NCT ID: NCT03558048 (https://clinicaltrials.gov/study/NCT03558048)

Evaluation of the Natera Colorectal Cancer Screening Test in an Average Risk Population (FIND-CRC)
NCT ID: NCT07046585 (https://clinicaltrials.gov/study/NCT07046585)

Collection of Samples USOPTIVAL Study
NCT ID: NCT04792684 (https://clinicaltrials.gov/study/NCT04792684)

Ph II Study of Enfortumab Vedotin in Patients With Advanced or Metastatic CRC or HCC
NCT ID: NCT06553885 (https://clinicaltrials.gov/study/NCT06553885)

Blood Markers of Early Pancreas Cancer
NCT ID: NCT03568630 (https://clinicaltrials.gov/study/NCT03568630)

Sentinel Node Biopsy in Endometrial Cancer
NCT ID: NCT04073706 (https://clinicaltrials.gov/study/NCT04073706)

ALPINE: Maintenance Letrozole/Abemaciclib
NCT ID: NCT06366347 (https://clinicaltrials.gov/study/NCT06366347)

ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
NCT ID: NCT06876714 (https://clinicaltrials.gov/study/NCT06876714)

A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
NCT ID: NCT06824467 (https://clinicaltrials.gov/study/NCT06824467)

COMPASS Study for Metastatic Castration-resistant Prostate Cancer
NCT ID: NCT07050433 (https://clinicaltrials.gov/study/NCT07050433)

WALNUTS for POWER: Polyphenols, Omega-3 Fatty Acids, Weight Loss, and EneRgy
NCT ID: NCT03824652 (https://clinicaltrials.gov/study/NCT03824652)

A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)
NCT ID: NCT06843447 (https://clinicaltrials.gov/study/NCT06843447)

Study of ORIC-944 in Patients With Metastatic Prostate Cancer
NCT ID: NCT05413421 (https://clinicaltrials.gov/study/NCT05413421)

Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
NCT ID: NCT06218914 (https://clinicaltrials.gov/study/NCT06218914)

IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
NCT ID: NCT05039801 (https://clinicaltrials.gov/study/NCT05039801)

Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer
NCT ID: NCT04329065 (https://clinicaltrials.gov/study/NCT04329065)

Prostate Active Surveillance Study
NCT ID: NCT00756665 (https://clinicaltrials.gov/study/NCT00756665)

LuCarbo - a Study of 177Lu-PSMA-617 Plus Carboplatin in Metastatic Castrate-resistant Prostate Cancer
NCT ID: NCT06303713 (https://clinicaltrials.gov/study/NCT06303713)

Phase 1 Clinical Trial of Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for pMMR Recurrent/Unresectable Endometrial Carcinoma
NCT ID: NCT05603910 (https://clinicaltrials.gov/study/NCT05603910)

HER2 Vaccine for Locally Advanced Breast Cancer
NCT ID: NCT06949410 (https://clinicaltrials.gov/study/NCT06949410)

An Ophthalmic Safety Study in Patients With Breast Cancer
NCT ID: NCT06767462 (https://clinicaltrials.gov/study/NCT06767462)

Using a mHealth App to Improve Quality-of-Life Outcomes in Black Prostate Cancer Survivors
NCT ID: NCT06651359 (https://clinicaltrials.gov/study/NCT06651359)

Evaluating and Monitoring Immune and Clinical Responses in Early-Stage Triple Negative Breast Cancer Undergoing Neoadjuvant Chemo-immunotherapy With Pembrolizumab
NCT ID: NCT05877859 (https://clinicaltrials.gov/study/NCT05877859)

Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
NCT ID: NCT06562192 (https://clinicaltrials.gov/study/NCT06562192)

Microdevice In Ovarian, Fallopian Tube, And Peritoneal Cancer
NCT ID: NCT04701645 (https://clinicaltrials.gov/study/NCT04701645)

Metabolic Impact and Compliance of Controlled, Varying, Mediterranean Diets in Pre-Surgical Prostate Cancer Populations (PROVISIONS)
NCT ID: NCT06487507 (https://clinicaltrials.gov/study/NCT06487507)

A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.
NCT ID: NCT07470853 (https://clinicaltrials.gov/study/NCT07470853)

Prostate Cancer IMAGing IN Early Detection (IMAGINED Trial)
NCT ID: NCT05882253 (https://clinicaltrials.gov/study/NCT05882253)

Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer
NCT ID: NCT04734730 (https://clinicaltrials.gov/study/NCT04734730)

Mirai-MRI: Validation of AI Models for Breast Cancer Risk
NCT ID: NCT07121972 (https://clinicaltrials.gov/study/NCT07121972)

Impact of Aromatase Inhibitor Therapy on Glucose Homeostasis and Diabetes Risk
NCT ID: NCT06557057 (https://clinicaltrials.gov/study/NCT06557057)

Biopsy After Radioembolization to Identify Changes in Tumor Cells From the Radiation
NCT ID: NCT04668872 (https://clinicaltrials.gov/study/NCT04668872)

An Investigational Scan (18F-rhPSMA-7.3 PET-mpMRI) for Targeted Prostate Biopsy Using TRUS-MR Fusion Technique
NCT ID: NCT06865768 (https://clinicaltrials.gov/study/NCT06865768)

Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
NCT ID: NCT02830724 (https://clinicaltrials.gov/study/NCT02830724)

Older Men's Decision Making About Active Surveillance for Prostate Cancer - Aim 3: Decision Aid Cognitive and Usability Testing
NCT ID: NCT05497024 (https://clinicaltrials.gov/study/NCT05497024)

HIIT Following Breast Cancer Chemotherapy
NCT ID: NCT05913713 (https://clinicaltrials.gov/study/NCT05913713)

A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation
NCT ID: NCT06385925 (https://clinicaltrials.gov/study/NCT06385925)

Serial MRI Scans During Radiation Therapy
NCT ID: NCT04188535 (https://clinicaltrials.gov/study/NCT04188535)

Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies
NCT ID: NCT04541108 (https://clinicaltrials.gov/study/NCT04541108)

Feasibility Study of CBCT for IGRT in Cancer Patients
NCT ID: NCT06681233 (https://clinicaltrials.gov/study/NCT06681233)

About FORCE

FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.